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Abstract 
 
As Blood-brain barrier (BBB) breakdown is central to inflammatory lesion formation, it 
presents a potential target in the formulation of putative therapeutic agents in MS. The 
action of natalizumab, a monoclonal antibody acting at the BBB, is investigated through 
a phase III monotherapy trial (AFFIRM) and associated substudies.  
 
Subtle BBB disruption from non-inflamed lesions, which could contribute to axonal 
damage through leakage of inflammatory cells and associated mediators into 
surrounding parenchyma, is also studied. 
 
Introductory chapters (1-3) provide a brief overview of MS, clinical trials, magnetic 
resonance imaging (MRI), the BBB and natalizumab. 
 
Chapter four describes MRI results of AFFIRM- a 2 year multi-centre trial involving 
942 patients. Compared with placebo, natalizumab reduced number of gadolinium (Gd)-
enhancing lesions by 92%, new/enlarging T2-hyperintense lesions by 83%, and new T1-
hypointense lesions by 76%. 
 
Chapter five describes a 57 patient AFFIRM trial substudy in which the influence of 
natalizumab on segmental atrophy was investigated. Atrophy was predominant in grey 
matter (GM) and was independent of lesion load. Fluctuations in white matter (WM) 
volume followed changes in inflammatory lesion load. Atrophy was not influenced by 
natalizumab 
 14 
The effect of natalizumab on subtle BBB disruption (inferred by measuring the post-Gd 
%change in T1 weighted signal intensity) is studied in chapter 6. This AFFIRM 
substudy involved 40 patients (27 on natalizumab, 13 on placebo.) Although subtle 
BBB leakage was consistently detected in non-visibly enhancing lesions, natalizumab 
did not influence the degree of leakage.   
 
Chapter 7 describes a cross-sectional study which utilised post-Gd change in R1 (1/T1) 
as a marker BBB leakage. 19 patients (10 RRMS, 9 SPMS) were involved in this study. 
The subtle leakage observed from non-visibly enhancing lesions was distinct from 
leakage from visibly enhancing lesions. This was sustained over 60 minutes, greater in 
smaller lesions and in size-adjusted T1 hypointense lesions.  
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CHAPTER 1 
Multiple Sclerosis and Treatment Trials 
 
1.1 Introduction  
 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system 
(CNS). The hallmark of the disease is the temporal and anatomical dissemination of 
multiple lesions in the brain and spinal cord. Initially, such lesions in the white matter 
(WM)  are  associated  with  inflammation  -  perivascular  lymphocyte  infiltration  and 
blood-brain  barrier  (BBB)  breakdown  (Adams  et  al.,  1985).  The  resolution  of 
inflammation  is  frequently  accompanied  by  axonal  loss  (Trapp  et  al.,  1998;  van 
Waesberghe  et  al.,  1999)  and  associated  gliosis  and  induration,  the  most  visible 
macroscopic pathological manifestation of the disease, earning it its name (Compston et 
al., 2006a). Nonetheless, the pathology of MS is not solely confined to lesions in the 
WM. Demyelinated plaques are widespread in grey matter (GM) (Pirko et al., 2007; 
Kidd et al., 1999) and represent a population of lesions which are histologically distinct 
from their WM counterparts (Peterson et al., 2001; Bo et al., 2003). Normal appearing 
white  matter  (NAWM)  also  bears  evidence  of  axonal  damage  and  additional 
pathological features such as astrocyte proliferation and microglial activation (Trapp et 
al., 1998; Allen et al., 2001).  
 
Possibly  the  first  clearly  described  case  of  MS  was  that  of  Augustus  d’Este,  the 
illegitimate  grandson  of  George  III.  Augustus  d’Este  kept  a  diary  recording  his 
symptoms from the start of his illness in 1822 to his death in 1848 (Firth, 1941). In it  
accounts of such symptoms as leg weakness, ataxia, bladder disturbance and erectile 
dysfunction  are  given.  The  earliest  descriptive  accounts  of  MS  pathology  were 
documented by 2 people, Robert Carswell, and Leon Jean Baptiste Cruveilhier, working 
independently of each other. Both individuals published pathological descriptions of MS 
lesions within a short period of time over 1838 and 1841. (Compston, 1988)   
 
J.M. Charcot’s contribution to the disease in the 1860's was not just in describing the 
clinical  and  pathological  features,  including  demyelination  and  gliosis,  but  in 
recognising  that  these  constituted  a  separate  disease  in  itself,  which  he  termed  la 
sclerose en plaques disseminées. In addition, following the death of his housekeeper, he 
was  able  to  correlate  observed  clinical  features  with  the  pathology  of  the  disease.  
(Cook, 1998). 
 
An estimated 2.5 million people globally suffer from MS. In the UK, it is the most 
common  chronic  neurological  disease  that  results  in  locomotor  disability  in  young 
adults. The incidence in England and Wales has been estimated as between 3.5 and 6.6 
per  100000,  with  a  prevalence  of  100-120  per  100000  (Compston  and  Confavreux, 
2006b; NCC-CC, 2004). The cost of MS has been estimated at roughly £17000 per year 
per patient, which translates to a national burden of £1.34 billion per year (NCC-CC, 
2004).  
 
The age of onset of the disease in any particular individual can sometimes be difficult to 
pinpoint,  as  early  sensory  relapses  may  often  be  ignored  as  innocuous  or  forgotten 
entirely. However, MS begins typically early in life, with a peak age of onset roughly 
around  the  age  of  30.  (Confavreux  and  Compston,  2006)  The  majority  of  patients  
experience their first symptoms between 20 and 40 years of age.  A small proportion, 
roughly 5%, report symptoms before the age of 16 (Compston and Coles, 2002; Bauer et 
al., 1990). The female to male ratio of the disease is roughly 2:1. Patients with primary 
progressive MS (who represent 15% of all MS cases) tend to have a higher mean age of 
onset (~38 years) and a much more equal female to male ratio. (Cottrell et al., 1999; 
Thompson et al., 2000). 
 
1.2 Aetiology 
 
The  aetiology  of  MS  is  as  yet  poorly  understood.  An  interplay  of  genetic  and 
environmental factors are thought to be involved (Compston et al., 2006c). 
 
1.2.1 Environmental Factors 
 
The  monozygotic  twin  concordance  in  MS  is  35%,  indicating  major  environmental 
determinants  in  MS  risk.  Additional  support  for  this  comes  from  the  striking 
geographical variation in the prevalence of the disease. The worldwide distribution of 
the disease is divided into 3 zones of MS risk (Kurtzke, 1975; Kurtzke, 2000).  
 
1.  High  risk  areas  such  as  North  America,  Northern  Europe,  New  Zealand  with 
prevalence rates >30 per 100000 
2. Intermediate risk areas such as Australia, Southern United States and parts of Russia, 
with prevalence rates of between 5 and 30 per 100000 
3. Low risk areas such as equatorial Africa and much of Asia, with prevalence rates less  
than 5 per 100000. 
 
Moreover,  within  relatively  racially  homogenous  countries,  a  consistent  finding  in 
epidemiological  studies  is  an  increase  in  prevalence  with  distance  from  the  equator 
(Kurtzke et al., 1979; Skegg et al., 1987; Hammond et al., 1988)  
 
Migration studies from England (high prevalence) to South Africa (lower prevalence) 
have suggested that the risk of developing MS is determined by the environment to 
which the migrant is exposed before the age of 15. (Dean and Kurtzke, 1971; Dean et 
al., 1997). No such cut-off age was found in migrant studies of previous residents of the 
UK and Ireland into Australia (Hammond et al., 2000). Subjects in this study adopted 
the  reduced  risk  of  MS  associated  with  living  in  Australia,  regardless  of  age  at 
immigration.    
 
Taken  together,  the  above  studies  suggest  that  exposure  to  certain  environmental 
factors, probably early in life, could influence one’s risk for developing MS. To date, 
speculation on an environmental trigger has ranged from an infective agent (Martyn, 
1997; Sundstrom et al., 2004), to diet (Lauer, 1997; Munger et al., 2004) and exposure 
to sunlight (van der Mei et al., 2003). However, no definite link with any environmental 
factor has thus far been demonstrated.  
 
1.2.2 Ethnic Variation 
 
Susceptibility to MS varies from race to race. MS is low amongst Sami, Maoris and 
Blacks  and  high  amongst  people  of  European  origin.  (the  prevalence  in  North  
Americans of African origin is about half that found in those of northern European 
origin),(Rosati, 2001). Studies on US servicemen indicate a higher risk of developing 
MS amongst those with a northern European ancestry (Page et al., 1993). In addition, 
the prevalence of MS differs in racially distinct populations situated close to each other, 
for instance in Malta (4.2 per 100000) compared with neighbouring Sicily (53.3 per 
100000). (Dean et al., 1979; Vassallo et al., 1979).  
 
1.2.3 Genetic factors 
 
Whereas the lifetime risk of developing MS in the general population in the United 
Kingdom  is  about  1:600  to  1:800  (~0.1%),  close  relatives  of  MS  patients  bear  an 
increased risk of developing the disease. Age adjusted risk for developing MS is 3% for 
siblings and 2% for parents and children of subjects with MS. The risk of developing 
MS in the offspring of conjugal pairs is 20%, and the monozygotic twin concordance 
rate is 35% compared with a dizygotic twin rate of 3-5% (Compston and Coles, 2002). 
The risk for MS in non-biological adopted siblings is no higher than the population risk, 
confirming that familial increase in risk is due to genetic rather than environmental 
factors. 
 
MS does not follow any mendelian pattern of inheritance, and the disease appears to be 
genuinely polygenic (Compston, 1999), probably with a number of genes each having a 
limited  effect  on  susceptibility.  More  recently,  a  genome-wide  association  study 
identified a number of single nucleotide polymorphisms (including 2 within the gene for 
the  interleukin-2  receptor  α,  1  within  the  gene  for  the  interleukin-7  receptor  α  and 
several within the HLA-DRA locus) which were associated with an increased risk of  
MS (International Multiple Sclerosis Genetic Consortium et al., 2007).	 ﾠ	 ﾠ
 
The common Caucasian MHC class II HLA-DR2 (DRB1*1501) haplotype appears to 
be linked with relapsing disease in northern European populations (Olerup and Hillert, 
1991; Compston and Sadovnick, 1992) HLA-DR2 also appears more common in the 
typical forms of relapsing MS in the Japanese population (Kira, 2003), which has seen 
an  increase  in  prevalence  in  the  disease  in  the  last  3  decades  (Compston    and 
Confavreux, 2006b). Progressive forms of MS have also been linked with HLA DR4 
(Kantarci  et  al.,  2002)  but  a  consistent  gene  association  with  disease  course  and 
prognosis has not emerged. Somewhat different HLA associations have emerged with 
MS in Sardinia (Marrosu et al., 1997). Known carriers of the apolipoprotein E4 allele 
appeared in one study to have an earlier onset and more aggressive course of the disease 
(Enzinger et al., 2004), however this was not confirmed by other investigators.  
 
1.3 Pathology 
 
The pathological hallmark of MS is the presence of demyelinating plaques of varying 
age  distributed  in  space  and  time  within  the  CNS.  Because  of  better  contrast  and 
detectability  on  conventional  magnetic  resonance  imaging  (MRI)  and  histological 
methods, lesions within the WM have to date been the focus of much of the study of 
MS. It is hoped that the advent of high field MRI will facilitate the further study of GM 
lesions  in  the  future.    The  main  pathological  features  of  MS  plaques  are  1) 
demyelination which is complete in many chronic lesions, 2) relative preservation of 
axons and glia (although axonal loss can be profound in some lesions especially when  
chronic), 3) perivenule location and 4) variable amounts of gliosis, inflammation and 
remyelination which may partly depend on lesion age but also on other factors that are 
not well understood. 
 
Lesions in the WM have a predilection for certain brain regions, particular around the 
ventricles, periaqueductal sites and optic nerves. Cord lesions are frequently subpial in 
location. The mechanism(s) for preferential periventricular distribution of MS lesions 
remain  unclear.  Possible  explanations  include:  1)  Slower  bloodflow  in  postcapillary 
venules, facilitating leucocyte adhesion in such areas, 2) regional variation in microglia 
or capillary pericytes and 3) the local effects of toxins or cytokines in the CSF.   
 
1.3.1 The Active lesion 
 
The  classic  acute  WM  lesion  of  MS  displays  perivascular  inflammation,  with  BBB  
breakdown and active demyelination. The precise triggers are unclear but the following 
sequence of events may be relevant. A rise in circulating cytokines such as TNFα and 
IFNγ  (Beck J et al., 1998; Dettke et al., 1997) may precede lesion formation. This 
stimulates endothelial cells in the postcapillary venules to express adhesion molecules 
and MHC class II molecules, facilitating the adhesion of circulating leucocytes. These 
inflammatory  cells  infiltrate  the  parenchyma,  release  cytokines  and  chemokines 
(Balashov et al., 1999) and express costimulatory molecules which further enhance T-
cell proliferation and activation (Prat et al., 2000). A pro-inflammatory loop is initiated 
(Compston and Coles, 2002) in which CD8+ T cells dominate in a Th1 type immune 
response.  Inflammatory  mediators  stimulate  disruption  of  the    BBB  (Minagar  and 
Alexander, 2003) and the resultant perivascular cuff consists of local oedema and a  
lymphocytic infiltrate (Adams et al., 1985).  Myelin and oligodendrocytes, which form 
myelin  sheaths  around  neighbouring  axons,  are  opsonised  and  phagocytosed  by 
macrophages and activated microglia. Oligodendrocyte loss correlates significantly with 
the number of macrophages in histological studies (Lucchinetti et al., 1999).  
 
1.3.2 Mechanisms of axonal loss 
 
Although the most visible features of MS lesions are myelin sheath damage and 
oligodendrocyte death/dysfunction, axonal damage has been well described (Trapp et 
al., 1998; Bjartmar and Trapp, 2001). The degree of axonal loss varies between patients 
and lesions (Bitsch et al., 2000). Amyloid precursor protein (APP), a marker of acute 
axonal damage, is expressed in high levels in active lesions (Ferguson et al., 1997; 
Kuhlmann et al., 2002) and is also present in the active edges of chronic lesions. Local 
concentrations of APP correlate with severity of inflammation as measured by numbers 
of microglia and CD8 T-cells (Bitsch et al., 2000). Axonal loss is at its most severe 
early on in inflammation.  The degree of axonal damage has been correlated with 
disability in Extrinsic Allergic Encephalomyelitis (EAE), the animal model of MS, 
(Wujeket al., 2002) and with spectroscopic markers of axonal integrity such as N-
Acetyl Aspartate (NAA) in MS patients (Davie et al., 1995; De Stefano et al., 1998). 
Postulated mechanisms of injury include direct attack by immune cells, either cytotoxic 
T-cells (Neumann et al., 2002; Medana et al., 2001) or through NO mediated pathways 
(Smith KJ et al., 2001). The lack of a myelin sheath with its attendant provision of 
trophic factors and protection from the inflammatory milieu has also been cited as a 
possible contributor to axonal loss. Disturbances to the local vasculature through 
oedema and vessel wall inflammation could also contribute to axonal damage.  
Thrombotic occlusion of microvessels have been observed in MS (Lassmann, 2003), 
suggesting, in some cases, an ischaemic mechanism for axonal death. 
 
1.3.3 Pathological Heterogeneity in lesions 
 
Histological study of active lesions taken from biopsies and autopsies of MS patients 
has demonstrated heterogeneity in the phenotype of MS lesions. Acute lesions have 
been categorised into 4 distinct pathological patterns (table 1.1), according to the degree 
of T-cell involvement, oligodendroglial dysfunction and complement activation. 
(Lucchinetti et al., 2000) 
Patterns of lesion pathology (Lucchinetti et al., 2000) 
Table 1.1Patterns of lesion pathology (Lucchinetti et al., 2000) 
 
 
 
 
An inflammatory infiltrate is present in all 4 lesion patterns. Patterns I and II are marked 
by  an  intense  perivenous  immune  reaction  with  a  sharply  demarcated  area  of 
inflammation and demyelination and the attendant damage of axons, oligodendroglia 
and  astrocytes,  with  pattern  II  having  the  additional  association  of  complement 
Subtype  Immunology  Oligodendrocytes  Border 
I  
18%  
CD8 T cells 
and macrophage  
mediated  
demyelination 
Survival of 
oligodendrocytes with 
rapid remyelination 
Sharp 
Centred around  
Venules 
II 
56% 
As in I, plus 
antibody 
& complement  
deposition 
Survival of 
oligodendrocytes with 
rapid remyelination 
Sharp 
III 
24% 
Microglial 
activation 
Oligodendrocyte 
destruction 
Distal oligo-opathy and 
dystrophy. 
Early myelin loss 
Axonal damage 
Indistinct 
Not centred around 
Venule 
IV 
2% 
Macrophages 
and T cells. Only 
seen in PPMS 
Primary oligodendrocyte 
degeneration.  
Axonal damage 
Sharp, perivenous  
activation  and  IgG  deposition.  Types  III  and  IV  appear  to  be  the  result  of  primary 
oligodendroglial dysfunction and apoptosis with subsequent demyelination.   
 
Patterns I and II are seen in all disease subtypes, whereas pattern III has been observed 
largely in cases with disease duration less than 2 months. Pattern IV, the rarest, has only 
been observed in primary progressive disease. It has been suggested that while lesion 
patterns vary between different patients, lesions found within an individual patient share 
the same pattern. 
 
As the lesions examined in the Lucchinetti study have been obtained through biopsy or 
autopsy, a selection bias may exist within the study toward larger, more severe, lesions, 
and as such, the lesions studied may not reflect active lesions in general. Nonetheless 
the findings of the study point strongly toward a pathological heterogeneity within the 
disease of MS and is consistent with the observations of diversity in disease course, 
presentation and response to treatment.  Such heterogeneity has prompted speculation 
that MS may represent a collection of neuroinflammatory diseases rather than a single 
entity (Compston and Sadovnick, 2002) 
 
1.3.4 Chronic Lesions 
 
The inflammatory cellular infiltrate associated with demyelination decreases over time 
(Kuhlmann  et  al.,  2002).  A  glial  scar  develops  amidst  a  residue  of  occasional 
inflammatory cells and damaged and demyelinated axons. Although oligodendrocyte 
precursors are present, the presence of viable oligodendrocytes and remyelination is 
variable. Ongoing inflammation and neuronal damage can still occur at the lesion edge  
(Bitsch et al., 2000). 
 
1.3.5 Remyelination  
 
Between  13-42%  of  lesions  show  evidence  of  remyelination  (Barkhof  et  al.,  2003; 
Schmierer et al., 2004). Remyelination can occur early in lesion genesis and appears to 
be most successful in lesions in which there are a large number of macrophages, and 
oligodendrocytes (Bruck et al., 2003). Remyelinated plaques are frequently described as 
‘shadow  plaques’  (Prineas  et  al.,  1993).  Such  plaques  display  minimal  axonal  loss 
(Kornek  et  al.,  2000)  and  preservation  of  function.  The  factors  that  regulate 
remyelination are still poorly understood, but are thought to include the presence of 
signalling factors in the local environment, the proximity of viable oligodendrocytes or 
oligodendrocyte precursor cells capable of effecting remyelination and the degree of 
gliosis in the lesion, which may provide a mechanical barrier to remyelination. (Bruck et 
al., 2003).  
 
1.3.6 Grey Matter involvement 
 
Demyelinating lesions also occur in the cortical GM. (Kidd et al., 1999, Peterson et al., 
2001).  They can be contiguous with subcortical lesions (type 1), confined to within the 
cortex (type 2) or can involve the pial surface (type 3) (Peterson et al., 2001). They are 
associated with fewer inflammatory cells than WM lesions with 13 times fewer T cells 
and 6 times fewer macrophages and microglia (Peterson et al., 2001). GM lesions may 
exhibit significant amounts of axonal loss and have significantly more apoptotic neurons  
than surrounding GM.  
 
1.4 Clinical manifestations of multiple sclerosis 
 
1.4.1 Symptoms and signs 
 
Clinically, MS is characterised by symptoms reflective of lesions separated in time and 
space. Symptoms arise from the interruption of pathways, either through failure of 
saltatory conduction from demyelination, or by interruption or transection of axons. 
Demyelinated axons are more vulnerable to changes in the environment. For instance, 
an increase in temperature can exacerbate existing symptoms (Uhthoff phenomenon), as 
can the application of mechanical pressure (Lhermitte phenomeonon). Concurrent 
infection can also worsen pre-existing or re-awaken old neurological symptoms, either 
through changes in temperature or possibly – an effect of cytokines on nerve conduction 
(Moreau et al., 1996).  
 
Certain symptoms reflect specific locations of lesions. For instance myelopathic 
symptoms are likely to arise from spinal cord lesions, and dysdiadochokinesis and 
dysmetria from lesions in the cerebellum (including cerebellar peduncles). Given the 
predilection of lesions for certain anatomical locations within the CNS, specific 
symptoms and signs are encountered with greater frequency in MS. Table 1.2 gives a 
list of the most frequently encountered clinical findings in MS clinics at the Universities 
of British Columbia and Western Onatario, Canada, as provided by Paty and Ebers. 
  
Table 1.2 Predominance of clinical findings in MS clinics in Canada (Paty and Ebers, 1997) 
 
Not all MS lesions give rise to symptoms. The clinical eloquence of a lesion depends on 
its location - lesions in the deep WM and not involving key pathways such as the 
corticospinal tract are less likely to cause acute symptoms when they appear.  However, 
such lesions may contribute to cognitive impairment, especially with accumulation of 
multiple cerebral lesions. Cognitive deficits are detectable on formal testing, especially 
in attention, information processing and verbal memory (Piras et al., 2003). Such 
changes are correlated with lesion load seen in the cerebral hemisphere in the WM on 
MRI (Hohol et al., 1997). Fatigue is also common in MS patients, estimated at up to 
80% MS sufferers (Bakshi, 2003), although its relationship with the underlying 
pathology is not well understood.  
 
Acute lesions may also be asymptomatic if there is axonal preservation and rapid 
remyelination, whereas persistent deficits will be more likely if persistent demyelination 
results in substantial axonal loss.  
 
1.4.2 Clinical course 
 
MS  is  a  diverse  disease  in  terms  of  pathology,  presentation  and  clinical  course.  
 
Symptom and signs           % Frequency 
Increased deep tendon reflexes                     90 
Sensory loss  
(most commonly in legs and implicating the  
posterior columns of cord) 
                   90 
Leg weakness                     90 
Spasticity                     90 
Nystagmus                     85  
Bladder disturbance                     80 
Fatigue                     80 
Optic atrophy                     77 
  
Following a survey of clinicians involved with MS, Lublin and Reingold put forward 
the following clinical classification of the disease (FIG 1.1) which now has widespread 
recognition. (Lublin and Reingold, 1996).   
 
 
FIG 1.1 The disease course in 4 MS disease subtypes. a)RRMS; b)SPMS; c)PPMS; d) benign MS 
 
Roughly  85%  of  MS  patients  present  with  relapsing  remitting  (RR)MS.    This  is 
associated with clearly defined relapses with or without full recovery, with no evidence 
of clinical progression between relapses. Average relapse rate varies between 0.1 and 1 
per year (Weinshenker and Ebers, 1987) Good prognostic markers in RRMS include 
young age at onset, mainly sensory symptoms, symptoms implicating single site on 
  
onset, a long interval between the first and second relapse, and good recovery from 
initial relapse (Runmarker and Anderson, 1993) 
 
Secondary Progressive (SP) MS is characterised by secondary progression, defined as 
gradually  increasing  disability  progression  for  more  than  6  months  independent  of 
relapses, following a period of relapsing remitting disease. A significant proportion of 
RRMS patients convert to SPMS, with a median time of onset of progression at 10 years 
from the start of the disease (Runmarker and Anderson, 1993; Confavreux et al., 1980).  
 
15% of MS patients develop the primary progressive (PP) form of the disease. (Cottrell 
et  al.,  1999)  This  is  characterised  by  progression  of  disability  from  onset  with 
occasional plateaus and temporary (mild) improvements allowed. This clinical subgroup 
tends  to  have  an  onset  later  in  life  and  80-90%  present  with  a  progressive  cord 
syndrome.  
 
A minority of patients evolve to develop a benign MS course, which is defined as a 
relapsing remitting time course with minimal or no disability up to 15 years after onset. 
Other  terms  such  as  relapsing  progressive  and  progressive  relapsing  have  been  less 
clearly defined and are not commonly used to define patients for inclusion treatment 
trials.  
 
1.5 Diagnosis of multiple sclerosis 
 
The diagnosis of MS rests primarily on evidence of lesions disseminated in space and 
time.  Clinical  evidence  through  carefully  taken  history  and  examination  formed  the  
cornerstone of the formalised set of diagnostic criteria set out in the 1960s (Schumacher 
et al., 1965) (FIG 1.2) and every set of diagnostic criteria since. More recent revisions 
of  the  diagnostic  criteria  incorporate  data  from  imaging,  evoked  responses  and 
cerebrospinal fluid (CSF) electrophoresis (Poser et al., 1983; McDonald et al., 2001; 
Polman et al., 2005) in recognition of the contribution of these investigations toward the 
diagnostic process. 
 
Two successively proposed diagnostic criteria will be described in this section. Both are 
widely  employed  at  present  in  clinical  and  academic  settings.  They  are  the  Poser 
Committee  Criteria  (Poser  et  al.,  1983),  devised  to  incorporate  data  from  evoked 
responses and  CSF electrophoresis, and the subsequent McDonald criteria (McDonald 
et al., 2001), and its succesive revision (Polman et al., 2005) devised to adapt to the 
increasing use of MRI as a sensitive and effective diagnostic tool.  
 
FIG 1.2 Schumacher Criteria for the diagnosis of MS 
 
The Poser committee criteria were drawn up in 1983 as a result of a workshop on the 
diagnosis of MS attended by experts from the United States, Canada and the United 
Kingdom (Poser et al., 1983) The criteria expanded on pre-existing Schumacher criteria 
to  incorporate  data  from  CSF  electrophoresis  and  what  was  termed  paraclinical 
1. Objective signs of dysfunction of the central nervous system; symptoms not acceptable 
2. Evidence of damage to two or more sites 
3. Predominantly damage to the white matter 
4a. Two or more episodes of at least 24 h separated by at least 6 months 
4b. Progression over 6 months 
5.  Age of onset 10–50 years 
6. Diagnosis by a neurologist; signs and cannot be explained by other disease  
evidence, described as “demonstration by means of various tests and procedures of the 
existence of a lesion in the CNS ... include the hot bath test, evoked response studies, 
imaging procedure and reliable, expert urological assessment”. Diagnostic certainty was 
stratified into 3 levels: definite, probable and possible. In addition,  the basis of the 
evidence (ie clinical vs laboratory supported) is described for each level. (Table 1.3) 
 
Table 1.3 Poser Committee Criteria for diagnosis of MS (From Poser et al., 1983) 
Category  Number of 
Relapses 
Number of 
 CNS sites involved  
  Paraclinical 
evidence 
CSF  
Oligoclonal 
bands 
Clinically 
Definite 
2 
2 
2 
1 
 
and 
 
1 
 
Clinically 
Probable 
2 
1 
1 
2 
 
 
   
Laboratory 
Supported 
Definite 
2 
1 
1 
2 
or  1  + 
+ 
Laboratory 
Supported 
Probable 
1 
2 
1  and  1  + 
+ 
 
Following a meeting of the international committee of MS diagnosis, a revised set of 
diagnostic criteria was proposed in 2001 which incorporates the use of MRI findings to 
allow for earlier and accurate diagnosis of MS (McDonald et al., 2001). The levels of 
diagnostic certainty proposed by the Poser Committee were replaced with “MS”, “not 
MS” and “possible MS” for cases with equivocal clinical and paraclinical findings. MRI 
criteria incorporated into the new set of diagnostic criteria were based on the findings of 
previous prospective studies on patients with single neurological episodes, the so called 
clinically isolated syndrome (CIS), (Barkhof et al., 1997; Tintore et al., 2000) and those 
with primary progressive MS (Thompson et al., 2000) Criteria drawn up for MRI 
included evidence of dissemination in space, dissemination in time, and MRI evidence 
for primary progressive MS.  
 
 FIG 1.3 MRI criteria employed with McDonald Criteria for diagnosis of MS (McDonald et al 2001; 
Polman et al., 2005) 
 
The McDonald Criteria retains as its focus evidence of dissemination of MS lesions in 
time and space. Clinical evaluation remains critical and necessary for a diagnosis of MS. 
An advantage of the McDonald Criteria is that MS can now be made based on a history 
Criteria for Dissemination in Space  
Three of the following
a: 
1. At least one gadolinium-enhancing lesion or nine T2 hyperintense lesions if there is 
no gadolinium enhancing lesion 
2. At least one infratentorial lesion 
3. At least one juxtacortical lesion 
4. At least three periventricular lesions 
NOTE: A spinal cord lesion can be considered equivalent to a brain infratentorial lesion: an 
enhancing spinal cord lesion is considered to be equivalent to an enhancing brain lesion, and 
individual spinal cord lesions can contribute together with individual brain lesions to reach the 
required number of T2 lesions 
 
Criteria for Dissemination in Time  
a. Detection of gadolinium enhancement at least 3 months after the onset of the 
initial clinical event, if not at the site corresponding to the initial event 
or 
b. Detection of a new T2 lesion if it appears at any time compared with a reference 
scan done at least 30 days after the onset of the initial clinical event 
MRI criteria for disease of insidious onset suggestive of PPMS 
1. One year of disease progression (retrospectively or prospectively determined) 
2. Plus two of the following: 
a. Positive brain MRI (nine T2 lesions or four or more T2  lesions with positive VEP) 
b. Positive spinal cord MRI (two focal T2  lesions) 
c. Positive CSF (isoelectric focusing evidence of oligoclonal IgG bands or increased IgG  
index, or both).  
of  a  single  relapse  in  which  there  was  clinical  confirmation  of  a  CNS  lesion.  The 
application of the McDonald criteria to such patients revealed a specificity of 83-86% 
for the subsequent development of clinically definite MS by Poser criteria (Dalton et al., 
2002a; Tintore et al., 2003).  
 
Revisions to the McDonald Criteria have been published, allowing for a greater role in 
spinal cord lesions (Polman et al., 2005) and a reduction in the interval between scans to 
determine a new lesion (Swanton et al., 2006). Such revisions allow a greater sensitivity 
for the  diagnosis of MS whilst retaining diagnostic accuracy and specificity (Swanton  
et al., 2007). The latest accepted version of the McDonald Criteria is outlined in FIG 
1.3. 
 
1.6 Management of multiple sclerosis 
 
Management  of  the  MS  patient  encompasses  both  pharmacological  and  non-
pharmacological approaches. Education about the disease and psychological support can 
be provided by MS specialist nurses and active support groups, either in terms of family 
members and loved ones, or in organised patient interest groups such as the MS Society. 
The provision of physiotherapy and occupational therapy, especially within an inpatient 
neuro-rehabilitation  setting,  has  been  shown  to  improve  functional  independence  in 
disabled MS patients (Freeman et al., 1997, Solari et al., 1999).  
 
Pharmacological  therapy  can  be  categorised  into  symptomatic  treatment  and  disease 
modifying  therapy.  Several  specific  MS  related  symptoms  are  amenable  to 
pharmacological  therapy,  including  spasticity,  bladder  dysfunction,  pain,  fatigue  and  
depression. The administration of high dose steroids in the event of an acute relapse has 
been shown to hasten recovery of function (Brusaferri et al., 2000; Miller DM et al., 
2000).  However,  there  is  no  evidence  that  steroids  affect  the  long  term  outcome 
following a relapse. 
 
Disease  modifying  therapies  now  available  and  licensed  for  use  in  MS  include 
interferon β (IFNβ), glatiramer acetate, mitoxantrone and natalizumab.  Amongst these, 
the  most  widely  used  are  IFNβ  in  its  various  preparations  and  glatiramer  acetate. 
IFNβ comes in two forms. IFNβ-1a (avonex and rebif) and IFNβ-1b (betaferon).  IFNβ 
and glatiramer acetate reduce annualised relapse rate by 30% in patients with RRMS 
(IFNB  MS  Study  Group,  1993;  IFNB  MS  Study  Group  and  University  of  British 
Columbia MS/MRI analysis  Group, 1995; Johnson et al., 1995; Jacobs et al., 1996; 
PRISMS  Study  Group,  1998),  with  minimal  effect  on  long  term  overall  disability.  
While reducing relapse rate, Neither glatiramer acetate nor IFNβ exerts any significant 
effect on relapse-independent disability progression in SPMS and PPMS (Wolinsky et 
al., 2007; European Study Group on interferon beta-1b in secondary progressive MS, 
1998;  Panitch  et  al.,  2004;  Secondary  Progressive  Efficacy  Clinical  Trial  of 
Recombinant  Interferon-beta-1a  in  MS  (SPECTRIMS),  2001;  Leary  et  al.,  2003). 
Neither are therefore indicated for the treatment of PPMS. IFNβ−1b is used in SPMS 
only  if  concurrent  relapses  in  these  patients  are  significantly  responsible  for  overall 
clinical dysfunction.  
 
Evidence-based criteria dictating the prescription of IFNβ and glatiramer acetate in the 
United Kingdom have been drawn up by the Association of British Neurologists (ABN). 
In essence, treatment with IFNβ  or glatiramer acetate is indicated in ambulant RRMS  
patients over the age of 18, with at least two relapses in two years. Prescription of these 
agents in the United Kingdom is coordinated and monitored through the Department of 
Health risk sharing scheme in which the long term efficacy and cost-effectiveness of 
these agents are investigated through annual assessments (Department of Health, 2002; 
Sudlow and Counsell, 2003). 
 
1.7 Treatment trials 
 
1.7.1 Definition and background 
 
Treatment  trials  are  planned  experimental  studies  designed  to  evaluate  the  effect  of 
putative  treatments  in  humans.  In  general,  they  follow  extensive  pre-clinical  studies 
using in-vitro and on animal models.  
 
Preliminary  treatment  trials  focus  on  safety  and  pharmacokinetics  (absorption, 
metabolism and excretion). Further trials investigate efficacy by comparing  against a 
control (standard treatment or placebo).  
 
Prior to the 20
th century, clinical trials took the form of uncontrolled empirical and 
observational studies, in which the putative agent is given to the patient, who is then 
observed for a therapeutic response. The identity of the treatment was known to both 
patient  and  observer  (non-blinded).  These  trials  were  open  to  confounding  by  the 
placebo response (a response arising from the subject's or observer's expectations of the 
treatment, rather than from any specific therapeutic property of the treatment itself)  and  
other sources of observer bias.  
 
Double blinded Randomized Controlled Trials (RCT) compare the efficacy of an agent 
against that of a placebo, or existing treatment. In doing so, any response due to a 
placebo  effect  is  allowed  for  by  subtracting  the  response  to  placebo  from  the  the 
response to the active agent. Treatment designation (ie whether one receives the agent or 
placebo) occurs in a randomized, systematic manner which minimizes the differences 
among groups by equally distributing people with particular characteristics among the 
different  trial  arms.  Treatment  designation  is  not  revealed  to  the  study  subjects  or 
investigators until the end of the trial, therefore removing observer bias.. Such trials 
have become increasingly used in the course of the 20
th century and are the predominant 
design in phase III studies.  Uncontrolled open-label studies, in which the study subjects 
and the investigators are aware of their treatment, are still used, particularly in long term 
and follow-up studies, although by virtue of their trial design and confounding placebo 
effect, the evidence provided by such trials is not as robust as RCTs. 
 
1.7.2 Trial Design 
 
The clinical development of a putative agent follows multiple stages, from phase 0 to 
phase IV studies. 
 
Phase 0 studies involve administering a tiny dose of the agent (frequently one hundredth 
of  a  pharmacologically  active  dose)  to  healthy  volunteers.    Such  studies  serve  as 
preliminary investigations into the safety of an agent, and the findings can influence the 
decision to proceed to phase 1 studies.  
 
Phase I studies ascertain the safety and tolerability of the agent in healthy volunteers at 
doses  approximating  the  pharmacologically  active  dose.  Typically,  subjects  are 
observed through a period spanning several half-lives of the drug, allowing assessment 
of  the  agent's  pharmacokinetics.  Dose-ranging  studies,  where  the  medication  is 
administered in ascending doses, determine the maximum tolerated dose.  
 
Phase II studies serve as proof-of-concept efficacy assessments. They are intermediate 
in size and rarely involve more than a few hundred patients. Preliminary observations 
are made on efficacy and dose response, and a dosing regime is determined. 
Assessments on safety and pharmacokinetics started in phase I trials are extended. 
Surrogate outcome measures (which may be more sensitive than definitive clinical 
outcome measures) are often employed: MRI is used in this way in MS phase II trials.  
 
Phase  III  trials  are  conducted  after  efficacy  of  treatment  has  been  preliminarily 
demonstrated  in  phase  II  trials.  These  trials  typically  involve  several  hundreds  of 
patients  from multiple centres. They serve as definitive efficacy assessments on a large 
number  of  patients  for  whom  the  medication  is  intended.  As  such,  these  trials  are 
designed as double-blinded RCT, with clearly defined inclusion criteria and outcome 
measures. The usual primary outcome measures in phase III MS trials are annualised 
relapse rate and changes in measured disability. 
 
Phase IV trials extend the study of the drug in its post-licencing period.  The trials are 
by necessity uncontrolled, open-labelled studies. They  serve to provide continuing data 
on long term safety and, to a lesser extent, efficacy.  
 
1.7.3 Outcome measures in MS trials 
 
In MS drug trials, response to a drug is measured through changes in clinical and 
surrogate markers of disease activity and severity.   
 
1.7.3.1 Clinical measures in MS 
 
Clinical measures form the primary outcome measure in phase III MS trials.  These are 
divided into those that reflect disease activity (relapse rate) and those that reflect the 
disability accrued as a result of the disease, such as the Expanded Disablity Status Scale 
(EDSS) and the Multiple Sclerosis Functional Composite (MSFC). 
 
Relapses are the clinical expression of underlying disease activity. As such, despite 
variations in definition (Liu and Blumhardt, 1999), relapse frequency has been 
employed as a primary outcome measure in many pivotal MS treatment trials to date 
(IFNB MS study group, 1995; IFNB MS study group, 1993; PRISMS study group, 
1998; Johnson et al., 1995; Polman et al., 2006). However, the relationship between 
relapses and long term disability is uncertain (Runmarker and Anderson, 1993). 
Moreover relapse frequency decreases over time as part of the natural history of MS 
(Weinshenker and Ebers, 1987). For these reasons, relapse frequency on its own 
provides an inadequate picture of the disease and other clinical markers are required in 
conjunction with relapse rate.  
  
Disability scales are designed to provide objective measures of disability as a result of 
disease, and indirectly reflect disease progression and recovery. They are therefore 
useful and relevant in determining the efficacy of therapeutic intervention. The 
disability status scale (DSS) (Kurtzke, 1955) was developed to reflect and monitor MS-
related disability within the context of a treatment trial involving isoniazid (Kurtzke, 
2007).  It incorporated functional scores from a set of clinical subsystems (pyramidal; 
brainstem; cerebellar; sensory; bowel and bladder; vision; cerebral; other) to provide a 
composite score on a graded scale, which encompassed a wide range of functional states 
extending from normality (DSS score 0) to death (DSS score 10). Refinements of the 
DSS led to the EDSS (Kurtzke, 1983), which provides greater differentiation of 
functional status, and is based on identifying neurological signs from a range of 
functional systems as well as evaluating ambulation. Like its predecessor, the EDSS is 
on an ordinal, albeit non-linear scale between 0 (normal  neurological function) and 10 
(death) with increments of 0.5. (FIG 1.4)  
 
FIG 1.4 The expanded disability status scale (Kurtzke, 1983) 
 
The EDSS provides an objective framework with which to assess MS related disability 
in cross sectional and longitudinal studies. It is the single most widely used disability 
scale  used  to  assess  MS  patients  in  clinical  trials  and  natural  history  studies.  The 
overriding advantages of the EDSS are its ease of administration and familiarity with 
investigating clinicians. However, it is not without its limitations (Willoughby and Paty, 
1988;  Sharrack  and  Hughes,  1996).  Distinguishing  between  mild  and  moderate 
Kurtzke expanded disability status scale 
 
0.0 = normal neurological examination 
1.0 = no disability, minimal signs in one FS 
1.5 = no disability, minimal signs in more than one FS 
2.0 = minimal disability in one FS  
2.5 = minimal disability in two FS  
3.0 = moderate disability in one FS or mild disability in three of four FS  though fully ambulatory 
3.5 = fully ambulatory but with moderate disability in one FS  and minimal disability in one or two FS; or moderate disability in 2 FS, or five FS with 
minimal disability 
4.0 = fully ambulatory without aid, self-sufficient up and about some 12 hours a day despite relatively severe disability in one FS or combinations of lesser 
grades exceeding limits of previous steps; able to walk without aid or rest some 500 m 
4.5 = fully ambulatory without aid, up and about much of the day, able to work a full day , may otherwise have some limitation of full activity or require 
minimal assistance, characterisd by relatively severe disability in one FS or combinations of lesser grades exceeding limits of previous steps; able to walk 
without aid or rest some 300 m 
5.0 = ambulatory without aid or rest for about 200 m; disability severe enough to impair full daily activities (e.g. to work a full day without special 
provisions) 
5.5 = ambulatory without aid or rest for about 100 m, disability severe enough to preclude full daily activities 
6.0 = intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100m with or without resting 
6.5 = constant bilateral assistance (canes, crutches or braces) required to walk about 100 m with or without resting 
7.0 = unable to walk beyond approximately five meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers 
alone, up and about in wheelchair some 12 hours a day 
7.5 = unable to take more than a few steps; restricted to wheelchair; may need aid in transfer, wheels self but cannot carry on in standard wheelchair a 
full day; may require motorised wheelchair 
8.0 = essentially restricted to bed or chair or perambulated in wheelchair, but may be our of bed itself much of the day; retains many self care functions; 
generally has effective use of arms 
8.5 = essentially restricted to bed much of the day; has some effective use of arm(s); retains some self care functions 
9.0 = helpless bed patient; can communicate and eat 
9.5 = totally helpless bed patient, unable to communicate effectively or eat/swallow 
10.0 = death due to MS 
  
disability can be difficult, particularly within subsystems reflecting bowel and bladder, 
and cerebral function. Scores above 4.5 being heavily weighted towards ambulation, 
with less emphasis on upper limb and cognitive function. 
 
To provide a better reflection of the latter two, the EDSS is frequently combined with 
the multiple sclerosis functional composite (MSFC) score ( Rudick et al., 1997; Fischer 
JS et al., 1999). The MSFC combines assessments of ambulation (25 foot timed walk), 
upper limb function (nine hole peg test) and cognition (Paced Auditory Serial Addition 
test) to obtain a composite z-score reflective of disability. As such, it is not as weighted 
as the EDSS towards ambulation.   
 
Limited  sensitivity  of  clinical  markers,  coupled  with  a  variability  in  disease  course 
require  that  MS  treatment  trials  be  of  sufficient  size  and  duration  to  be  adequately 
powered  to  demonstrate  efficacy.    Efforts  have  therefore  been  directed  toward  the 
identification of a suitable cost-effective and reproducible surrogate marker. 
 
1.7.3.2 Surrogate markers in MS:  
 
A surrogate marker is a non clinical measure that can be used in place of a clinical 
outcome index as a measure of disease activity and severity.  It should accurately reflect 
disease severity and be sensitive in detecting clinically important change.  
 
The following criteria have been suggested for the validation of surrogate markers for 
use in clinical trials (Prentice, 1989): 
  
1. A given treatment should influence the clinical endpoint of interest and the surrogate 
in the same way. 
 
2. The surrogate and clinical endpoints should be significantly correlated.   
 
3. The effect of a given treatment on the clinical endpoint should be mediated through 
an effect on the surrogate endpoint . 
 
To date, no single biomarker has satisfied all the above criteria for MS.  
 
Nonetheless, as a potential surrogate marker of MS, MRI bears  the following 
advantages: 
 
1. Objectivity: MRI provides an objective picture of disease load and severity. Blinding 
of the observer is also easily maintained since analysis can be performed remote from 
the patient. 
 
2. Sensitivity: Serial Gadolinium (Gd) enhanced monthly MR detects 5-10 new 
inflammatory lesions for every clinical relapse in both relapsing remitting and 
secondary progressive MS patients. Natural history studies have demonstrated frequent 
enhancing lesions occuring even during periods of clinical remission (Grossman et al., 
1986; Miller DH et al., 1988; McFarland et al., 1992). MRI thus provides a sensitive 
measure of inflammation by detecting many active but clinically silent lesions. 
 
3. Archivability: MRI is easily archivable and retrievable, allowing future re-analysis  
and audit. 
 
4. Cost-effectiveness: MRI provides a reproducible and objective  measure of severity 
and activity of the disease, Moreover, the use of MRI markers significantly improves 
the power of trials, allowing study populations in phase II clinical trials to be kept low 
(Tubridy et al.,1998a). 
 
The reproducibility and objectivity of MRI variables make their use as surrogate 
markers an attractive possibility. However, for such a role to exist requires 
demonstration of correlation between the MR parameter and clinical outcome with a 
robust prediction of clinical effect on the MR outcome studied. Unfortunately, although 
MRI outcome variables correlate moderately with clinical outcome in early disease, the 
correlation with long term outcomes is weaker. For this reason, existing MRI measures 
are not regarded as fully adequate or validated surrogate measures (McFarland et al., 
2002). Their use is therefore limited to primary outcome measures in phase II proof of 
concept trials, and as supplementary outcome measures in phase III trials.  
 
The principles of  MRI and its use in the investigation of MS will be the focus of the 
next chapter 
 
 
 
 
 
  
CHAPTER 2 
Magnetic Resonance Imaging 
 
MRI is a non-invasive method of obtaining high resolution images of internal structures 
within the body. Unlike X-rays, no ionizing radiation is involved in the acquisition 
procedure, making MRI relatively safe.  
 
2.1 Basic Principles of MRI 
 
2.1.1 Nuclear induction and the behaviour of protons in a magnetic field 
 
Felix Bloch first described the phenomenon of nuclear induction, the main principle on 
which MRI is based (Block, 1946). Nuclear induction is the creation of a local magnetic 
field by the  spinning of a charged particle (that is with an odd number of nucleons: 
protons and neutrons combined).  
 
Hydrogen is present in abundance in biological structures as a constituent of water, fat 
and protein. MRI techniques manipulate hydrogen nuclei (protons) as their primary 
charged particle to generate images of biological structures. 
 
Protons spin in their natural state, each one generating a local magnetic field (a 
magnetic dipole moment) aligned along its axis. In the absence of an external magnetic 
field, the axes of all protons face different directions and no net magnetic field is 
exerted. The application of an external magnetic field (B0) causes an alignment of the  
axes of protons, either in the direction of the magnetic field (parallel) or opposite to it 
(antiparallel). As more parallel than non-parallel protons  exist, a net magnetic moment 
aligned along the axis B0 results. (FIG 2.1) 
FIG 2.1 Random alignment of protons in the absence of an external magnetic field. The 
introduction of the external magnetic field (B0) causes alignment of the protons in relation to the 
field, with a net magnetic moment in the direction of B0.  
 
Precession is the gyration of protons about the axis of the prevalent magnetic field, 
somewhat similar to the movement of a spinning top. This takes place in addition to the 
spinning movement of the proton about its axis (FIG 2.2). The frequency at which a 
proton precesses is given in the Larmor equation below: 
 
      ω = γ B0 
 
ω = Precessional, or Larmor frequency (radians/sec or MHz),  
γ = gyromagnetic ratio, constant for a given nucleus (in radians/secT or MHz/T) 
B0 = strength of the external magnetic field (T). 
  
 
FIG 2.2 Precession of a spinning proton about the axis of the  magnetic field Bo 
 
In their natural state, the precessional position, or phase of protons varies between 
protons (FIG2.3) 
                 
FIG 2.3 Protons precessing out of phase (A) and in phase (B) with each other 
 
The introduction of a radiofrequency (RF) pulse at the precessional or Larmor 
frequency induces resonance, in which protons absorb the energy inherent in the RF 
pulse to attain a higher energy state.  This results in (i) deviation of the net magnetic 
vector away from B0 at a flip angle α; and (ii) attainment of phase coherence, in which 
the protons precess in phase with each other. 
 
Therefore, a 90
o RF pulse will result in the 90
o deflection of the net magnetic vector 
 
 
  
from one aligned with Bo, (z axis), to one within the transverse (x-y) plane (FIG 2.4). 
The net rotating vector then induces an electrical voltage in a receiver coil or antenna 
orientated in the transverse plane, translating the spin into an oscillating electrical 
voltage, or signal, which can be read to construct an image. 
FIG 2.4 Re-orientation of net magnetisation into transverse (x-y) plane as a result of a 900 RF pulse 
 
2.1.2 T1, T2* and T2 relaxation 
 
Following the cessation of the RF pulse, two principal processes take place: 
 
1. Resumption of net longitudinal magnetization along B0: T1 relaxation 
 
2. Loss of phase coherence, or dephasement, due to T2 and T2* relaxation. This results 
in a loss of transverse magnetisation. 
 
T1, T2 and T2* relaxation occur independently of each other. 
 
T2 and T2* relaxation occurs at a higher rate than T1 relaxation (roughly 10-fold quicker  
  
for various tissues at typical clinical field strengths). This results in a much quicker 
decay of transverse magnetisation  than the recovery of longitudinal magnetisation.  
 
T1 relaxation, also known as spin-lattice relaxation, is the resumption of longitudinal 
magnetization along B0. It results from the dissipation of extra energy  absorbed from 
the RF pulse. This occurs once the RF pulse stops and results in  a re-orientation of the 
axes of the protons to pre-pulse directions.  T1 relaxation is an exponential process 
governed by a recovery time constant T1(FIG 2.5).  T1 is  influenced by chemical lattice 
structure, and is shortest when efficient energy dissipation is facilitated.  
 
FIG 2.5 Resumption of net longitudinal magnetization: T1 relaxation 
 
Two processes drive the loss of phase coherence in protons following the cessation of 
the RF pulse. These are: 
 
1. Spin interaction: Each spinning proton, by virtue of its magnetic dipole moment, 
causes minute variations in the local magnetic field of neighbouring protons. This 
results in subtle differences in precessional rate which in turn leads to dephasement. The  
decay is determined by the time constant T2 and is called T2 relaxation, or spin-spin 
  
relaxation.  
 
2. External magnetic field inhomogeneity: Local variations in magnetic field strength 
cause discrepancies in precessional frequency and dephasement over and above local 
spin-spin relaxation.  This is called T2* relaxation, the rate of which is governed by the 
time constant  T2*.  
 
T1 and T2 vary with the chemical environment. For instance, fat has a short T1 due to 
efficient dissipation of energy as facilitated by the structured molecular lattice. 
Conversely, T1 is long in water, where the lack of such a lattice impedes the efficiency 
of energy transfer. 
 
Tissues which are made of molecules with a large number of protons (for example 
lipids and proteins) have short T2 due to the increased amount of spin-spin interactions 
within the molecule.  In contrast T2 is longer in water, where protons are more freely 
spaced apart and therefore subject to a relatively low number of spin interactions. 
 
Differences in T1 and T2 in neighbouring structures can be exploited by MRI to generate 
contrast and delineate relevant tissue and pathology. 
 
2.1.3 Repetition time (TR) and echo time (TE)  
 
Repetition time (TR) and echo time (TE) are principal parameters within MRI. They 
can be manipulated to generate images which are weighted toward T1, T2 or proton 
density (PD) (Table 2.1).   
 
In a spin echo sequence, signal intensity is given in the following equation: 
 
€ 
SI ∝ N(H)(1−e
−TR
T1 )(e
−TE
T2 ) 
 
SI=   Signal Intensity 
N(H)=   Proton Density 
TR=   Repetition Time 
TE=   Echo Time  
 
TR is the time elapsed between subsequent applications of the same pulse sequence 
(FIG 2.6). 
 
FIG 2.6 Pulse sequence diagram of a conventional spin echo (CSE) sequence. Net magnetization is 
reorientated into the X-Y plane as a result of the initial 900 RF pulse. This produces an oscillating 
signal which decays rapidly to T2 and T2* relaxation: free induction decay (FID). A subsequent 
1800 pulse rephases the protons, forming an echo which is received through the coil. The process is 
repeated a set number of times, the time between subsequent 900 pulses is the TR, and the time 
between 900 pulse and echo is TE. In reality, TR is of much greater magnitude than TE (3000-
4000ms for the former and <100ms for the latter) 
 
Lengthening the TR minimizes T1 weighting as follows: 
 
From: 
€ 
SI ∝ N(H)(1−e
−TR
T1 )(e
−TE
T2 ) 
 
as 
€ 
TR →∞, 
€ 
e
−TR
T1 →0, 
  
therefore 
€ 
SI →N(H)e
−TE
T2  
 
In other words, a sequence with a long TR will produce a signal intensity influenced 
preferentially by PD and T2. 
 
A long TR allows full T1 relaxation of protons between 90
o pulses, and minimizes the 
effect of different T1 properties of tissue. Conversely, a short TR maximizes differences 
between tissues with long (e.g. water) and short(e.g. fat) T1 by only allowing full 
relaxation of protons with short T1. Tissues with a short T1 will appear bright and those 
with a long T1 will appear dark on these so-called T1 weighted images.  
 
TE is the time elapsed between the 90
0 pulse and the reading of the signal formed from  
protons within the x-y plane, the so-called echo (FIG 2.6). Variation of TE  influences 
the amount of T2 weighting of an image, with a short TE minimising the T2 weighting of 
the sequence as follows: 
 
From: 
€ 
SI ∝ N(H)(1−e
−TR
T1 )(e
−TE
T2 ) 
 
as 
€ 
TE →0, 
€ 
e
−TE
T2 →1 
therefore  
€ 
SI →N(H)(1−e
−TR
T1 ) 
 
A sequence with a long TE accentuates the the differences in T2 between tissues by 
allowing relatively more dephasement (and therefore signal decay) in tissues with short 
T2 when the signal is received and read. In such a sequence, pixel intensity is positively  
related to T2, where tissues with longer T2 appear brighter than their counterparts.   
 
Both T1 and T2 effects can be minimised by applying a sequence with a long TR and 
short TE. Such as sequence is known as a proton density (PD) weighted sequence. Pixel 
intensity in this case is then related to the local concentration of free protons.  
 
Table 2.1 Manipulation of TR and TE to produce images of different weighting 
  TR  TE 
T1 weighted Image  Short  Short 
T2 weighted image  Long  Long 
PD weighted image  Long  Short 
 
2.1.4 Signal intensity of normal and pathological tissue on MRI   
 
CSF consists predominantly of free water and thus has a relatively long T1 and T2. 
Consequently, it appears dark on T1 weighted images and bright on T2 weighted images.  
 
WM primarily contains closely packed axons and myelin sheaths- consisting largely of 
fat and macromolecules with relatively short T1 and T2.  WM therefore appears brighter 
on T1 weighted images, and less bright on T2 weighted images compared with CSF.  
 
GM consists largely of cell bodies which are  a mixture of cytoplasm and 
macromolecules, resulting in an intermediate T1 and T2 (greater than WM and much less 
than CSF). This causes an intermediate signal intensity between the two on both T1- and 
T2-weighted sequences.  
 
In relation to surrounding WM, MS lesions appear hyperintense on T2 weighted images. 
This T2 hyperintensity represents a heterogenous pathology (Barkhof et al., 2003)  
including inflammation, gliosis, axonal loss and remyelination. MS lesions can appear 
isointense or hypointense on T1 weighted MRI, the latter either representing a 
population of lesions in which active inflammation and oedema occurs-  the “acute 
black holes” (ABH) (van Waesberghe et al., 1998; Bagnato et al., 2003) or more 
chronic lesions associated with gliosis and axonal loss- “persistent black holes” (PBH) 
(van Walderveen et al., 1998; van Waesberghe et al., 1999). 
 
2.1.5 Spatial Encoding 
 
The generation of anatomical images requires discernment of signal intensity at each 
location. This is performed through the imparting of spatial information into the 
received signal: so-called spatial encoding.  
 
Spatial encoding is achieved through 3 orthogonal gradient coils corresponding to the x, 
y and z axes (Gx,, Gy and Gz respectively). These coils apply magnetic field gradients 
along their axes at predetermined times in the pulse sequence (FIG 2.7).  
 
 
FIG 2.7 Pulse sequence diagram of CSE with orthogonal magnetic gradients Gs (slice select), Gp 
(phase encode) and Gf (frequency encode).  
 
  
 
FIG 2.8  x,y and z axes in relation to the patient. The specific application of the orthogonal 
magnetic gradients as slice select, frequency encode or phase encode gradient is dependent on slice 
orientation 
 
For axial slices, the slice select, phase encode and frequency encode gradients are along 
the  z, y and x axes respectively. However, magnetic gradients can be used 
interchangeably depending on the slice orientation (FIG 2.8) 
 
The slice select gradient is applied with the RF pulse (FIG 2.7) and causes a linear 
variation in precessional frequency along the z-axis. This allows selective excitation of 
the protons by the application of an RF pulse at the appropriate preceissional frequency, 
and  therefore specific x-y slice  selection.  
 
The frequency encoding gradient is applied during the echo, causing a linear increase in 
precessional frequency along the x-axis, such that each successive column of pixels 
precesses at a greater rate.  
 
The phase encode gradient is briefly applied between the 90
0 RF pulse and the echo. 
This transient gradient causes a brief variation in precessional frequency along the y 
  
axis, and when turned off, a linear variation in phase along the axis.  
 
The phase encode gradient is re-applied with increasing magnitude at each repetition 
within a sequence, the number of phase encoding steps in the sequence equal to the 
number of rows of pixels in the image matrix (typically 256). 
 
The result of the application of the above gradients is that the protons at each location 
within the selected slice will precess at their own unique phase and frequency 
depending on location within the x-y plane.  
 
2.1.6 k-space 
 
K-space is the data space in which the mathematically transformed signal is stored, and 
from which the image is constructed.  Each slice has its own k-space.  
 
In k-space, the received MR signal, or echo, is converted from the time domain to the 
frequency domain using a mathematical transformation called the fourier transform.  
Each transformed echo is then used to fill a row of k-space, the number of rows in k-
space being equivalent to the number of rows within the image matrix (and the number 
of phase encodes in the sequence).   
 
Echoes which fill rows in the centre of k-space have undergone the least dephasement 
and contain the highest signal. Rows further away from the centre are filled with echoes 
with increasing dephasement, such that rows at the edges of k-space contain the echoes 
which have undergone the largest phase encoding gradients. Thus, the centre of k-space  
contains most of the image signal, whereas the edges of k-space hold the finest 
anatomical detail. 
 
As frequency and phase correspond to pixel position, image construction is possible 
using the data in k-space, which is in the frequency domain and organised in terms of 
degree of dephasement. 
 
2.1.7 Image attributes 
 
Image parameters can be manipulated to influence image attributes. An example of this 
is the manipulation of TR and TE to influence image weighting (2.1.3). The following 
section describes further image attributes of relevance to the MR sequences employed 
in this thesis 
 
2.1.7.1 Field of View (FOV) 
 
The field of view (FOV) is the size of the area studied (FIG 2.9).  
 
FIG 2.9 The image matrix consists of rows along the x axis and columns along the y axis. FOVxand 
FOVy are the dimensions of the image along the x-axis and y-axis respectively. Typical FOV for an 
axial brain scan is 240mm X 240mm 
  
FOV of an axis is related to the magnetic gradient applied along it as follows: 
 
€ 
FOV ∝
BW
G
 
Where 
FOV= Field of View (mm) 
BW= Bandwidth (MHz) 
G= magnitude of gradient (Mhz/mm) 
 
 
The bandwidth is the range between the highest and lowest frequencies in the applied 
magnetic gradient. FOV increases with increasing bandwidth. FOV is inversely 
proportional to the magnitude, or steepness of the gradient applied. For a given 
bandwidth, a steeper gradient is associated with a smaller FOV. 
 
A typical FOV of 240mm by 240mm provides adequate brain coverage. 
 
  
2.1.7.2 Resolution 
 
Image resolution determines the level of detail in an image. It describes the number of 
distinct points (generally black and white line pairs) that can be discerned over 1mm 
(lp/mm). Resolution is inversely related to pixel size. 
 
Resolution is associated with the magnitude of the magnetic gradient, with steeper 
gradients resulting in higher resolution. A typical matrix along the phase and frequency 
encoding gradients is 256 columns and rows respectively (which approximates to an in-
plane resolution of 1mm
-1 using a standard 240 X 240mm field of view).  
 
2.1.7.3 Signal to Noise Ratio (SNR) 
 
Signal to noise ratio (SNR) is a measure of the signal strength relative to background 
noise. The higher the SNR, the more sensitive the sequence is at detecting subtle 
changes in tissue which may reflect early, subclinical pathological processes. SNR is 
given in the following formula: 
 
€ 
SNR ∝ (VoxelVolume)
(Np)(NEX)
BW
 
 
where 
SNR=  Signal to Noise Ratio 
Np=   Number of phase encoding steps 
NEX= Number of excitations 
BW=   Bandwidth 
  
SNR is proportional to voxel volume, in that larger voxels contain more protons, and 
therefore emit a proportionately higher amount of signal. Conversely, higher resolution 
(with smaller voxels) is associated with a lower SNR.  
 
SNR can be improved by repeating the sequence and averaging the signal. The number 
of times this is done is called the number of excitations (NEX).  A higher number of 
phase encoding steps (Np) (and therefore increasing the number of repetitions in a 
sequence) also increases the SNR. 
 
For a given voxel size and Np, SNR is inversely proportional to the square root of the 
bandwidth of the phase and frequency encoding gradients.  
 
2.1.7.4 Acquisition time 
 
Acquisition time is the time required to undertake the MR scan. A short acquisition time 
is of relevance in the scanning of subjects with limited tolerance for lying within the 
scanner for extended periods. Acquisition time in a CSE sequence is given by the 
following formula: 
 
TA= TR.NEX.Np 
where 
TA= Acquisition time  
TR= Repetition time 
NEX= number of excitations 
Np= number of phase encodes 
 
 
As shall be illustrated in the following sections, certain scan sequences can reduce  
acquisition time by alterations in the flip angle and in the manner in which k-space is 
filled. 
 
2.2 Imaging Sequences 
 
The following section will describe some of the sequences used in the ensuing chapters. 
 
2.2.1 Conventional Spin Echo Sequence (FIG 2.6; FIG 2.7) 
 
The CSE sequence is one of the most commonly used sequences in MRI studies of MS.  
Each repetition of the pulse sequence consists of an initial 90
0 RF pulse, followed 
shortly after by a 180
0 refocusing pulse 
 
The initial 90
o RF pulse shifts the net magnetization vector into the transverse plane, 
creating an oscillating transverse magnetization which decays due to loss of phase 
coherence from T2 and T2* decay. This initial decaying signal is the Free induction 
decay (FID).  
 
Loss of phase coherence from T2* relaxation is recaptured by applying a subsequent 
180
o (refocusing) pulse at time TE/2 after the 90
0 RF pulse. This pulse reverses the 
position of the magnetic vector and allows the protons spinning at different speeds due 
to external field inhomogeneities to regain phase coherence, generating a signal, or  
‘spin echo’ which is received and stored in k-space.  
  
In this thesis, CSE is employed in obtaining pre and post-contrast T1 weighted 
sequences (4.2.4; 6.2.2). 
 
2.2.2 Fast Spin Echo (FSE) Sequence 
 
In CSE sequences, a single phase encode is performed at each TR, which is then 
repeated by the number of phase encodes per image, most often 128 or 256. In FSE, 
instead of a single 180
o refocusing pulse, a string of such pulses can be employed within 
each TR to generate multiple echoes and therefore multiple phase encodes. (FIG 2.10) 
The number of echoes per repetition is the echo train length (ETL). 
 
Multiple echoes per TR gives rise to multiple TEs per TR, which could confound the T2 
weighting of the resultant image.  This is addressed by applying weighting onto echoes 
closest to the desired, or effective TE. Such echoes undergo the lowest phase encoding 
gradients, with increasing gradients dephasing echoes further away from the effective 
TE. The result is that while all echoes contribute to the image, echoes approximating the 
effective TE will have the highest amplitude and contribute most to the image contrast. 
The resultant image has a contrast very similar to that of a CSE with the same (real) TE. 
 
 
FIG 2.10 Multiple echoes per repetition in FSE sequence.  
 
  
As each echo fills a line of k-space, a number of lines per TR is filled, equivalent to the 
ETL. Image acquisition time is therefore a fraction of that in conventional spin echo.  
 
€ 
TA =
TR.NEX.Np
ETL
 
 
where 
TA= Acquisition time 
TR= Repetition time 
NEX= Number of excitations 
Np= Number of phase encodes 
ETL= Echo train length 
 
The main advantage of FSE is that it allows the acquisition of high resolution images 
using a short acquisition time, with the attendant advantages discussed above, as well as 
potentially reducing motion artifact. Magnetic susceptibility artefacts from metallic 
objects are also reduced due to the multiple spins. 
 
However, the greater number of echoes per repetition leaves a shorter inactive time 
period per repetition. This inactive time would normally be used in CSE to scan further 
slices. (FIG 2.11)  
 
  
FIG 2.11 TE<< TR in most sequences. Therefore, in a significant proportion of TR, no further 
activity occurs. This is the inactive time. In CSE, further slices are scanned during this inactive 
time. 
 
Therefore, slice coverage could potentially be compromised in FSE. In images where 
  
strong T1 weighting is not required, inactive time and therefore slice coverage can be 
increased by lengthening the TR.  
 
A further potential shortcoming of FSE is the deterioration of signal from echoes 
occuring later in the repetition. This is due to spin-spin interactions intrinsic within the 
imaged tissue (T2 decay) and occurs independent of the refocusing pulses. 
 
In this thesis, FSE is employed in the acquisition of PD weighted and T2 weighted scans 
in a phase III treatment trial involving natalizumab (4.2.4), and further studies on BBB 
integrity. (6.2.2; 7.2.2.1) 
 
2.2.3 Gradient Echo Sequences 
 
Gradient echo (GE) sequences employ a smaller flip angle  α. This results in a quicker 
restoration of longitudinal magnetization, allowing a shorter TR, and consequently a 
shorter acquisition time. No 180
0 refocusing pulse is employed, the application of which 
would result in an inversion of net magnetization along the z axis. This lack of 
refocusing pulse confers a greater magnetic susceptibility to the signal. The resultant 
echo undergoes T2* as opposed to T2 decay.  
 
Image contrast is determined by α, TR and TE. Small values of α cause quicker 
restoration of longitudinal magnetization, minimizing the contrast between tissues of 
differing T1 and reducing T1 weighting.  The converse is true with larger values of α. 
 
In this thesis, GE sequences are employed in the acquisition of T1 maps (7.2.2.1) and in  
the study of GM and WM atrophy (5.2.2) 
 
2.2.3.1 High resolution three dimensional gradient echo imaging. 
 
Three dimensional imaging employs an additional phase encoding gradient along the z 
(slice selection)-axis. This allows the acquisition of further data along the axis, and 
information is collected in three dimensional slabs, from which thin, contiguous slices 
are obtained. Small voxel size results in good spatial resolution, suitable for volumetric 
studies. Provided the voxels are isometric, slices can be reconstructed in any plane 
within the three dimesions.  
 
In this thesis, a three dimensional inversion-recovery prepared fast spoiled gradient 
recall (FSPGR) sequence is employed to undertake volumetric measurements of the 
brain. In this sequence, an inversion pulse is added and the inversion time (TI), that is , 
the time between the inversion pulse and subsequent 90
0 pulse,  can be varied to give 
further control over the degree of T1 contrast. The multi-planar nature of the sequence 
with short TE and TR increases slice number and SNR in a rapid time period.   
 
2.2.3.2 T1 estimation 
 
T1 measurement is a potential method of detecting subtle parenchymal abnormality.  
Within the context of MS, T1 has been found to be abnormally prolonged in lesions as 
well as NAWM (Stevenson et al, 2000; Parry et al., 2002). The measurement of 
changes in T1 after administration of Gd in dynamic contrast enhanced also provide a  
potential method of investigating perfusion and BBB leakage (Parker and Padhani, 
2003) 
 
There are a number of approaches which can be adopted to measure T1. The gold 
standard utilises an inversion recovery sequence, in which a 180
0 pulse is employed to 
invert the net magnetization.  A subsequent 90
0 pulse is then applied at  inversion time 
TI, tipping the direction of magnetization onto the transverse plane and forming an FID, 
from whose amplitude the longitudinal magnetization can be measured. The process is 
repeated a number of times with varying TI. T1 is then estimated by solving the 
following equation: 
€ 
S(TI) = S0(1−2e
−TI
T1 ) 
Where 
S(TI)= Signal measured at time TI 
S0= Signal that would be acquired if 90
0 pulse were applied without inversion pulse ie 
base magnetization 
TI= inversion time 
 
In order to obtain a T1 map (as opposed to a single T1 measure for the area imaged), the 
signal is phase and frequency encoded, and the sequence is repeated Np times. To allow 
for adequate relaxation between inversion pulses, TR should be at least 5 times greater 
than T1. Acquisition time, which is the product of Np, number of inversions and TR, can 
sometimes become prohibitively long. 
 
The ratio of SI from two images (in which TR or flip angle is varied) can be used to 
estimate T1 using a look-up table. This so-called 2 point method offers the possibility of 
the construction of a T1 map with a shorter acquisition time than the inversion recovery 
approach. Unfortunately, 2 point methods are more susceptible to artefact from non- 
uniformities in the RF pulse.  
 
The method of obtaining T1 maps in this thesis adopts a 2 point approach (using T1 
weighted and PD weighted GE sequences) which corrects for RF profile non-uniformity 
by employing a  knowledge of the RF pulse profile and a map of the coil transmission 
B1 distribution. This method estimates T1 to an accuracy of 1.4% and a precision of 3%. 
(Parker et al., 2001) 
 
2.3 The use of MRI in clinical trials 
 
Trials based solely on existing clinical scales, such as EDSS and MSFC require large 
patient populations and need to be of sufficient duration to be adequately powered. The 
clinical scales employed, such as EDSS, although helpful, are frequently weighted 
towards locomotor function, and have poor reproducibility and sensitivity to change 
(Willoughby and Paty, 1988; Sharrack and Hughes, 1996). Even when combined with 
multi-domain clinical measures such as MSFC, such scales may lack the sensitivity to 
accurately reflect disease progress such as is seen in the complex and variable nature of 
MS. The advantage of MRI is in the provision of objective, reproducible measures, 
which are sensitive to pathological change.  
 
MRI measures also provide the potential for reducing the size of population cohorts 
required in drug trials: Based on a protocol of monthly Gd enhanced imaging in a 
placebo controlled parallel group design over 6 months involving patients with either 
RRMS or SPMS, it was demonstrated that in order to detect a 70% reduction in disease 
activity, a trial of 2X30 RRMS or 2X50 SPMS patients will be sufficient. With the  
addition of pre-treatment scans, the trial size could be further reduced (2X20 and 2X30 
for RRMS and SPMS patients respectively (Tubridy et al., 1998a). The use of MRI as a 
surrogate marker therefore represents an attractive complement to existing clinical 
indices.  
 
However, for such a role to exist, there needs to be a demonstration of correlation 
between the MR parameter and clinical outcome, with a robust prediction of clinical 
effect from the MR outcome studied. As previously discussed, MR parameters are 
presently used only as secondary endpoints in phase III studies, mainly because of the 
as yet limited relationship between clinical and MR markers of progression (McFarland 
et al., 2002). With the increasing range of quantitative MRI parameters and 
improvements in sequence methodology, further evaluation of cohorts in systemic 
cross-sectional and longitudinal studies and in well defined population groups may 
improve correlations with clinical disability. Should MRI outcomes eventually gain 
acceptance as primary endpoints in phase III studies, a potential benefit would be to 
increase the statistical power of clinical trials and reduce the cohort sizes required. The 
following sections will describe some of the MRI based measures of disease activity 
and progression employed in this study. 
 
2.3.1 Gadolinium enhanced MRI 
 
Gadolinium (Gd) is a paramagnetic element, that is, in an externally applied magnetic 
field, it enhances the relaxation of surrounding protons, resulting in a high signal on T1 
weighted imaging. In its chelated form (Gd-DTPA) (Mitchell, 1997), it is used as a 
contrast agent in MRI. In a combined MRI-pathology study of EAE- an animal model  
for MS- Gd enhancement in lesions was correlated with histopathological evidence for 
BBB breakdown using the marker horseradish peroxidase (Hawkins CP et al., 1990). 
Histo-MRI correlative studies show that Gd enhancing lesions exhibit local 
inflammatory features. (Katz et al., 1993; Bruck et al., 1997). Serial analysis studies  
indicate that Gd enhancement is a consistent feature of new lesions (Bastianello et al., 
1990;  Lai et al., 1996; Tortorella et al., 1998). Gd enhancement lasts approximately 4-6 
weeks in new lesions (Miller DH et al., 1988; Barkhof et al., 1992; Thompson et al., 
1992; McFarland et al., 1992; Smith ME et al., 1993). Such lesions are also more 
commonly seen in relapses (Grossman et al., 1986; Tubridy et al., 1998b), although the 
majority of such lesions are clinically silent.(Harris JO et al., 1991; Thompson  et al., 
1992). Lesions are more likely to result in a relapse if they are located in a clinically 
eloquent place, such as the spinal cord (Thorpe et al., 1996) and optic nerves (Youl et 
al., 1991; Hickman et al., 2004). A meta analysis of 9 studies showed that the relapse 
rate in a year was weakly related with the number of Gd lesions in the first 6 months 
(Kappos et al., 1999). The number of  Gd enhancing lesions correlate moderately with 
the number of Gd enhancing lesions in the ensuing 11 months (Molyneux et al., 1998). 
 
Serial Gd enhanced MRI has been used as a primary outcome measure in phase II trials 
of RRMS and SPMS (Paty and Li, 1993; Durelli et al., 1994; Stone et al., 1997; Jacobs 
et al., 1996; Pozzilli et al., 1996; Moreau et al., 1994, Sipe et al., 1994; Edan et al., 
1997; Karussis et al., 1996; Mancardi et al., 1998). The utility of Gd enhanced MRI is 
as a marker of inflammation, and indirectly, of the underlying processes which cause 
clinical relapses. This is supported by the generally concordant effect which exists of 
disease modifying therapy reducing both relapses and Gd enhancing lesions, although 
the magnitude of the effect on each may differ.  
 
Although more enhancement is potentially picked up by increasing the frequency of the 
scans to once a week (Lai et al., 1996), modifying the dosage of Gd (Fillipi et al.,1996), 
or employing the use of additional MT sequences (Silver et al., 1997), such changes 
also introduce a proportionate increase in variability of activity between subjects, which 
counterbalances the greater number of Gd enhancing lesions picked up, conferring no 
net benefit in terms of sample size requirements for phase II trials. (Silver et al., 2001a) 
 
Gd enhancement as detected in monthly scans is therefore best regarded as a proof-of-
concept marker for identifying agents that have the potential to reduce relapse rate in 
relapsing MS. The utility of Gd enhanced MRI in clinical trials is also tempered by the 
finding that the correlation of enhancement with clinical disability over the medium or 
longer term is poor or even absent (Kappos et al., 1999). 
 
2.3.2 Total T2 lesion load 
 
T2 weighted MRI is sensitive in detecting focal MS lesions in the WM, and total T2 
lesion load is the most established MR surrogate. As serial studies on RRMS 
demonstrate that almost all new T2 lesions start as Gd enhancing lesions, T2 lesion load 
can be seen as a plausible marker of the total amount of inflammation to date. An 
exception to this would be in advanced disease and in progressive MS, where the 
association between new T2 lesions and BBB breakdown is less strong (Thompson et 
al., 1991).  
 
Nonetheless, studies of early relapse-onset MS show that volume of T2 lesions in the 1
st  
14 years is at least partly related to concurrent and to disability at timepoints up to 20 
years, with the greatest correlation between lesion load and disability occuring within 
the 1
st 5 years of disease (Brex et al., 2002; Fisniku et al., 2008a).  
 
Relapse rate in the early years has also been related to time to develop moderate 
disability (EDSS 4) but not more severe disability (Confavreux et al., 2000; 2003). 
 
Although Gd enhancement and T2 lesions can be related to relapses, the relationship 
with long term disability is modest (Kappos et al., 1999; Truyen et al., 1996; Mammi  et 
al., 1996; Gawne-Caine et al., 1998, Riahi et al., 1998). The imperfect correlation with 
disability can be demonstrated in lesions in corticospinal tracts, indicating that lesions in 
such tracts alone are insufficient in accounting for all disability (Riahi  et al., 1998). 
Interestingly, there is little correlation between cord lesion volume and EDSS (Kidd et 
al., 1993).   
 
Reasons for the discrepancy between radiological findings and clinical indices include 
limitations of the EDSS previously alluded to in chapter 1. In addition, T2 hyperintense 
lesions represent quite heterogeneous pathology, including variable amounts of acute 
inflammation, axonal loss and remyelination (Barkhof et al., 2003). There is also 
growing evidence of pathology in the NAWM (Trapp et al., 1988;  Werring et al., 1999; 
Stevenson et al., 2000). Similarly, the contribution of cortical lesions to the total disease 
burden is being increasingly recognised (Pirko et al., 2007; Kutzelnigg et al., 2005), 
many such lesions being invisible on standard MRI sequences (Guerts et al., ; Kidd et 
al., 1999).  
  
Taken together it would appear that focal inflammation inferred from the development 
of new/enhancing MRI lesions may only partially predict short and medium term 
relapses but less so later disability.  
 
2.3.3 T1 hypointense lesions 
 
Roughly 20-30% of T2 lesions appear hypointense to surrounding NAWM on T1 
weighted imaging. Such T1 hypointense lesions  are associated with a greater degree of 
demyelination and extracellular matrix disruption than their T1 isointense counterparts. 
T1 hypointense lesion load correlates well with T2 lesion load (O’Riordan et al., 1998). 
These lesions may be associated with oedema and lymphocytic infiltration (Bruck et al., 
1997) or with axonal damage and extracellular matrix disruption (van Walderveen et 
al., 1998) depending on the stage of evolution of the lesion itself.  
 
T1 hypointense lesion volume has been shown to correlate more closely with disability 
and progression than more conventional MRI markers of disease such as T2 lesion load 
(Truyen et al., 1996; van Walderveen et al., 2001). In-vivo spectroscopy studies of T1 
hypointense lesions reveal lower concentrations of the neuronal marker N-acetyl 
aspartate (van Walderveen et al., 1999). Further evidence of axonal loss associated with 
such lesions is provided by the relation between T1 hypointense lesions and atrophy 
(Sailer et al., 2001). Magnetisation transfer ratio (MTR) is also significantly lower in T1 
hypointense lesions (Hiehle et al., 1995), suggesting a greater degree of demyelination 
than lesions which are T1 isointense. Histological studies show a greater degree of 
demyelination, axonal loss and extracellular matrix disruption in T1-hypointense lesions 
(van Walderveen et al., 1999; van Waesberghe et al., 1999; Bruck et al., 1997; Barkhof  
et al., 2003), than in T2 lesions which are T1 isointense, wherein remyelination tends to 
be a more common feature (Barkhof et al., 2003).  
 
It may be useful to monitor conversion of individual Gd enhancing lesions into more 
persistent T1 hypointense lesions as a surrogate marker for poor recovery from relapses. 
Glatiramer acetate (Filippi et al., 2001) and Natalizumab (Dalton et al., 2004a), but not 
IFNβ (Brex et al., 2001) have been reported to reduce the conversion of Gd 
enhancement into permanent T1 hypointense lesions 
 
2.3.4 Volumetric measures 
 
Sequential volumetric MRI measures of the brain provide a reproducible and often 
sensitive marker of brain tissue loss (atrophy), and have been used in the study of 
neurodegenerative diseases such as Alzheimer disease (Fox and Freeborough, 1997). In 
MS, this approach has facilitated in vivo studies of brain atrophy (Anderson et al., 
2006). 
 
Axons and myelin constitute the largest volume in WM, with GM consisting mostly  of 
neuronal cell bodies, axons and myelin. (Miller DH, 2004) It follows that volume loss in 
MS likely reflects loss of axons and neurones, a process which contributes to permanent 
disability progression. An important caveat is that within the setting of acute 
inflammation, the volume loss from such neuro-axonal degeneration may be masked by 
a concommitant increase in oedema, and latterly gliosis.  Similarly, acute reduction in 
volume may reflect the resolution of oedema, rather than neuronal loss. For this reason, 
any therapeutic trial using brain atrophy as a measure has to take into account the effect  
of the agent on inflammation and the subsequent impact on volumetric measures.  
 
In general, 3D sequences are more reliable than 2D sequences in volumetric 
measurements due to a lower dependence on slice re-orientation and easier 
segmentation (Sharma et al., 2004). A number of measures have been adopted in the 
estimation of brain volume loss, including ventricular enlargement (Sharma et al., 2004; 
Turner et al., 2001) to brain width (Simon et al., 1999) and corpus callosum cross 
sectional area (Paolillo et al., 2000). Methods which adopt GM, WM and BP volume as 
measures have to overcome the problem of accurate segmentation of the brain from 
surrounding tissue and indeed the individual segments from each other. This is most 
efficiently achieved through semi or fully automated thresholding techniques (Rudick et 
al., 1999; Smith SM et al., 2002; Ashburner and Friston, 1997; Ashburner and Friston, 
2000). Normalization to head size should be performed because small volume changes 
tend to be masked by the biological interindividual variability in absolute brain 
volumes. Normalization methods include standardizing to the scalp (Freeborough and 
Fox, 1997) or to a calculated total intracranial volume (Chard et al., 2002a). Volume 
change can then be estimated by comparison of calculated normalized volumes in 
consecutive scans This is the method adopted in this thesis. 
 
CIS patients who develop MS have significantly greater atrophy than their counterparts 
who do not develop MS (Brex et al., 2000; Dalton et al., 2002b, Filippi, 2004). The 
volume loss is predominantly in the GM (Dalton et al., 2004b) and is associated with 
previous inflammatory lesion load (Paolillo et al., 2004).  Atrophy of about 10-15%, as 
measured by optic nerve cross sectional area reduction is also seen in patients with 
isolated optic neuritis (Hickman et al., 2001).  
 
Brain volumes in RRMS patients are consistently lower than their healthy counterparts 
(Chard et al., 2002a; Bermel et al., 2003; De Stefano et al., 2003; Lin et al., 2003a). In 
early MS, volume loss appears once more to be most pronounced in GM (Tiberio et al., 
2005). 
 
A number of studies have indicated a greater degree of atrophy in progressive MS 
patients than those with RRMS (Stevenson et al., 1998; Kalkers et al., 2001; Lin et al., 
2003a; Dalton et al.,  2006; Fisher et al., 2008; Fisniku et al., 2008b). Some studies 
indicate a correlation between atrophy in SPMS and disability (Kalkers et al.,  2001; 
Lin et al., 2003b; Fisniku et al., 2008b; Fisher et al., 2008). Taken together, these 
studies point to a considerable correlation between GM atrophy and disease progression 
and disability. Longer follow up studies of 5 years also indicate ongoing atrophy in 
patients with primary progressive MS, as measured by ventricular enlargement and cord 
cross sectional area, which was correlated with ongoing EDSS progression (Ingle et al., 
2003).  
 
Thus, using a number of volumetric measures, atrophy is demonstrable in the earliest 
stages of MS. Such atrophy has a moderate relation with disability progression and is 
the preferred method at present for monitoring neurodegeneration. It is therefore 
frequently used as an outcome measure in therapeutic trials within MS. 
 
In a IFNβ trial of RRMS patients, brain volume was analysed 6 months prior to and 24 
months after starting IFNβ. Reduction in brain volume weakly correlated with Gd 
lesions on the 6 months pre-treatment monthly scans. A weak association was also  
detected between disability and atrophy (Gasperini et al., 2002). However, there was no 
difference in volume change between treatment groups. The finding of an association 
between disability and atrophy was in agreement with those of previous studies (Losseff 
et al., 1996; Paolillo et al., 1999).  
 
Another 2 year trial examined the effect of IFNβ on the brain parenchymal fraction 
(BPF), a derived measure of the total volume of the brain, divided by the total 
intracranial volume. BPF decrease was noted to be smaller in the IFNβ arm in year 2 
(Rudick  et al., 1999) but there was little correlation with lesion measures. An 8 year 
follow up of this study found that those with greater atrophy in the 1
st 2 years were more 
likely to develop severe disability in the long term (Fisher et al., 2002).  
 
A trial of glatiramer acetate on 239 patients showed over 9 months a 0.7-0.8% reduction 
in central cerebral volume with no patient group differences (Rovaris et al., 2001).  
 
Overall, there  is little evidence to suggest that any of the existing anti-inflammatory 
agents to date have a robust effect on volume change.  
 
2.3.5 Detection of low grade BBB leakage 
 
2.3.5.1 Evidence for BBB leakage in MS lesions 
 
BBB disruption is evident in active lesions from visible Gd enhancement. In chapters 6 
and 7 of this thesis, changes following the administration of triple dose Gd are studied  
to infer low grade BBB leakage in non- visibly enhancing lesions.  
 
Tryptan blue dye injected supravitally has provided evidence of detectable BBB 
disruption, mainly in acute lesions, but also to a lesser degree in chronic lesions 
(Broman, 1964). Histological studies in the 1980’s demonstrated perivenular fibrinous 
exudates and lymphocytic infiltration in acute and to a lesser extent chronic lesions, 
providing histological evidence of both widespread BBB leakage and inflammation in 
MS lesions (Adams et al., 1985). In addition, the detection of extravascular deposits of 
fibrin in chronic lesions further support the presence of low grade BBB leakage in such 
lesions (Kwon et al., 1994; Claudio et al., 1995). An as yet unproven hypothesis is that 
low grade BBB disruption in non-visibly lesions could lead to the leakage of pathogenic 
mediators of tissue damage (e.g. inflammatory cytokines) that contribute to 
demyelination and axonal loss, and hence disability. It is therefore of interest and 
relevance to study low grade leakage in such lesions. 
 
The use of Gd enhanced MRI studies to detect focal BBB disruption in new or actively 
inflamed MS lesions has been described previously.  
 
Quantitative investigations, where the Gd mediated change is measured, could facilitate 
the detection of more subtle, low grade BBB leakage. Such studies have been performed 
in the ischaemic rat brain (Harris NG et al., 2002) and intracranial tumours (Zhu et al., 
2000). Using the proportional change of T1 weighted signal intensity as a marker for 
BBB leakage, Gd-DTPA enhanced studies on MS lesions have demonstrated subtle 
leakage from visibly non-enhancing lesions up to 40 minutes following the 
administration of Gd-DTPA. (Silver et al., 2001b). This method has been adopted in  
Chapter 6 of this thesis in which the effect of natalizumab, a VLA4 antagonist, on low 
grade BBB leakage was determined.  
 
2.3.5.2 Using ΔR1/Δt as an index of BBB leakage 
 
Longitudinal relaxation rate (R1), is the inverse of T1. The change in R1 following Gd 
administration, or ΔR1, is described in the following equation: 
 
€ 
ΔR1 =
1
T 1
−
1
T 1(0)
= r 1Ct(t) 
 
where 
Ct(t)= local concentration of Gd at time t following its administration (mM) 
T1  = T1  at the time t following Gd administration (s) 
T10 = T1 before Gd administration, or native T1 (s) 
 r1 is the relaxivity of Gd, a constant (s
-1mM
-1) 
 
 
 From in-vitro studies, r1 for Gd- DTPA is estimated as 4.5 s
-1mM
-1 (Tofts and 
Kermode, 1991; Tofts et al., 1999).  
 
The gradient of ΔR1 over time elapsed (ΔR1/Δt) is proportional to the change in local Gd 
concentration over time and can serve as a quantitative marker for BBB leakage which 
is more sensitive and potentially more reproducible than measuring change in T1 
weighted signal intensity per se. The usage of this marker to measure low grade leakage 
in RRMS and SPMS will explored in chapter 7 of this thesis.  
  
2.4 Methods employed in analysis 
 
2.4.1 Region of interest analysis 
 
A region of interest (ROI) is a subset of pixels within the image defined by manually or 
automatically applied boundaries, and selected for further analysis. ROIs may be used 
to delineate MS lesions or anatomical structures (for instance deep gray matter).  
 
The total volume encompassed within ROIs applied to MRI visible lesions can be 
calculated to infer a total MS lesion load. In addition, to look for changes over time, 
ROIs applied to an initial image can be re-applied to spatially registered successive 
images.   
 
A semi-automated method is adopted in the delineation of lesions in this thesis 
(Plummer, 1992). This employs a local thresholding technique based upon local 
environmental intensity within the lesion. The operator places the cursor at or near the 
edge of the object of interest, from which an outline of the object is provided by 
adopting an algorithm based on locating, in successive iterations, the “strongest edge 
point”,  that is, the points representing the greatest change in intensity from one pixel to 
another.  This approach provides an intra-rater coefficient of variation (CoV) of 2.5 ± 
2.1 and inter-rater CoV of 4.5 ± 1.6. (Grimaud et al., 1996) 
 
 
  
2.4.2  Spatial Registration 
 
Registration is the process in which electronic images are aligned with each other. In 
doing  so,  common  features  overlap  and  differences  between    images  are  readily 
identifiable and measurable. Intrasubject registration in longitudinal studies can help to 
overcome small positioning errors and allows comparison of images taken across a time 
interval.  Across-subject  (inter-subject)  registration  allows  pooling  of  images  from 
different subjects, such that group comparisons can be made. 
 
Registration transforms an image (target image) such that it is spatially aligned with its 
counterpart (source/reference image).  This spatial transformation may preserve the 
distance between all points within the image, known as rigid body registration, in which 
the target image is translated and rotated to best fit the the source image. Alternatively, 
it may allow for a global change of scale and shear, known as affine or non-rigid 
transformation. This latter form of registration more closely approximates the behaviour 
of biological systems, and is the form of registration adopted in the studies described in 
this thesis.  
 
2.4.3 Segmentation 
 
Segmentation is the process of dividing an image into distinct tissue segments, ie the 
GM, WM and CSF in the brain. Together with ROI based analysis, it facilitates more 
detailed study of specific brain segments, including analysis of segmental atrophy. 
 
Automated approaches toward segmentation are favoured because of a high degree of  
reproducibility and reduced operator bias.  
 
Segmentation of the brain into GM, WM and CSF is achieved in this thesis using 
statistical parametric mapping (SPM) (Ashburner and Friston, 1997; 2000). This 
employs a general linear model with Gaussian field theory to make inferences about 
regional effects. Brain tissue types are identified by intensity thresholding, and 
intensities are then remodelled by a mixture of K Gaussian distributions, parameterised 
by means, variances and mixing proportions. Segmentation is assisted by overlying 
probability maps derived from segmented images of healthy subjects assumed to be 
representative (Montreal neurological institute brain template). It is a process which 
requires initial registration of the images to standard space.  
 
However, this approach may be affected by partial volume error interfering with the 
Gaussian distribution. Mis-registration with the prior probability images, based entirely 
on relatively young and healthy brains rather than on subjects with neurological disease 
can be another source of error. The segmentation is at risk of failing if the contrast in 
the relevant image is poor. Misclassification of lesions can also occur, and indeed often 
does unless additional lesion-masking strategies are employed (Chard et al., 2002b).  
 
Based on these potential pitfalls, the sequences that lend themselves the most to 
automated segmentation are high resolution, high contrast volumetric data sets, such as 
three dimensional IR prepared FSPGR. When SPM segmentation has been applied to 
these sequences, scan-rescan volume CoVs of 0.5%, 0.7% and 1.1% for brain 
parenchymal, GM and WM segments respectively have been achieved (Chard et al., 
2002b).  
 
2.5 Summary 
 
MRI is a sensitive and objective measure of evolving MS pathology in vivo, with the 
potential to reduce the number of patients required to demonstrate a treatment effect in 
drug trials. However, its applicability as a primary outcome measure in phase III trials is 
limited by the imperfect correlation with disability. Gd enhancement and T2 lesion load 
reflect relapses and history of relapses, especially in early disease. T1 lesion load – or at 
least its persistent, non-reversible component - may to an extent reflect accumulated 
disability from relapses. Volumetric measurements (extent and rate of atrophy) provide 
inferential information on myelin and axonal loss that may occur in parallel with clinical 
disease progression, although the sensitivity of such measures may be affected by 
fluctuations in inflammation. Quantitative measures of Gd enhancement provide a 
potentially useful tool to detect subtle BBB disruption, the significance of which is as 
yet uncertain. 
 
 
 
 
 
 
 
 
 
  
CHAPTER 3 
 
The Blood-brain barrier, α4β1 integrin and Natalizumab 
 
3.1 The blood-brain barrier 
 
3.1.1 Introduction and History 
 
The BBB is an anatomical and biochemical barrier of the brain microvasculature, 
situated at the level of the endothelium. It serves to regulate the exchange of substances 
between the blood and the brain, and in doing so performs a protective function by 
controlling the influx of neurotransmitters and potential toxins from the blood.  
 
The concept of the BBB first emerged with the discovery  by Paul Ehrlich that aniline 
dyes  injected intravenously stained somatic organs, but not the brain (Ehrlich, 1885). 
Shortly after, Lewandowsky postulated the existence of the BBB, or bluthirnschranke, 
while studying potassium ferrocyanide penetration into the brain (Lewandowsky, 1900).  
Edwin Goldmann, a student of Ehrlich, demonstrated that tryptan blue dye injected 
intrathecally stained the brain but not the somatic organs, providing further evidence for 
a barrier between the blood and the brain which was impermeable to all but small 
molecules (Goldmann 1914). Electron microscopic studies in the late 1960's and early 
1970's demonstrated that intrathecally injected horseradish peroxidase, a substance to 
which the BBB is impermeable, traversed the astrocytic foot processes without crossing 
the endothelium, locating the BBB principally at the level of the endothelium.  
(Brightman and Reese, 1969)  
 
Because of the low permeability to charged particles, trans-endothelial electrical 
resistance is much greater across the BBB than across endothelium in somatic 
capillaries (Crone and Christensen, 1981; Crone and Olesen, 1982). Electrical resistance 
studies have been useful in determining the integrity of the BBB in endothelia in vitro 
and have been employed to study the development of the BBB in neonatal rats (Butt et 
al., 1990) 
 
3.1.2 Anatomy  
 
The BBB is present in more than 99% of the capillaries of the brain (de Vries et al., 
1997), covering an enormous surface area of roughly 100- 180cm
2/g of brain tissue.  In 
certain areas, it is replaced by a blood-CSF barrier, which, although more permeable 
than the BBB, still prevents the entry of many blood borne compounds into the CSF and 
hence the brain. This occurs in areas which serve a neurosecretory function, such as the 
posterior pituitary gland, and in areas which perform a chemoreceptive function, such as 
the circumventricular organs.  
 
3.1.3 Constituents of the blood-brain barrier 
 
A typical capillary in the brain consists of an endothelial layer, which, together with 
abluminal pericytes, is enveloped by a basement membrane, the basal lamina. 
Astrocytes communicate with this unit by astrocytic foot processes (FIG 3.1)  
 
 
FIG 3.1 Schematic cross section of a brain capillary 
 
3.1.3.1 Endothelium 
 
The endothelium in a typical brain capillary differs from its somatic counterparts in a 
number of respects. They lack fenestrations (Fenstermacher et al., 1988), which are 
trans-endothelial openings through which substances can flow.  There is also a paucity 
of pinocytic vesicles (Coomber and Stewart, 1985; Sedlakova et al., 1999), and a high 
concentration of mitochondria (Oldendorf and Brown, 1975; Oldendorf et al., 1977), 
related to the large number of energy dependent transcapillary transport systems at the 
level of the BBB. The neutralisation of blood-borne substances which may interfere 
with normal brain function, such as  catecholamines and other neurotransmitters,  is  
carried out by the enzymatic barrier at the level of the endothelium (Minn et al., 1991). 
The asymmetry in the luminal/abluminal distribution of the enzymes and channels such 
as Na/K ATPase results in the generation of a transendothelial polarity.  
 
The most significant difference between endothelial cells in the brain and in the body is 
the abundance of transmembrane protein complexes which cause the adhesion of 
adjacent endothelial cells. These so-called junctional complexes were first described 
from electron microscopic studies on the rat and guinea pig (Farquhar and Palade, 
1963). Junctional complexes form interconnected, intermembrane strands arranged as a 
series of multiple barriers to paracellular diffusion of molecules (Schneeberger and 
Karnovsky, 1976).  
 
There are two main subtypes of junctional complexes: adherens junctions (zonula 
adherens) and tight junctions (zonula occludens).  
 
Adherens junctions consist mainly of calcium dependent cell surface molecules known 
as cadherins. They are thought to play a role in the modulation of cell polarity, cell-cell 
interaction and paracellular permeability.  
 
Tight junctions are the most abundant form of junctional complexes at the BBB, and 
together with the endothelial cell layer, form the anatomical basis of the BBB. In vitro 
studies on endothelial cell cultures demonstrated a reduction in permeability to sucrose 
associated with an induced increased expression of tight junctions (Romero et al., 
2003). In addition, horseradish peroxidase, a marker of BBB integrity, is stopped at the 
level of the tight junction (Sedlakova et al., 1999).    
 
Tight junctions consist of:  
 
1. Junctional adhesion molecules: thought to mediate adhesion at cell apices and 
contribute to paracellular permeability 
 
2. Occludins: which form the structural basis of tight junctions and which interact with 
the cytoskeleton via membrane associated guanylate kinase proteins  
 
3. Claudins: which form strong homologous dimers with claudins on adjacent 
endothelial cells. 
 
In addition to the junctional complexes, gap junctions exist between endothelial cells, 
which facilitate cell-cell communications (Bazzoni and Dejana, 2004) 
 
3.1.3.2 Pericytes 
 
Pericytes are located on the abluminal surface of the endothelium, and together with the 
endothelial layer are ensheathed by the basement membrane. They are thought to 
facilitate endothelial-astrocyte interaction (Ramsauer et al., 2002). In vitro studies (Hori 
et al., 2004) also indicate that pericytes stimulate the manufacture of occludin, a 
constituent protein in tight junctions. Finally, evidence of the contractile protein α actin 
in pericytes in vitro (Bandopadhyay et al., 2001) also suggests an additional role for 
pericytes which is not dissimilar to that of smooth muscle in larger blood vessels. 
  
3.1.3.3 Basal Lamina 
 
The basal lamina is the extracellular matrix on the abluminal surface of the 
endothelium. It is trilaminar in structure, with an endothelial layer (lamina rara interna), 
an astrocytic layer (lamina rara externa) and an intermediate layer consisting mainly of 
the structural constituent, collagen type IV. It provides physical support to microvessels, 
and provides the anchor for endothelial cells via the interaction of proteins intrinsic to 
the basal lamina such as laminin and integrin receptors on endothelial cells (Hawkins 
BT et al., 2005). Proteins found in basal lamina also modulate the expression of 
occludin in endothelial cells (Savettieri et al., 2000) and can stimulate high electrical 
resistance in endothelial cells in vitro (Tilling et al., 1998). The basal lamina also filters 
macromolecules and therefore affords a degree of protection to the brain against 
extravasated proteins. 
 
3.1.3.4 Astrocytes and Neurons 
 
Astrocytes belong to a subgroup of glial cells, which have a star-shaped morphology. 
They are characterized by long processes which form close apposition with synapses 
and blood vessels. The proximity of astrocytic foot processes with brain 
microvasculature is thought to induce BBB characteristics in the endothelium (Stewart 
and Wiley, 1981; Tao-Cheng et al., 1987, Neuhaus et al., 1991). In addition, their 
continued association with endothelial cells is necessary for the maintenance of the 
BBB phenotype, with the injection of gliotoxic substances causing a consequent BBB 
breakdown (Bondan et al., 2002). Astrocytes are thought to induce changes in 
endothelium through secreted factors (Maxwell et al., 1987), possibly through  
substances such as nitric oxide, endothelin and TNF α (Abbott et al., 2006).  
 
Although the interaction between neurons and the microvasculature is less well 
understood than that of astrocytes, there is evidence of direct innervation of the 
neurovasculature (Cohen et al., 1997; Tong and Hamel, 2000; Vaucher et al., 1997). 
However, the significance of the role of neurons in inducing or maintaining the integrity 
of the BBB is unclear. 
 
3.1.4 Transport across the BBB 
 
The controlled transit of substances across the BBB between the brain parenchyma and 
blood is essential for normal brain function. This is achieved by a variety of 
mechanisms, depending on the fat- solubility of the substance in question.  
 
Efficient exchange of lipid soluble gases such as O2 and CO2 occurs through direct 
diffusion across the BBB, driven by concentration differences between brain and blood. 
The permeability coefficient of the BBB for many substances is directly proportional to 
the lipid solubility of the substance. 
 
For water soluble, or lipophobic molecules, transport across the BBB occurs through 
specific carrier-mediated transport systems. For instance, glucose is transported 
primarily through the GLUT1 transport system. Three distinct carrier systems exist for 
the transport of amino acids. These are the L, A and ASC systems, each system 
transporting a different set of amino acids depending on the polarity and size of the 
amino acids concerned. MDR transmembrane proteins, or P-glycoproteins, are thought  
to be involved in the expulsion of harmful substances, and MDR deletion mice are more 
sensitive to circulating neurotoxins such as ivermectin (Schinkel et al., 1994). 
Electrolyte balance and trans-BBB polarity is maintained by specific ion channels and 
transporters, especially a high concentration of Na/K ATPase exchange transporters on 
the abluminal surface of the endothlial layer. 
 
3.1.5 Pathological BBB disruption 
 
Besides BBB disruption in MS, BBB disruption also occurs in a wide range of 
conditions, as listed below. 
•  Tumours (Davies, 2002) 
•  Trauma (Povlishock et al., 1978) 
•  Infection (Clawson et al., 1966) 
•  Ischaemic Injury (Kuroiwa et al., 1988) 
•  Alzheimer’s Disease (Berzin et al., 2000) 
•  Epileptic seizures (Cornford and Oldendorf, 1986) 
•  Diabetes Mellitus (Mooradian, 1997) 
 
Hypoxia induces BBB leakage (Kempski, 2001; Witt et al., 2003), and vasogenic 
oedema frequently follows ischaemia-reperfusion events. A number of possible 
mechanisms for BBB disruption in hypoxia have been proposed, including tight 
junction disruption (Mark and Davis, 2002; Fischer S et al., 2002) and increased 
transcellular pathways (Cipolla et al., 2004; Plateel et al., 2004). Also thought to be 
involved in the process are nitric oxide (Mark et al., 2004) and vascular endothelial 
growth factor (VEGF) ( Fischer S et al., 2002 ). Co-culture with astrocytes and  
pericytes has been observed to ameliorate the effects of hypoxia on BBB disruption 
(Abbruscato and Davis, 1999; Fischer S et al., 2000; Hayashi et al., 2004). In this 
respect, astrocytes and pericytes may play a protective role against hypoxic insult.   
 
BBB disruption is also well recognised in the two commonest intracranial malignancies: 
high grade gliomas and metastatic adenocarcinoma. BBB leakage in these 
circumstances leads to the vasogenic oedema which contributes to the morbidity and 
mortality associated with these tumours. Microvessels in metastatic adenocarcinomas 
are phenotypically similar to vessels in the tissue from which the tumours are derived. 
They therefore do not form as many tight junctions as are observed in cerebral 
microvessels (Long, 1979).  
 
The mechanism for the breakdown of the BBB in gliomas is less certain. One possibility 
is that the loss of differentiation in glial cells causes a disruption of the secretion of 
factors necessary to maintain the BBB. An alternative explanation is that gliomas 
display accelerated angiogenesis associated with high levels of VEGF (Davies, 2002). 
 
Disruption of the BBB also appears to occur in sepsis, as evidenced by the increased  
passage of albumin through the BBB in rats treated with endotoxin (Deng et al., 1995). 
Microscopically, BBB of disruption in sepsis is associated with swelling of astrocytic 
end feet, neuronal degeneration and microvessel oedema (Papadopoulos et al., 1999). 
 
3.1.5.1 BBB disruption in MS 
 
The existing evidence for BBB disruption in acute and, to a lesser extent, chronic MS  
lesions has been discussed in chapter 2.  Breakdown of the BBB is most dramatic in the 
early stages of lesion formation, although histological and limited radiological evidence 
exists for persisting BBB leakage in more long-standing and (on MRI) visibly non-
enhancing lesions. The following section will focus on postulated mechanisms 
governing BBB breakdown in acute and chronic lesions in MS 
 
3.1.5.1.1 BBB breakdown in acute lesions 
 
Histological studies on active MS lesions reveal the presence of local oedema, 
lymphocytic infiltration and extravascular fibrin deposition (Adams et al.,  1985), all 
indicative of a breakdown of the BBB. Gd-enhanced MRI studies indicate that BBB 
disruption is a consistent finding in new or actively inflamed lesions. (Bruck et al., 
1997; Grossman et al., 1986; Katz et al., 1993; Miller DH  et al., 1988; Lai et al., 1996) 
Disruption of tight junctions in vessels within acute lesions has also been demonstrated 
in confocal laser microscopic studies (Plumb et al., 2002).  
 
BBB breakdown in acute lesions is thought to result from the migration, proliferation 
and activation of leucocytes, with consequent cytokine release. (Minagar and 
Alexander, 2003). Cytokines and oxidants compromise the BBB by the phosphorylation 
of occludin and associated proteins, causing dissociation from the cytoskeleton and tight 
junction breakdown.  In vitro studies indicate that chronic exposure of endothelium to 
cytokines involved in the Th1 immune response (central in the acute inflammatory 
process in MS) is associated with reduced tight junction expression and trans-
endothelial resistance (Oshima et al., 2001; Minagar et al., 2003). This  process was 
ameliorated if the endothelium was pre-treated with IFN-β (Minagar et al., 2003).   
 
VEGF may also contribute to BBB breakdown in acute lesions. Elevated levels of 
VEGF have been found in MS plaques, and the administration of VEGF to myelin basic 
protein sensitized rats is associated with an increase in EAE plaques (Proescholdt  et al., 
2002), although a similar reaction is not observed in non-sensitized rats, suggesting that 
VEGF can amplify the inflammatory process and associated BBB breakdown, but is not 
on its own sufficient to trigger disease.  
 
3.1.5.1.2 BBB breakdown in non-active and more longstanding MS lesions 
 
Confocal laser microscopy studies provide evidence of abnormal tight junctions in 
lesions which do not show evidence of active inflammation (Leech et al., 2007). In 
addition, extravascular fibrin deposits  are found in chronic, non-active MS lesions, 
(Claudio et al., 1995; Adams et al., 1985; Kwon and Prineas, 1994). Taken together, 
these studies provide histological evidence of BBB disruption in such lesions. Vessels 
in non-active lesions often exhibit reparative wall thickening in concert with fibrin 
deposition, (Adams et al., 1985) suggesting that leakage from these lesions might at 
least in part be due to incomplete BBB repair, with some permanent structural and 
functional changes following resolution of inflammation. Supporting this hypothesis  
are findings from morphometric analysis of capillaries in non-active MS lesions, which 
have demonstrated a reduction in mitochondria and a rise in pinocytic vesicles, in 
concert with evidence, in terms of extravascular fibrin deposits, of BBB disruption. 
(Claudio et al., 1995) Such findings imply a shift in the physiology of these vessels to a 
more energy deficient state, hindering the energy dependent transport mechanisms 
essential in maintaining the BBB. It is conceivable that such changes could contribute to  
the low grade BBB leakage detected in chronic MS lesions. 
 
3.2  α4β1 integrin and other molecules involved in the MS inflammatory process 
 
The following sections give a brief description of some of the key molecules 
contributing to leucocyte adhesion and activation.  In particular, very late antigen-4 
(VLA-4), or α4β1 integrin, which mediates the adhesion of leucocytes onto the 
endothelial wall and subsequent trans-BBB migration. 
 
3.2.1 Cell adhesion molecules 
 
Cell adhesion molecules are a diverse group of cell-surface and extracellular 
glycoproteins which are involved in cell-cell or cell-matrix interaction, adhesion, and 
cell recognition. They consist of 4 classes of molecules: selectins, cadherins, integrins 
and  members of the immunoglobulin superfamily, including inter-cellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) 
 
Selectins are molecules expressed on leucocytes (L-selectin) and endothelial cells (P-
selectin). They have a lectin-like domain, and are involved in the initial contact between 
leucocyte and endothelium in leucocyte adhesion. 
 
Cadherins are calcium dependent cell adhesion molecules which form homophilic 
bonds to other cadherins. They form a major constituent of the previously mentioned 
intercellular adherens junctions.   
 
Integrins are integral membrane proteins involved in cell signalling and interaction 
between cells or between the cell and the extracellular matrix. Integrins are 
heterodimers, consisting of an α and a β subunit. Cell signalling following contact with 
ligand is mediated through protein kinase. Integrins which contain the α4 subunit are 
expressed on most leucocytes, with the exception of neutrophils. α4  dimerises with 
either β1 or β7  (Rice et al.,  2005). α4β1 integrin plays an important role in the 
adhesion and migration of leucocytes across the BBB, whereas α4β7 facilitates the 
migration of leucocytes across the intestinal mucosa. α4 integrin blockage is the 
probable mechanism of the therapeutic trial agent reported in this thesis.   
 
α4β1 integrin interacts principally with the immunoglobulin VCAM-1. VCAM-1 is 
expressed on activated endothelial cells and in astrocytes in response to cytokines 
(Rosenman et al., 1995; Lee and Benveniste, 1999). The VCAM-1-α4β1 interaction is 
thought to underlie many of the processes in leucocyte adhesion, migration and 
activation within the context of MS.  
 
Fibronectin and osteopontin also form ligands for interaction with α4β1 .  
 
Fibronectin is abundant in the extracellular matrix (Guan and Hynes, 1990) and plays 
important roles in cell adhesion, migration, growth and differentiation (Pankov and 
Yamada, 2002). CD3 mediated proliferation of T-cells is co-stimulated by concurrent 
interaction between fibronectin and the integrins VLA-4 (α4β1)  and VLA-5  (Shimizu 
et al., 1990).  
  
Osteopontin is a matrix protein that has both adhesive and Th-1-like cytokine activity. 
Osteopontin cDNA is found in higher levels in MS plaques and in mice with EAE 
(Chabas et al., 2001).  Mice deficient in osteopontin exhibit a relative resistance to 
EAE. 
  
3.2.2 Chemokines and matrix metalloproteinases 
 
Chemokines are 8-10kDa proteins secreted by activated macrophages and microglia. 
They consist of 4 subfamilies: α,β,δ, and γ, and can be divided broadly into 
inflammatory and homeostatic chemokines. Whereas homeostatic chemokines are 
constitutively expressed and can play roles in neuronal migration and synaptic 
modulation, inflammatory chemokines are are secreted in response to cytokines, and 
modulate the interaction between endothelial cells and leucocytes. Inflammatory 
chemokines from the α subfamily affect T-cells and those from the β subfamily affect 
monocytes/macrophages. Both these classes of chemokines have been reported to be 
raised in MS (Trebst et al., 2003) and are thought to convert the leucocyte- endothelial 
cell interaction from one of low affinity (selectin mediated) to high affinity (integrin 
mediated) (Minagar and Alexander, 2003) 
 
Matrix metalloproteinases are Zn dependent peptidases which degrade protein 
components of extracellular matrix. These molecules, especially MMP9, are implicated 
in MS. Elevated levels of MMP7 and MMP9 are found in MS lesions (Cossins et al., 
1997; Maeda and Sobel, 1996), and lesion formation is frequently preceded by increase 
in the serum level of MMP9 (Waubant et al., 1999). IFNβ appears to reduce the level of 
MMP9 (Trojano et al.,  1999)  
 
3.2.3 Overview of the role of α4β1 in cell adhesion and BBB breakdown 
 
Inflammation within the acute MS plaque is a process that is thought to be driven 
primarily by Th1 cytokines such as IL1-b, IL6, IFNγ  and TNFα (Dettke et al., 1997; 
Beck J et al., 1998). It is thought that the presence of such cytokines activates 
endothelial cells, with increased expression of MHC II molecules (van der Maesen et 
al., 1999) and cell adhesion molecules such as VCAM-1 and E-selectin (Pober et al., 
1986; Dustin et al., 1986; Dore-Duffy et al., 1993).  
 
Activated endothelium also releases cell adhesion molecules such as VCAM-1 and 
platelet endothelial cell adhesion molecule (PECAM-1) into the circulation in vesicles 
called endothelial microparticles. Serum levels of cell adhesion molecules have been 
correlated with markers of disease severity in MS, including the presence of Gd- 
enhancing lesions (Giovannoni et al.,  1997; Hartung et al., 1995) and relapses 
(Rieckmann et al., 1994).  In addition, high levels of ICAM and TNF have been 
reported in CSF in patients with relapses (Tsukuda et al.,  1993) 
 
The expression of adhesion molecules by activated endothelium is reduced in the 
presence of steroids (Elovaara et al., 1998) and IFNβ (Jimenez et al., 2005)  
 
The interaction between activated endothelium and leucocytes appears to occur in 
several stages (Butcher, 1991), with the initial contact being mediated principally by 
selectins and their respective carbohydrate ligands, resulting in the slowing, or tethering 
of the leucocyte (Engelhardt and Ransohoff, 2005;  Carrithers et al., 2000).   
 
Subsequent ‘rolling’ of the leucocyte along the endothelial surface is facilitated by the 
interaction between α4β1 integrin and VCAM-1, as well as selectins and their  ligands. 
(Piccio et al., 2002; Carvalho-Tavares et al., 2000; Kerfoot and Kubes, 2002). It is 
thought that rolling brings chemokines on the endothelial surface into proximity with 
their respective ligands on the leucocyte, and their interaction initiates a G- protein 
linked signal within the leucocyte (Piccio et al., 2002, Vajkoczy et al., 2001). This 
results in the activation of integrins expressed on the leucocyte, which facilitates much 
higher affinity binding between α4β1 and its ligand VCAM-1. 
 
The high affinity binding leads to the arrest of the leucocyte and is known as adhesion.  
Leucocyte adhesion can be inhibited by antibodies directed against VCAM-1 (Bochner 
et al., 1991) or α4 integrin (Vajkoczy et al., 2001). A similar adhesion to cytokine-
activated endothelium was demonstrated in cells transfected with α4β1 cDNA, a 
process inhibited once more with antibodies directed against α4 (Elices et al.,  1990). 
 
The leucocyte then travels across the BBB, a process known as diapedesis. In the 
inflamed vessel, the leucocyte adopts both transcellular and paracellular routes 
(Engelhardt and Ransohoff, 2005; Carman and Springer, 2004), and the process 
involves other adhesion molecules such as ICAM-1, the integrin Lymphocyte Function 
Associated Antigen 1(LFA-1) (Laschinger et al.,  2002), and monocyte chemoattractant 
protein-1 (MCP-1) (Weiss et al., 1998) which is expressed on activated astrocytes. 
 
The α4β1-VCAM-1 interaction plays a role in the migration of the leucocyte in the 
extracellular matrix, most probably through the stimulation of production of the matrix  
metalloproteinase MMP2 (Madri et al., 1996).  
 
The α4β1-VCAM-1 interaction is also implicated in T-cell proliferation (Burkly et al., 
1991; Damle and Aruffo, 1991) and activation (Damle and Aruffo, 1991), in concert 
with stimulation by locally produced chemokines and cytokines. 
 
Human umbilical vein endothelium expresses VCAM-1 when stimulated with TNF-α. 
The resultant adherence of lymphocytes is inhibited by VCAM-1 blockade (Carlos et 
al., 1990)  
 
Evidence that α4β1 integrin plays a role in the pathogenesis of EAE comes indirectly 
from the finding that encephalitogenic clones from a Th1 cell line had a 10-fold greater 
surface expression of α4β1 integrin than non-encephalitogenic variants. (Baron et al., 
1993) It was also observed, by the same group, that α4β1 positive cells readily crossed 
the BBB to enter the brain parenchyma in EAE mice, whereas no such migration was 
observed in α4β1 negative cells. Administration of antibodies to VLA-4 and VCAM-1 
hampered the transmigration of leucocytes. The finding that antibodies to α4 integrin 
can induce a protein kinase dependent apoptosis of CD4 and CD8 cells in mice 
(Tchilian et al., 1997) and subsequently in Lewis rats (Leussink et al., 2002) might 
point to an additional role for α4 integrin in the prolongation of the lifespan of 
inflammatory cells and the prolongation of the inflammatory process itself. 
 
Antibodies to α4 integrin inhibit adhesion of leucocytes onto endothelium in EAE mice 
(Yednock et al., 1992). In addition to this, the administration of anti-α4 prevents the 
development of EAE in mice following the injection of encephalitogenic T-cells  
(Brocke et al., 1999).  
 
There is considerable evidence that antibodies directed against α4 integrin ameliorate 
the clinical (Yednock et al., 1992; Van der Laan et al.,  2002; Soilu- Hanninen et al., 
1997 ), MRI (Kent et al., 1995a) and pathological (Kent et al., 1995b) changes seen in 
EAE. Conversely, a study on EAE mice appeared to indicate that the effect of anti−α4 
was dependent on the timing of its administration; anti-α4 administered after the peak 
of EAE or in remission appeared to exacerbate disease (Theien et al.,2001) . The 
findings from this study suggest that the role of α4 integrin in EAE might be a complex 
one. However, the findings have not been replicated in further animal or human studies. 
 
Anti-α4 also exerts its action on pathways mediated by α4β7, an integrin which is 
involved in the trafficking of leucocytes across the gastrointestinal mucosa. Studies with 
the cotton top tamarin, a new-world monkey that has spontaneous colitis, show a limited 
benefit from treatment with anti α4 (Podolsky et al., 1993). 
 
3.3 Natalizumab 
 
Natalizumab is a humanized anti α4 antibody made from by grafting the 
complementarity determining region of the murine antibody AN100226m onto an inert 
human IgG4 frame (Leger et al., 1997). The grafting to the human IgG frame reduces 
immunogenicity and improves half life in vivo. Natalizumab and AN100226m have 
nearly identical binding affinities to α4 integrin.  Natalizumab appears to follow linear 
kinetics over a wide range of body weight, and is relatively fat insoluble. Natalizumab  
has a reported pharmacological half life of 11 days in healthy volunteers (Cada et al., 
2005), a shorter half life of 4.8 days has been reported  on patients with Crohn disease. 
(Gordon et al., 2001). 80-90% saturation of α4β1 integrin receptors can be achieved 
with 3 - 6mg/kg monthly injections (Miller DH et al., 2003).  
 
3.3.1 The use of Natalizumab in MS trials 
 
An early phase II trial involving 72 patients in a single centre examined the effect of 
two doses of 3mg/kg natalizumab given a month apart on MRI markers of MS. (Tubridy 
et al., 1999). This demonstrated a 50% reduction in Gd enhancing lesions in the first 12 
weeks of the trial, which was not sustained in the second 12 weeks of the trial, with no 
significant difference in the number of relapses for the period of observation (6 
months). A raised lymphocyte count was observed in the treatment group in the first 12 
weeks of the trial, and 11% of patients in the treatment group developed antibodies to 
natalizumab. .  
 
The results of the initial trial provided the impetus for the conduct of a proof of concept 
phase IIb multicentre trial, examining the effect of natalizumab on patients with RRMS 
or SPMS with superimposed relapses (Miller DH et al., 2003). Two hundred and 
thirteen patients were involved in the trial, and patients were randomized to receive 
placebo, natalizumab 3mg/kg and 6mg/kg. They received monthly injections for 6 
months and had a follow-up period of a year. Natalizumab was found to markedly 
reduce the number of new Gd enhancing lesions (9.6 in the placebo group as opposed to 
0.7 in the 3mg/kg group and 1.1 in the group receiving 6mg/kg) and the number of 
persistent Gd enhancing lesions (3.6 in the placebo group vs 0.8 in the 3mg/kg group  
and 1.3 in the 6mg/kg group), with a reduction in relapse rate of 50%, and no significant 
treatment difference seen in the 2 dosage groups. Adverse events were similar in all 3 
arms. A lymphocytosis in the treatment arms, similar to that seen in the previous trial 
(Tubridy et al., 1999) 
 
A substudy of the above trial demonstrated that administration of natalizumab also 
influenced the evolution of Gd enhancing lesions into T1 hypointense lesions, which are 
generally associated with greater axonal damage and extracellular matrix disruption. 
Administration of natalizumab was associated with an odds ratio of conversion to T1 
hypointense lesions of roughly 0.5, (Dalton et al., 2004a). This finding suggests that in 
addition to suppressing the formation of new lesions, natalizumab ameliorates 
destructive α4β1 mediated processes once inflammation has  started. 
 
Based on the results of the phase IIb proof of concept study, two further placebo-
controlled phase III trials were organised. 
 
The first such phase III placebo controlled trial (AFFIRM) compared the use of monthly 
administration of natalizumab as monotherapy against placebo in 942 patients over two 
years. Natalizumab was associated with a 68% reduction in relapse rate and a 42% 
reduction in disability progression when compared against placebo (Polman et al., 
2006). The use of natalizumab was also associated with a significant reduction in MRI 
markers of disease activity and severity (Miller DH et al., 2007). This will be described 
in more detail in chapter 4 of this thesis. 
 
The second phase III trial (SENTINEL) recruited patients who were already receiving  
IFNβ-1a (avonex) but had experienced at least one documented relapse in the previous 
year. This study compared the use of IFNβ-1a and placebo against the combination of  
IFNβ-1a and natalizumab in 1171 patients. The use of IFNβ-1a – natalizumab 
combination resulted in significant reductions in relapse rate and disability progression 
when compared against  the group receiving  IFNβ-1a and placebo (Rudick et al., 
2006). 
 
Patients from the two aforementioned phase III trials were also tested for visual acuity 
and the ability to distinguish  letters of low contrast. Natalizumab was associated with a 
reduction in risk of low level visual loss in both these trials (Balcer et al., 2007) 
 
Another randomized multi-centre placebo controlled trial of natalizumab investigated 
the effect of a single dose given during acute relapse on relapse outcome. (O' Connor  et 
al.,  2004). The study was based on the principle that the reduced trafficking of 
leucocytes across the BBB into the brain parenchyma may shorten the period of lesion 
inflammation and therefore improve outcomes from relapses. Patients who had 
developed relapse symptoms in the preceding 24 to 96 hours were recruited into the 
study, received a single intravenous infusion of agent, and were then followed up for 14 
weeks. Although the treatment cohort had an overall smaller volume of Gd enhancing 
lesions than those receiving placebo after 14 weeks, no significant difference in the 
change in clinical relapse outcome was detected between the treatment groups.  
 
3.3.2 The use of natalizumab in treatment trials of Crohn’s disease 
 
As natalizumab is directed against the α4 component of the integrin subtype α, it was  
postulated that it would exhibit efficacy in antagonising α4β7, an integrin involved in 
the migration of leucocytes in Crohn’s disease. Animal studies supported this postulate, 
with anti α4 ameliorating the symptoms of colitis in golden top tamarin monkeys 
(Podolsky et al., 2003). In controlled clinical trials in Crohn disease, natalizumab has 
been associated with modest improvements in clnical indices (Sandborn et al., 2005) 
and in remission and response rates (Ghosh et al., 2003) 
 
3.3.3 Adverse effects of natalizumab 
 
Natalizumab appeared on the whole to be fairly well tolerated, with generally similar 
rates of adverse events between natalizumab and treatment groups, in the phase II 
clinical trials (Keeley et al., 2003; Miller DH et al.,  2003; ). In the phase III treatment 
trial of natalizumab monotherapy against placebo, fatigue and hypersensitivity were  
found to be more frequent in the natalizumab treated group (Polman et al., 2006). 
Postmarketing reports of clinically significant liver injury have recently been made,  
(Food and Drug Administration, 2008), with a recommendation to discontinue 
natalizumab in the presence of clinical or laboratory evidence of hepatic derangement.  
 
A number of cases of progressive multifocal leukoencephalopathy (PML) have been 
reported on patients receiving natalizumab (Kleinschmidt-DeMasters and Tyler, 2005; 
Langer-Gould et al., 2005; Van Assche et al., 2005; Hartung, 2009).  PML is a 
potentially fatal glial infection by the polyoma JC virus.   The emergence of PML, 
which is usually seen in immunocompromised patients, was an unexpected consequence 
of the drug. A  retrospective study conducted of 3417 patients exposed to the agent to 
date estimated an annual risk of  1.0 per 1000 patients, with necessarily wide confidence  
intervals (0.2 to 2.8 per 1000) given the paucity of available data. (Yousry et al., 2006)  
 
It is not known exactly how treatment with natalizumab gives rise to PML. It has been 
suggested that natalizumab interferes with the normal ingress of lymphocytes into the 
nervous system and compromises the normal immune surveillance, allowing unchecked 
replication of JC virus (Berger and Koralnik, 2005). CSF studies on patients receiving 
natalizumab reveal a marked reduction in leucocyte counts which persists up to 6 
months after the discontinuation of the drug (Stuve et al., 2006).  
 
The first reported cases of PML emerged after more than 2 years of otherwise 
uneventful exposure to natalizumab. This late emergence of a serious adverse event 
underlines the need for long term careful and sustained follow-up in the monitoring of 
patients who are receiving new treatments for which previous long term data is lacking. 
 
 
 
 
 
 
 
 
 
 
 
  
Thesis outline 
 
This thesis describes the imaging results of the trial of an agent that acts at the level of 
the BBB by blocking α4 integrin, and in doing so investigates the role of the BBB in the 
pathogenesis of MRI-measured disease activity in MS. 
 
Chapter four reports the main MRI outcomes in the phase III placebo-controlled trial of 
natalizumab in relapsing MS (AFFIRM). 942 patients participated in the trial, whose 
MRI outcomes included the number of new Gd enhancing lesions, new or enlarging T2 
lesions, and new T1-hypointense lesions.  Lesion volumes were also studied. In 
addition, the ratio of volume between T1-hypointense lesions and T2 lesions was studied 
to ascertain whether natalizumab influenced the formation of T1 hypointense lesions per 
se.   
 
The subsequent two chapters describe substudies of the AFFIRM trial which employed 
additional MRI measures to assess the effect of natalizumab therapy on segmental brain 
atrophy (Chapter five) and on low grade BBB leakage, inferred by measuring T1 
weighted signal change after administration of triple dose Gd (Chapter six).  
 
In chapter five the effect of natalizumab on segmental atrophy in a patient population of 
fifty-seven patients was investigated. GM and WM segments were obtained from 3D 
volumetric scans taken at baseline, year 1 and year 2 using an automated segmentation 
procedure. GMF, WMF and BPF were then calculated as a fraction of total intracranial 
volume. Correlations between atrophy measures and measures of disability as well as 
lesion load were sought.  
Chapter six describes a further substudy of the AFFIRM trial involving 40 patients, in 
which low grade BBB leakage from visibly non-enhancing lesions was investigated by 
studying T1 weighted signal intensity change following the administration of triple dose 
Gd. Leakage was compared between patients receiving natalizumab vs placebo, leakage 
was also compared between T1 hypointense and T1 isointense lesions. 
  
Chapter seven describes a pilot study of a non-trial MS cohort (19 patients, 10 RRMS 
and 9 SPMS) wherein the post-Gd change in the 1/T1 (∆R1) is used to infer BBB leakage 
in visibly enhancing and visibly non-enhancing lesions. ∆R1 represents a more 
reproducible and potentially more sensitive marker of subtle BBB disruption. 
Comparisons were made between disease subtypes and lesion types. A number of 
patients who participated in the study were receiving disease modifying therapy, either 
IFNβ or glatiramer acetate. This allowed for the investigation of possible effects of 
these agents on subtle BBB permeability.  Correlations were also sought between 
inferred BBB disruption and disability. 
 
 
 
 
 
 
 
 
  
CHAPTER 4 
 
MRI results from a phase III trial of natalizumab vs placebo in subjects with 
relapsing MS 
 
4.1 Introduction 
 
4.1.1 α4β1 integrin and  lesion formation in multiple sclerosis 
 
The role of α4β1 integrin in the formation and continued activity of MS lesions has 
been described at length in chapter 3. α4β1 integrin, through its interaction with its 
principal ligand VCAM1, and to a lesser extent with its supplementary ligands 
osteopontin and fibronectin, plays an integral role in leucocyte adhesion (Yednock et 
al.,  1992; Bochner et al., 1991; Elices et al., 1990; Carlos et al., 1990), 
intraparenchymal activation (Damle and Aruffo, 1991), migration (Madri et al.,1996 ) 
and proliferation (Burkly et al., 1991).  Antibodies directed against α4β1 integrin 
ameliorate disease progression in animal models of MS (Yednock et al.,1992; Kent et 
al., 1995b) 
 
Limited Phase I and II clinical trials of natalizumab versus placebo have demonstrated 
the efficacy of the agent in reducing relapse rates and disease progression (Miller DH et 
al., 2003; Tubridy et al.,1999). Over a period of 6 months, the use of natalizumab was 
associated with a 90% decrease in the number of Gd enhancing lesions (Miller DH et 
al.,  2003). Further analysis of the trial data has demonstrated that the use of  
natalizumab is associated with a reduced likelihood of new lesions evolving into T1-
hypointense lesions (Dalton et al., 2004a) a subset of lesions associated with a greater 
degree of axonal loss and demyelination and disability (van Waesberghe et al., 1999; 
Barkhof et al., 2003; Truyen et al., 1996).  
 
4.1.2 Phase III clinical trials involving natalizumab 
 
The results of the clinical trials described in the previous section provided the impetus 
for 2 large, randomized multi-centre placebo controlled trials involving either 
natalizumab as monotherapy (AFFIRM trial) (Polman et al., 2006; Miller DH et al., 
2007) or in combination with IFNβ−1a (SENTINEL trial) (Rudick et al., 2006). These 
trials provided the opportunity to determine if the natalizumab-mediated effects seen in 
the previous trials were sustained over 2 years.  
 
The primary clinical efficacy end points in the trials were the clinical relapse rate at 1 
year, and cumulative probability of sustained disability progression at 2 years, defined 
as an EDSS progression of 1, or (if baseline EDSS was 0) of 1.5 with no improvement 
over 12 weeks. The trials demonstrated that natalizumab as monotherapy was associated 
with a 68% reduction in annualised relapse rate and a 42% reduction in sustained 
disability progression when compared against placebo (Polman et al., 2006), and 
natalizumab in combination with IFNβ-1a was associated with a significant reduction in 
annualised relapse rate (54% in the 1
st year and 55% in the 2
nd year) and a 24% 
reduction in disability progression compared with IFNβ −1a alone in subjects who had 
previously had a limited response to IFNβ-1a. This chapter will describe the 
methodology and results of the MRI scans that were obtained in the natalizumab  
monotherapy (AFFIRM) trial. 
 
4.2 Methods 
 
4.2.1 Trial Design 
 
The study was a multi-centre, randomized, double-blind, placebo controlled, parallel 
group treatment trial. The protocol was developed by the trial sponsors (Biogen Idec 
and Elan) and a central investigator advisory committee, and was approved by central 
and local ethics committees. 
 
4.2.2 Recruitment 
 
942 subjects from 99 centres in Europe, North America, Australia and New Zealand 
were recruited into the study. Informed consent was obtained from each subject 
participating in the trial. Criteria for trial participation are described in FIG 4.1.  
 
FIG 4.1 Inclusion and exclusion criteria for trial entry  
 
 
Inclusion Criteria 
1. Diagnosis of Relapsing MS, as according to 2001 McDonald Criteria (McDonald et al., 2001) 
2. Age between 18 and 50, inclusive 
3. EDSS between 0 and 5.0 inclusive 
4. One or more documented relapse in the 12 months prior to randomization 
5. Cranial MRI demonstrating changes consistent with MS 
6. Provision of written informed consent for participation in the study 
 
Exclusion Criteria 
1. Primary Progressive, Secondary Progressive or Relapsing Progressive MS (Lublin and Reingold, 1996) 
2. Documented MS relapse within 50 days prior to randomization  
3. Clinically significant infectious illness within 30 days prior to randomization. 
4. Abnormal investigation results suggestive of condition that may preclude administration of agent 
5. Abnormal blood tests at the screening visit as defined below: 
a) Alanine transaminase or aspartate transaminase > 3 times upper limit of normal. 
b) Total white blood cell count < 2,300/mm3. 
c) Platelet count < 100,000/mm3. 
d) Creatinine > 2 times upper limit of normal 
e) Prothrombin time > Upper imit of normal 
6. History of severe allergic or anaphylactic reactions or known drug hypersensitivity. 
7. Unable to perform MSFC  
8. Prior treatment with  
  a) cladribine 
  b) any monoclonal therapeutic antibody 
  c) total lymphoid irradiation 
  d) T-cell receptor vaccination 
 9. Treatment within the year prior to randomization with  
a) mitoxantrone  
b) cyclophosphamide 
10. Treatment within 6 months prior to randomization with the following agents 
a) cyclosporine 
b) azathioprine 
c) methotrexate,  
d) intravenous immunoglobulin  
4.2.3 Randomization 
 
Subjects were randomized during the baseline visit to receive infusions of either 
natalizumab 300mg or placebo every 4 weeks up to 116 weeks at a ratio of 2:1 (ie, 
twice as many subjects receive natalizumab than placebo) Randomization was stratified 
by centre, using a centralized computer-generated block randomization schedule to 
balance treatment group assignments within centres. Subjects and study personnel were 
blinded to treatment assignment. 
 
4.2.4 MRI protocol 
 
Each participating centre designated a specific MRI technician who was responsible for 
the site-specific implementation of the trial MRI protocol. These scans were undertaken 
at baseline, year 1 and year 2 of the study as according to a standard acquisition 
protocol which defined allowable ranges for all scanning parameters. The protocol 
consisted of (i) PD/T2-weighted FSE (TR = 2000 to 3200 ms; TE = 20 to 50 ms [short] / 
TE = 80 to120 ms [long]); (ii) pre- contrast T1-weighted SE (TR = 500 to 600 ms; TE = 
10 to 20 ms); (iii) IV injection of 0.1 mmoL/kg of a Gd-chelated MRI contrast agent; 
(iv) post- contrast T1-weighted SE starting 5 minutes after the injection of contrast. The 
slice thickness was 3 mm and the matrix size was 256 x 256, with contiguous oblique-
axial plane slices (parallel to the line joining the anterior and posterior commissures) 
being obtained through the entire brain. Repositioning of follow-up scans was achieved 
using a protocol based on the identification of predefined anatomic landmarks 
(Gallagher et al., 1997). 
  
4.2.5 MRI Analysis 
 
Hard copy films and electronic data from image acquisitions were sent to the central 
MRI analysis centre at the Institute of Neurology, London, where MRI analysis was 
performed by investigators blinded to subject designation and treatment code. Newly- 
arrived scans were checked for compliance with study protocol such as slice thickness, 
TR and TE,  FOV and matrix, slice positioning as well as for lack of artefact. In cases 
where significant protocol deviation occurred, the relevant centre was notified and scans 
were repeated and resent within 4 weeks.  
 
4.2.5.1 Identification and marking of lesions 
 
Two clinical fellows (DS and KF) received training and validation in the identification 
and marking of lesions on hard copy films by an expert neuroradiologist (TY) using 
non-trial MRI data. To minimise error caused by inter-observer variation, each clinical 
fellow analysed scans for the same subjects throughout the study. Lesion identification 
was supervised by TY throughout the study. 
 
Lesions were identified as follows: T2-hyperintense lesions (lesions which appeared  
more intense than surrounding NAWM on T2 weighted scans) were identified and 
marked on PD weighted hard copy films after confirmation of their presence on the 
more heavily T2 weighted scans.  
 
The identification of T1-hypointense lesions (lesions which have a lower intensity than 
surrounding NAWM on pre- contrast T1 weighted scans) and Gd enhancing lesions  
(lesions which have a higher intensity on post-contrast T1 weighted scans when 
compared against pre-contrast T1 weighted scans) also involved confirmation of the 
presence of a corresponding T2-hyperintense lesion in an anatomically analogous 
position.  
  
Analysis of scans from subsequent timepoints (year 1 and year 2) involved comparison 
with the previous scans to detect new or enlarging T2-hyperintense lesions and new T1-
hypointense lesions. T2-hyperintense lesions were identified as enlarging if they either 
a) appeared larger than previously on 2 contiguous slices, or  b) were at least twice the 
diameter compared with the diameter from the previous image. Lesions less than 5 mm 
had to satisfy both criteria before being marked as enlarging lesions. (Molyneux et al. 
1999)  
 
4.2.5.2 Calculation of lesion volume and T1/ T2 lesion volume ratio 
 
Total lesion volume was calculated from electronic data following conversion to a 
standard format (Supervised by trial and electronic data coordinator, GJB). All lesions 
previously identified on hard copy films were outlined on the electronic images. This 
was performed by a team of raters using a semi-automated lesion contouring protocol 
(Plummer, 1992) based on local intensity thresholding, with manual editing when 
necessary. Volumes of ring enhancing lesions included everything within it if the ring 
was complete, or if the ring was incomplete, only the area of enhancement itself. All 
raters underwent a formalised training programme in the contouring of T2-hyperintense, 
T1-hypointense and Gd enhancing lesions using non-trial MRI data. Target intra-rater 
coefficients of variation for lesion volumes in contour re-contour exercises (on a pre- 
determined set of scans) were as follows: <3% for T2 lesion volume, <5% for T1-
hypointense lesion volume, <5% for volume of Gd enhancing lesions. Validation of 
raters was performed before analysis of trial data, and repeated before the reception of 
data from year 2. All contoured electronic data at each timepoint was checked by 
clinical fellows (DS and KF) for consistency. Once the volumes for T1-hypointense and 
T2-hyperintense lesions were determined, the ratio of volume of T1-hypointense lesions 
over that of T2-hyperintense lesions (T1/ T2 lesion volume ratio (LVR)) was calculated 
at each timepoint. The purpose of this was to explore whether natalizumab had an 
additional effect on T1-hypointense lesions per se, over and above a general effect on 
T2-hyperintense lesions (of which T1-hypointense lesions form a subset). 
 
4.2.6 Trial end points 
 
A set of pre-determined clinical and MRI end points were devised prospectively. These 
were broadly designed to assess for  i) ongoing inflammatory activity (rate of clinical 
relapse, number of new or enlarging T2-hyperintense lesions, number and volume of Gd 
enhancing lesions); and ii) evidence of more persistent deficit or pathology (sustained 
EDSS progression, progression on MSFC assessments and total T2 hyperintense and T1 
hypointense MRI lesion volume measures, although it was recognised that reversibility 
of a portion of these total lesion volumes may occur). 
 
4.2.6.1 Clinical end points 
 
Clinical end points formed the primary outcome measures of the trial. EDSS and MSFC  
assessments were performed at each site by specified assessing physicians blinded to 
treatment assignment. Subjects underwent these assessments in 12 weekly visits 
throughout the trial duration. The primary clinical end points for the trial were i) annual 
rate of documented relapse, defined as the presence of new or recurrent neurological 
symptoms in the absence of fever or infection, lasting 24 hours or more, and 
accompanied by the presence of new neurological findings on clinical examination; ii) 
cumulative probability of disability progression with secondary clinical end points as 
follows: i) proportion of relapse free subjects; ii) MSFC progression. All end points 
were calculated at year 1 and year 2 of the trial 
 
4.2.6.2 MRI end points 
 
Pre-specified MRI end points for the trial were i) The number of Gd enhancing lesions 
at each timepoint; ii) the number of new or enlarging T2-hyperintense lesions at year 1 
and 2; iii) the number  of new T1-hypointense lesions at year 1 and 2; iv) volume of T2-
hyperintense, Gd enhancing lesions and T1-hypointense lesions at baseline, year 1 and 
year 2.  Additional end points were T1/ T2 LVR at year 1 and 2, as well as the absolute 
and relative changes of T1/ T2 LVRs over the trial period.  
 
4.2.7 Statistical analysis 
 
All analysis followed the intention to treat principle, and all reported P values are 2-
tailed 
  
4.2.7.1 Power calculations 
 
Sample size estimates were based on data from previous trial of natalizumab (Miller DH 
et al., 2003) and IFNb-1a (Jacobs et al., 1996). To determine sample size required for 90 
percent power with a 2:1 ratio of natalizumab to placebo, likelihood-ratio tests were 
employed based on predicted relapse rates of 0.6 with natalizumab and 0.9 with 
placebo. For an annualized relapse rate, a likelihood-ratio test was used to determine the 
sample size required for 90% power (n = 765), with a 2:1 ratio of natalizumab to 
placebo. With an assumed drop-out rate of 15% and rounding, the number of patients 
needed was estimated to be 900. 
 
In order to power the study for the two-year end point of disability progression, 
progression rates at the end of two years were assumed to be 34.9% for the placebo 
group and 22.7 percent for the natalizumab group. Simulations of log rank test for 
survival were run with a 60 percent accrual in the first 24 weeks and the remainder in 
the next 24 weeks, assuming a 20 percent dropout rate over the 2 year study. The 
sample size of 900 provided
 90 percent power with the use of a Bonferroni adjustment 
for
 multiple end points, maintaining the type 1 error rate of 0.05. 
  
4.2.7.2 Statistical analysis of clinical outcome measures 
 
Annual documented relapse rate was calculated using Poisson regression, while  
cumulative probability of sustained disability progression was assessed by an analysis 
of the time until the onset of the disability progression with the use of the Cox 
proportional-hazards model. Additional baseline factors were tested for inclusion in 
each of the models. This included the EDSS score, presence or absence of Gd 
enhancing lesions, the number of T2-hyperintense lesions (<9 or >9) and age (Beck RW 
et al.,  2002; Weinshenker et al., 1989). Only statistically significant covariates were 
included in the models. 
 
Differences between treatment groups with regard to adverse
 events were analyzed by 
the chi-square test, and serious adverse
 events were analyzed by Fisher's exact test. 
Poisson regression
 was used to calculate the difference between the rates of infection
 in 
each treatment group.
  
 
4.2.7.3 Statistical Analysis of MRI data 
 
Ordinal logistic regression was used to analyse MRI lesion numbers. For the analysis of 
Gd enhancing lesions and new/enlarging T2-hyperintense lesions, terms were included 
for treatment group and respective baseline measures, i.e. number of Gd enhancing 
lesions at baseline and number of T2 hyperintense lesions (less than 9 vs 9 or more) as 
covariates. The number of new T1-hypointense lesions was analyzed using ordinal 
logistic regression that included only a term for treatment group. This was because the 
number of T1-hypointense lesions at baseline was not found to be a statistically 
significant covariate.   
 
Absolute and percentage change in volumes of Gd-enhancing, T2-hyperintense, T1-
hypointense lesions, as well as T1/ T2 LVR were analyzed using Friedman’s analysis of 
covariance (ANCOVA), and included a term for treatment group and baseline values.  
 
Sensitivity analysis was conducted for each MRI endpoint. This consisted of 1) analysis 
that included only available MRI data (not imputed) and 2) analysis which imputed 
missing values at any timepoint. In the latter case, missing values at baseline and 1 year 
were imputed using the mean volume in the study population. Missing values at 2 years 
were imputed using last observation carried forward (LOCF), or if there was no value to 
carry forward, the mean of the observed population at 2 years was used. All analyses 
followed the intention-to-treat principle. All reported p-values are two-tailed with p≤ 
0.05 as statistical significance. 
 
Additional pre-specified subgroup analyses were performed on lesion measures using 
logistic regression that included a term for treatment group and its respective baseline 
measure as a covariate. The subgroups analysed were as described below: 
 
 (i) baseline age (<40 or ≥40 years);  
(ii) baseline EDSS score (≤ 3.5 or > 3.5);  
(iii) presence or absence of baseline Gd-enhancing lesions;  
(iv) number of baseline T2-hyperintense lesions (< 9 or ≥ 9);  
(v) gender 
(vi) number of relapses in the year prior to study entry (1, 2, or ≥ 3).  
  
4.3 Results 
 
4.3.1 Study Population 
 
Among the 942 subjects, 627 were assigned to receive natalizumab
 and 315 to receive 
placebo. There were no significant differences
 in baseline characteristics between the 
treatment groups (Table 4.1)  
 
Depending on the MRI measure, analyzable scans were not available for 4-5% patients 
at year 1 and 8-9% patients at year 2. (Tables 4.2-4.8)  The main reason for missing data 
(>80%) was the scan not being performed because patient withdrew from study; in the 
remainder (<20%), although the patient was still in the study, the scan was either not 
performed, or had not been received at the Central MRI Analysis Center, or had been 
received but was of inadequate quality for analysis.  
   
Table 4.1 Baseline demographic and clinical characteristics of subjects. IR = interquartile range. 
 
Characteristic 
Natalizumab 
(n = 627) 
Placebo 
(n = 315) 
Age, yr 
     Mean ± SD 
     Range 
 
35.6 ± 8.5 
18- 50 
 
36.7 ± 7.8 
19- 50 
Gender, no (%) 
     Female 
     Male 
 
449 (72) 
178 (28) 
 
211 (67) 
104 (33) 
Disease duration, yr 
     Median (range) 
 
5 (0- 34) 
 
6 (0- 33) 
EDSS score 
     Mean ± SD 
     Range 
 
2.3 ± 1.2 
0- 6 
 
2.3 ± 1.2 
0- 6 
Gd-enhancing lesions, no (%)     
  Mean ± SD  2.2 ± 4.7  2.0 ± 4.8 
      Median  1  0 
  Range  0- 36  0- 39 
Gd-enhancing lesion volume, mm
3     
      Mean ± SD  363.5 ± 797.5  332.7 ± 866.0 
      Median   31.0  0 
      IR  0- 353   0- 297 
T2-hyperintense lesions, no (%)     
      <9   29 (5)   15 (5) 
      ≥9  597 (95)  299 (95) 
      Missing   1 (< 1)   1 (< 1) 
T2 lesion volume, mm
3     
      Mean ± SD  15627.4 ± 17142.4   14962.3 ± 15792.5 
      Median  9772   9315 
      IR  3830- 21839   3790- 21022 
T1-hypointense lesion volume, mm
3     
      Mean ± SD  5752.4 ± 8182.5  5692.9 ± 7633.0 
      Median  2743  2681 
      IR  870- 7132  878- 7467 
T1/ T2 LVR     
      Mean ± SD  0.328 ± 0.19  0.343 ± 0.19 
      Median  0.319  0.349 
      IR  0.18- 0.46          0.19- 0.46         
 
 
4.3.2 Treatment arm comparisons in clinical endpoints 
 
While it is not within the scope of this chapter to describe the clinical findings of the 
study in detail, a brief summary of the clinical findings is nonetheless relevant in the 
reporting of the MRI end points. Natalizumab reduced the risk of sustained progression 
of disability by 42 % over 2 years (Relative risk 0.58, 95% CI 0.43 to 0.77, P<0.001).  
The cumulative probability of progression (based on Kaplan Meier analysis) was 17% 
in the natalizumab group vs 29% in the placebo group. Natalizumab treated subjects had 
a 68% reduction in relapse rate compared with placebo subjects ( 0.26 relapses per year 
compared with 0.81 in placebo subjects P<0.001), an effect which was maintained over 
2 years (P<0.001) (Polman et al.,  2006). 
 
4.3.3 Treatment arm comparisons in MRI end points 
 
4.3.3.1 Number of Gd Enhancing lesions (Table 4.2) 
 
There were 92% less Gd-enhancing lesions in the group receiving natalizumab 
compared with placebo at both year 1 (0.1 vs 1.3; p < 0.001), year 2 (0.1 vs 1.2; p < 
0.001) and at both timepoints combined (0.2 vs 2.5; p<0.001). 97% of subjects 
receiving natalizumab had no Gd-enhancing lesions on the year 2 MRI scan compared 
with 72% of subjects receiving placebo. 
 
Table 4.2 Number of Gd enhancing lesions detected in the trial (Intention-to-treat population, 
N=942) P<0.001 in comparisons at all timepoints (including year 1 and year 2 combined) 
Year 1  Year 2  Year 1 & 2  Number of Gd 
enhancing 
lesions 
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
N (observed n) 
Mean ± SD 
Median 
Min., max. 
627 (606) 
0.1 ± 1.3 
0 
0, 32 
315 (296) 
1.3 ± 3.2 
0 
0, 33 
627 (580) 
0.1 ± 1.4 
0 
0, 32 
315 (282) 
1.2 ± 3.9 
0 
0, 48 
627 (579) 
0.2 ± 2.7 
0 
0, 64 
315 (281) 
2.5 ± 6.7 
0 
0, 57 
 
4.3.3.2 Number of new or enlarging T2 lesions (Table 4.3) 
 
Compared with placebo, the natalizumab treated group had 83% fewer new or enlarging  
T2-hyperintense lesions (11.0 vs 1.9; p < 0.001) over 2 years. This effect was seen both 
in new (82% less than that observed in placebo treated arm) and enlarging (88% less 
when compared with placebo) lesions. However, there was more than 10 times the 
number of new lesions as compared with enlarging lesions in each study arm. 57% of 
subjects in the natalizumab group developed no new or enlarging T2-hyperintense 
lesions over the 2-year treatment period compared with 15% of placebo subjects. 
 
Table 4.3 Number of new or enlarging T2-hyperintense lesions detected in the trial.  P<0.001 for 
treatment arm comparisons at all timepoints in new, enlarging and combined lesion measures. 
Year 1  Year 2  Year 1 & 2   
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
New lesions             
N (observed n) 
Mean ± SD 
Median 
Min., max. 
627 (606) 
1.1 ± 4.5 
0 
0, 96 
315 (297) 
5.8 ± 8.3 
3.0 
0, 69 
627 (581) 
0.7 ± 4.7 
0 
0, 96 
315 (283) 
4.4 ± 7.8 
2.0 
0, 65 
627 (580) 
1.8 ± 9.0 
0 
0, 192 
315 (282) 
10.2 ± 14.4 
5 
0, 87 
Enlarging lesions           
N (observed n) 
Mean ± SD Median 
Min., max. 
627 (606) 
0.1 ± 0.3 
0 
0, 3 
315 (297) 
0.4 ± 1.1 
0 
0, 8 
627 (581)  
0.0 ± 0.3 
0 
0, 4 
315 (283) 
0.4 ± 1.4 
0 
0, 11 
627 (580) 
0.1 ± 0.5 
0 
0, 5 
315 (282) 
0.8 ± 2.2 
0 
0, 18 
New/ Enlarging 
Lesions (combined) 
           
N (observed n) 
Mean ± SD 
Median 
Min., max. 
627 (606) 
1.2 ± 4.7 
0 
0, 98 
315 (297) 
6.1 ± 9.0 
3.0 
0, 77 
627 (581) 
0.7 ± 4.8 
0 
0, 98 
315 (283) 
4.9 ± 8.5 
2.0 
0, 66 
627 (580) 
1.9 ± 9.2 
0 
0, 196 
315 (282) 
11.0 ±15.7 
5.0 
0, 91 
 
 
4.3.3.3 Number of new T1-hypointense lesions (Table 4.4) 
 
The mean number of new T1-hypointense lesions detected over 2 years was 1.1 in the 
natalizumab treated group, vs 4.6 in the placebo treated group. The natalizumab treated 
group therefore had 76% fewer new T1-hypointense lesions compared with the placebo 
group (p<0.001). This difference was observed over the two years of the trial (74% and 
83% fewer new T1-hypointense lesions in the natalizumab treated group at year 1 and 
year 2 respectively; p < 0.001). In line with the findings in other lesion types, a higher  
percentage of natalizumab-treated subjects (63%) had no new T1-hypointense lesions 
compared with placebo-treated subjects (27%), and substantially fewer natalizumab-
treated subjects (11%) had three or more new T1-hypointense lesions compared with 
placebo-treated subjects (44%).  Analysis of post-Gd scans showed that the mean 
number of non-enhancing new T1-hypointense lesions on Gd-enhanced scans over 2 
years was 1.0 in the natalizumab group and 3.8 in the placebo group. This represented a 
74% reduction in new non-enhancing T1-hypointense lesions with natalizumab 
(p<0.001) and was very similar to the results from the  analysis performed on 
precontrast scans (76%, p<0.001). 
 
Table 4.4 Number of new T1-hypointense lesions detected in the trial. All treatment arm 
comparisions revealed significant differences between arms (p<0.001) 
Year 1  Year 2  Year 1 & 2  New T1-
hypointense 
lesions 
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
N (observed n) 
Mean ± SD 
Median 
Min., max. 
627 (606) 
0.6 ± 1.9 
0 
0, 27 
315 (297) 
2.3 ± 4.0 
1.0 
0, 27 
627 (581) 
0.4 ± 1.8 
0 
0, 27 
315 (283) 
2.3 ± 4.5 
1.0 
0, 53 
627 (580) 
1.1 ± 3.3 
0 
0, 54 
315 (282) 
4.6 ± 7.3 
2.0 
0, 60 
 
Sensitivity analyses of data on the number of lesions showed results that were consistent 
with the primary analyses (data not shown). 
 
4.3.3.4 Gd enhancing lesion volumes (Table 4.5) 
 
Volume of Gd-enhancing lesions was significantly lower in subjects treated with 
natalizumab compared with those on placebo at both year 1 (mean 21 vs 207 mm
3; p < 
0.001) and year 2 (mean 32 vs 192 mm
3; p < 0.001); representing 90% and 83% 
reductions in volume at the year 1 and year 2 time points, respectively. In both 
treatment arms, Gd enhancing lesion volumes were lower during the trial than baseline  
values. The reduction in volume was greater in the natalizumab treated groups in both 
year 1 (-343 mm
3 vs -126 mm
3; p < 0.001) and year 2 (-332 mm
3 vs -141 mm
3; p < 
0.001). 
 
Table 4.5  Gd enhancing lesion volumes (mm3). IR= Interquartile Range 
Baseline  Year 1  Year 2   
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
Gd-enhancing lesions         
N (observed N) 
Mean ± SD 
Median 
IR 
627 (626) 
363.5 ± 797.5 
31.0 
0- 353 
315 (313) 
332.7 ±866.0 
0 
0- 297 
627 (605) 
20.7 ± 279.2 
0 
0- 0 
p < 0.001 
315 (295) 
206.9 ± 671.8 
0 
0- 88 
627 (580) 
31.8 ± 330.3 
0 
0- 0 
p < 0.001 
315 (282) 
191.5 ± 706.4 
0 
0- 72 
Change from baseline         
N (observed N) 
Mean ± SD 
Median 
IR 
    627 (604) 
-342.8 ± 810.8 
-11.0 
-343 to 0 
p < 0.001 
315 (294) 
-125.8 ± 840.1 
0 
-168 to 0 
 
627 (579) 
-331.6 ± 821.5 
0 
-334 to 0 
p < 0.001 
315 (281) 
-141.2 ± 922.0 
0 
-194 to 0 
 
% Change from baseline*          
N (observed N) 
Mean ± SD 
Median 
IR 
    320 (313) 
-93.3 ± 51.7 
-100.0 
-100.0 to -100.0 
p < 0.001 
145 (133) 
-33.4 ± 448.7 
-88.3 
-100.0 to -18.1 
320 (302) 
-90.7 ± 61.9 
-100.0 
-100.0 to -100.0 
p < 0.001 
145 (126) 
-25.2 ± 188.9 
-100.0 
-100.0 to -43.1 
*calculated for subjects with baseline values >0 
  
4.3.3.5 T2-hyperintense lesion volumes (FIG 4.2, table 4.6) 
 
 
FIG 4.2 Mean (top) and median (bottom) volumes (mm
3) of T2 -hyperintense lesions for 
natalizumab and placebo treated arms 
 
T2-hyperintense lesion volumes are shown in FIG 4.2. Over the first year of treatment, 
T2-hyperintense lesion volumes decreased in the natalizumab group and increased in the 
placebo group; the difference in volume between the treatment groups was statistically 
significant (p = 0.016).  During the second year of treatment, T2-hyperintense lesion 
volume continued to increase in the placebo group and remained stable in the 
natalizumab group (p < 0.001). Overall, mean T2 lesion volume was significantly lower 
in natalizumab-treated subjects (14,722 [95% CI: 13,238 to 16,206]) compared with 
placebo-treated subjects (17,853 [95% CI: 15,414 to 20,292]) (p < 0.001) after 2 years. 
The mean change  and median % change in T2-hyperintense lesion volume over 2 years 
was also significantly different between the two treatment arms ( mean volume change 
  
of -905 mm
3 for natalizumab vs 2,891 mm
3 for placebo;  Median percentage change of -
9.4% for natalizumab vs 8.8% for placebo; p < 0.001 for inter-treatment arm 
comparisons of both these measures). Although mean percentage change measures also 
reflect a marked difference between treatment arms, the apparent discrepancy in 
magnitude of percentage change between median and mean is explained by a skewing 
effect from very large percentage increases in a small number of individual subjects, 
especially among those who started with small lesion volumes.  
 
Table 4.6 T2-hyperintense lesion volumes (mm3). IR= interquartile range 
Baseline  Year 1  Year 2   
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
T2 -hyperintense lesions         
N (observed N) 
Mean ± SD 
Median 
IR 
627 (626) 
15627 ± 17142 
9772 
3830-21839 
 
315 (313) 
14962 ± 15792 
9315 
3790-21022 
627 (605) 
14303 ± 20982 
9260 
3665-17670 
p = 0.016 
315 (296) 
15703 ± 21055 
9447 
3647-20157 
 
627 (577) 
14722 ± 18918 
9175 
3611-18699 
p < 0.001 
315 (280) 
17853 ± 21997 
11137 
4112-23811 
 
Change from baseline         
N (observed N) 
Mean ± SD 
Median 
IR 
    627 (604) 
-1324 ± 16861 
-819 
-2975 to 202 
p < 0.001 
315 (295) 
741 ± 13278 
-115 
-1481 to 1098 
 
627 (576) 
-905 ± 12781 
-548 
-2852 to 405 
p < 0.001 
315 (279) 
2891 ± 15068 
583 
-549 to 3218 
 
% Change from baseline*         
N (observed N) 
Mean ± SD 
Median 
IR 
    626 (603) 
- 8.1 ± 160.2 
-12.1 
-26.2 to 4.4 
p < 0.001 
315 (295) 
43.5 ± 365.0 
-2.3 
-19.2 to 14.8 
626 (575) 
-10.1 ±  153.8 
-9.4 
-22.4 to 6.8 
p < 0.001 
315 (279) 
67.2 ± 412.7 
8.8 
-9.7 to 35.9 
 
*calculated for subjects with baseline values >0 
 
4.3.3.6 T1-hypointense lesion volumes (FIG 4.3, Table 4.7) 
 
Median and mean T1-hypointense lesion volumes are shown in FIG 4.3. T1-hypointense 
lesion volumes decreased over the first year in both treatment groups; however, the 
reduction in lesion volume was significantly greater in the natalizumab group compared 
with the placebo group (p = 0.004). T1- hypointense lesion volume was significantly  
increased in the placebo group over the second year, while remaining the same in the 
natalizumab group (p < 0.001). Mirroring the changes observed in T2 lesion volumes, 
the natalizumab arm experienced a greater mean reduction in T1-hypointense lesion 
volume compared against placebo (-1508mm
3 vs 548 mm
3; p < 0.001) and, accordingly, 
a greater median percentage change (-24% vs -2%; p<0.001) over the 2 years of the 
trial. 
 
FIG 4.3 Mean (top) and median (bottom) T1-hypointense lesion volumes for natalizumab and 
placebo treated arms 
 
As with T2 volume measures, the mean percentage change, while showing clear 
differences between treatment arms, is much larger than the median percentage change, 
due to the presence of a small number of subjects with small baseline lesion volumes 
and consequently large percentage change in lesion volume over the 2 years. 
 
  
Table 4.7 T1-hypointense lesion volumes. IR= interquartile range 
Baseline  Year 1  Year 2   
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
T1- hypointense lesions         
N (observed N) 
Mean ± SD 
Median 
IR 
627 (626) 
5752 ± 8183 
2743 
870-7132 
315 (313) 
5693 ± 7633 
2681 
878-7467 
627 (606) 
4149 ± 5591 
2025 
598-5030 
p = 0.004 
315 (297) 
4979 ± 7303 
2444 
846-6137 
 
627 (582) 
4244 ± 5652 
2031 
672-5169 
p < 0.001 
315 (283) 
6241 ± 14394 
2855 
1026-6801 
Change from baseline         
N (observed N) 
Mean ± SD 
Median 
IR 
    627 (605) 
-1604 ± 4677 
-556 
-1753 to -55 
p < 0.001 
315 (296) 
714 ± 5086 
-254 
-1274 to 
106 
627 (581) 
-1508 ± 4759 
-449 
-1786 to -3 
p < 0.001 
315 (282) 
548 ± 12314 
-6.0 
-881 to 475 
% Change from baseline*         
N (observed N) 
Mean ± SD 
Median 
IR 
    610 (588) 
14 ± 291 
-24 
-46 to -7 
p < 0.001 
308 (290) 
75 ± 1073 
-13 
-37 to 7 
610 (565) 
20 ± 322 
-22 
-43 to -4 
p < 0.001 
308 (278) 
109 ± 1362 
-2 
-28 to 25 
 *calculated for subjects with baseline values >0 
 
4.3.3.7 T1/ T2  Lesion Volume Ratio (Table 4.8) 
 
Table 4.8 T1/ T2 LVR at each trial timepoint. IR = interquartile range 
Baseline  Year 1  Year 2  T1/ T2 LVR 
Natalizumab  Placebo  Natalizumab  Placebo  Natalizumab  Placebo 
Mean ± SD 
Median 
IR 
0.328 ± 0.19 
0.319 
0.18-0.46 
0.343 ± 0.19 
0.349 
0.19-0.46 
0.275 ± 0.18 
0.261 
0.15- 0.38 
p=0.012 
0.298 ± 0.16 
0.300 
0.18- 0.39 
 
0.270 ± 0.17 
0.256 
0.15- 0.37 
p=0.002 
0.311 ± 0.24 
0.295 
0.18- 0.40 
Change from baseline         
Mean ± SD 
Median 
IR 
    -0.053 ± 0.13 
-0.044 
-0.12 to 0.00 
p=0.043 
-0.045 ± 0.11 
-0.037 
-0.09 to 0.01 
-0.058 ± 0.13 
-0.048 
-0.12 to 0.01 
p=0.002 
-0.032 ± 0.21 
-0.032 
-0.11 to 0.03 
 
% Change from baseline         
Mean ± SD 
Median 
IR 
    -9.6 ± 64.1 
-17.0 
-37.3 to 1.1 
p=0.024 
-0.9 ± 102.2 
-12.8 
-30.8 to 3.5 
-10.0 ± 64.6 
-17.4 
-36.6 to 2.1 
p=0.003 
7.7 ± 126.2 
-12.9 
-31.2 to 8.0 
 
Although the T1/ T2 LVR  was not significantly different between treatment arms at 
baseline, mean T1/ T2 LVR was lower in the natalizumab treated group versus the 
placebo treated group at year 1 (0.275 vs 0.298, p= 0.012)  and year 2 (0.270 vs 0.311 
p=0.002) (Table 4.8). In addition, the absolute and percentage reduction in T1/ T2 LVR 
was greater in the natalizumab treated group throughout the trial (table 4.8).   
 
Sensitivity analyses of lesion volume data showed results that were consistent with the 
primary analyses (data not shown). 
 
4.3.4 Subgroup analysis 
 
Subgroup analysis was performed on pre-specified baseline characteristics as described 
in the methods section (4.2.7.3) in order to determine whether certain baseline 
characteristics influenced disease activity and progression, and whether natalizumab 
exerted a differential effect on any particular subgroup. The results of the analysis will 
be described in the following sections. 
  
4.3.4.1 Gd enhancing lesions (Table 4.9) 
 
Table 4.9 Number of Gd-enhancing lesions over the trial period: prespecified subgroup analysis. 
Figures are in mean  ± standard deviation. All natalizumab vs placebo comparisons are 
significantly different to p<0.01 except for subjects with less than 9 T2 lesions at baseline: in which 
neither arm exhibited activity within the trial 
Subgroups  Natalizumab  Placebo 
Age, yr 
  <40 (n = 399, 188) 
   
≥40 (n = 228, 127) 
 
0.1 ± 0.6 
 
0.2 ± 2.2 
 
1.1 ± 3.0 
 
1.3 ± 4.9 
Gender 
  Female (n = 449, 211) 
 
  Male (n = 178, 104) 
 
0.1 ± 1.6 
 
0.1 ± 0.6 
 
1.3 ± 4.4 
 
0.9 ± 2.6 
EDSS 
  ≤3.5 (n = 548, 278) 
 
  >3.5 (n = 79, 37) 
 
0.1 ± 0.5 
 
0.5 ± 3.6 
 
1.2 ± 4.1 
 
0.8 ± 1.8 
No. of relapses in 
year prior to study 
  1 (n = 368, 180) 
 
  2 (n = 197, 102) 
 
  ≥3 (n = 56, 27) 
 
 
0.0 ± 0.1 
 
0.2 ± 0.9 
 
0.6 ± 4.3 
 
 
0.8 ± 2.4 
 
1.3 ± 3.1 
 
3.4 ± 10.0 
No. of Gd-enhancing lesions 
  0 (n = 308, 172) 
 
  ≥1 (n = 319, 143) 
 
0.0 ± 0.1 
 
0.2 ± 1.9 
 
0.4 ± 1.1 
 
2.1 ± 5.5 
No. of T2 lesions 
  <9 (n = 29, 15) 
 
  ≥9 (n = 598, 300) 
 
0.1 ± 0.2 
 
0.1 ± 1.4 
 
0.0 ±0.1 
 
1.3 ± 3.9 
 
Greater pre-study or baseline disease activity, as measured by number of relapses in the 
preceding year, and the presence of Gd enhancing lesions, were associated with a 
greater number of Gd enhancing lesions during the trial study period. Higher number of 
Gd enhancing lesions during the study period were also found in women, subjects at or 
over the age of 40, subjects with >9 T2 -hyperintense lesions at baseline, and 
paradoxically, subjects with a baseline EDSS score <3.5. Treatment with natalizumab 
was associated with a significantly lower number of Gd enhancing lesions compared 
with placebo, regardless of pre-study or baseline characteristics,  with the exception of 
the small group of subjects who had <9 T2-hyperintense lesions, in which neither 
treatment arm had demonstrable Gd-enhancing lesion activity.  
 
4.3.4.2 T2-hyperintense lesions (Table 4.10) 
 
Table 4.10 Number of new or enlargingT2 -hyperintense lesions over 2 years: prespecified subgroup 
analysis. Figures are in mean  ± standard deviation. All natalizumab vs placebo comparisons 
are significantly different to p<0.001 
Subgroups  Natalizumab  Placebo 
Age, yr 
  <40 (n = 399, 188) 
   
≥40 (n = 228, 127) 
 
1.7 ± 4.6 
 
2.2 ± 14.1 
 
12.2 ± 17.2 
 
9.2 ± 13.2 
Gender 
  Female (n = 449, 211) 
 
  Male (n = 178, 104) 
 
2.0 ± 10.7 
 
1.6 ± 3.4 
 
11.4 ± 16.5 
 
10.1 ± 14.2 
EDSS 
  ≤3.5 (n = 548, 278) 
 
  >3.5 (n = 79, 37) 
 
1.8 ± 9.2 
 
2.5 ± 9.3 
 
11.4 ± 16.1 
 
7.9 ± 12.1 
No. of relapses in 
year prior to study 
  1 (n = 368, 180) 
 
  2 (n = 197, 102) 
 
  ≥3 (n = 56, 27) 
 
 
1.3 ± 3.8 
 
2.1 ± 4.6 
 
5.6 ± 27.9 
 
 
10.0 ± 13.0 
 
12.1 ± 16.6 
 
14.6 ± 26.6 
No. of Gd-enhancing lesions 
  0 (n = 308, 172) 
 
  ≥1 (n = 319, 143) 
 
0.9 ± 2.0 
 
2.8 ± 12.7 
 
5.8 ± 8.3 
 
17.3 ± 19.8 
No. of T2 lesions 
  <9 (n = 29, 15) 
 
  ≥9 (n = 598, 300) 
 
0.2 ± 0.9 
 
2.0 ± 9.4 
 
2.6 ± 2.8 
 
11.4 ± 16.0 
 
Disease activity in the year prior to the study and at baseline was associated with a 
greater number of new or enlarging T2- hyperintense lesions during the study. These 
results echoed the findings of the subgroup analysis for the number of Gd-enhancing 
lesions. In addition, women and subjects with baseline EDSS scores ≤ 3.5 or ≥9 T2-
hyperintense lesions also had higher numbers of new/enlarging T2-hyperintense lesions 
on study. There was no effect of age on the number of new/enlarging T2-hyperintense 
lesions. Natalizumab treatment was associated with lower numbers of new/enlarging T2-
hyperintense lesions compared with placebo, regardless of prestudy/baseline 
characteristics.  
 
4.3.4.3 T1-hypointense lesions  
 
Table 4.11 Number of new T1-hypointense lesions over 2 years: prespecified subgroup analysis. 
Figures are in mean  ± standard deviation. All natalizumab vs placebo comparisons are 
significantly different to p<0.001 
Subgroups  Natalizumab  Placebo 
Age, yr 
  <40 (n = 399, 188) 
   
 ≥40 (n = 228, 127) 
 
1.1 ± 2.5 
 
1.0 ± 4.2 
 
4.9 ± 7.6 
 
4.2 ± 6.7 
Gender 
  Female (n = 449, 211) 
 
  Male (n = 178, 104) 
 
1.1 ± 3.7 
 
0.9 ± 1.8 
 
4.6 ± 7.6 
 
4.6 ± 6.6 
EDSS 
  ≤3.5 (n = 548, 278) 
 
  >3.5 (n = 79, 37) 
 
1.0 ± 3.1 
 
1.5 ± 3.9 
 
4.9 ± 7.6 
 
2.6 ± 3.3 
No. of relapses in 
year prior to study 
  1 (n = 368, 180) 
 
  2 (n = 197, 102) 
 
  ≥3 (n = 56, 27) 
 
 
0.7 ± 1.5 
 
1.4 ± 3.3 
 
2.1 ± 8.1 
 
 
4.7 ± 7.5 
 
4.3 ± 6.1 
 
5.5 ± 10.3 
No. of Gd-enhancing lesions 
  0 (n = 308, 172) 
 
  ≥1 (n = 319, 143) 
 
0.6 ± 1.2 
 
1.5 ± 4.3 
 
2.4 ± 3.4 
 
7.3 ± 9.5 
No. of T2 lesions 
  <9 (n = 29, 15) 
 
  ≥9 (n = 598, 300) 
 
0.3 ± 0.5 
 
1.1 ± 3.3 
 
1.5 ± 2.0 
 
4.8 ± 7.4 
 
Subjects with Gd-enhancing lesions at baseline had more on-study new T1-hypointense 
lesions. The relationship between number of relapses prior to study and number of new 
T1-hypointense lesions is less clear cut, although in general, it appears to show a trend 
toward a positive relation between number of pre-study relapses and number of new T1-
hypointense lesions. In addition, subjects with baseline EDSS scores ≤ 3.5 or ≥9 T2-
hyperintense lesions also had higher numbers of new T1-hypointense lesions on study. 
There was no clear effect of age or gender on the number of new T1-hypointense 
lesions. In line with the other subgroup analyses, treatment with natalizumab was 
associated with significantly fewer T1-hypointense lesions compared with placebo in all  
prespecified subgroups. 
 
4.4 Discussion 
 
Treatment of subjects with natalizumab was associated with marked improvements in 
MRI indices (number of Gd enhancing lesions, new/enlarging T2-hyperintense, new T1-
hypointense lesions) of MS when compared against placebo. These effects were 
sustained over the 2 year period of the study, and were consistent with the clinical 
findings of the study. In addition, they confirmed and extended the findings of the 
previous 6 month proof-of-concept trial ( Miller DH et al., 2003).   
 
4.4.1 Effect of natalizumab on Gd- enhancement 
 
Treatment with natalizumab was associated with a 92% reduction in the number of Gd-
enhancing lesions over 2 years. The changes in lesion volume mirrored the number of 
lesions, and an equally clear cut-difference was observed between treatment groups. Gd 
enhancing lesions represent areas of overt BBB breakdown. As such, these findings 
emphasize the efficacy of natalizumab in the suppression of lesions associated with 
overt BBB leakage, and are consistent with its mechanism as an α4β1 antagonist.  
 
4.4.2 Effect of natalizumab on new lesion formation and lesion volume 
 
Natalizumab was associated with a significant and sustained reduction in the  
accumulation of new lesions, seen either as areas of T2 hyperintensity (83% reduction) 
or T1 hypointensity (74% reduction), the latter representing about one-third of the 
former. While a clear difference in T2-hyperintense and T1-hypointense lesion volume 
evolution was also seen in favour of the natalizumab-treated group, the longitudinal 
pattern of change was nonlinear in both groups and warrants more detailed 
consideration.  
 
4.4.2.1 Changes in the volume of T2-hyperintense lesions 
 
Changes in total lesion volume are a result of the net effect from volume expansion 
through new and enlarging lesions against volume reduction through the resolution of 
pre-existing lesions. Within the placebo group, the relatively stable lesion volume over 
the 1
st year was followed by a clear increase in volume in the 2
nd year. Seen in the terms 
above, the results indicate that accumulation of new or enlarging lesions matched the 
resolution of pre-existing lesions during the 1
st year, with a much greater accumulation 
of new or enlarging lesions in the second year than lesion resolution. Because the 
number of new T2-hyperintense lesions in the placebo arm was similar in both years, the 
relative stability of lesion volume in the 1
st year compared with the 2
nd year is likely to 
be due to a greater proportion of potentially reversible subacute inflammatory lesions at 
study entry than was the case later on in the study.  This idea of greater inflammatory 
activity at baseline is supported by the observation that the total volume of Gd 
enhancing lesions in the placebo group was roughly 50% higher at baseline than at latter 
timepoints, and by the observation that the relapse rate during the year prior to study 
entry was 1.3 compared with 0.7 in the 1
st year of study.  
  
It may also be possible that enlargement of pre-existing lesions occurred which escaped 
visual detection, which was employed according to conservative criteria (Molyneux et 
al., 1999). Such enlargement may have contributed to the greater observed increase in 
total volume of T2-hyperintense lesions in the 2
nd year of the study, in the face of little 
apparent increase in the number of new or enlarging lesions.  
 
In the natalizumab-treated arm, there was a clear reduction in T2-hyperintense lesion 
volume in the 1
st year of study, with little change in the 2
nd year. These findings indicate 
that resolution of pre-existing lesions outweighed the development of new lesions 
(which were very few for subjects on treatment) in the 1
st year, while in the 2
nd year, 
when there were few lesions either resolving or appearing, total volumes were 
predictably stable. 
 
The relative stability of T2-hyperintense lesion volume in placebo-treated subjects in the 
first year of the study emphasizes the crucial importance of having a parallel control 
group to distinguish the effects of spontaneous regression in disease activity from 
genuine treatment effects.  
 
4.4.2.2 T1-hypointense lesion volume changes in the placebo treated arm 
 
The changes seen in T1-hypointense lesion volume changes were similar to those seen 
for lesion volume of T2-hyperintense lesions. Hence, the placebo treated arm 
experienced a relatively minor drop in T1-hypointense lesion volume over the 1
st year of 
the trial, followed by a clear increase in volume during the 2
nd year of the trial. The 
mechanisms underlying this evolution are likely to be similar to that seen for T2- 
hyperintense lesion volumes,  but the sharper initial drop in T1-hypointense lesion 
volume may reflect a relatively high proportion of subacute lesions at study entry that 
had resolution of edema and/or remyelination, both of which will favor evolution from 
T1 hypointensity to T1 isointensity.(Barkhof et al., 2003)  
 
The large drop in T1-hypointense volume in the natalizumab-treated group during the 1
st 
year is consistent with partial resolution of preexisting lesions, in addition to there being 
very few new lesions. As expected, with few new lesions in the second year and a stable 
pre-existing lesion load at year 1, the T1-hypointense lesion volumes were relatively 
stable during year 2.  
 
4.4.3 Changes in T1/ T2 LVR 
 
As T1-hypointense lesions form a subset of T2-hyperintense lesions associated with 
more profound damage, the observation that natalizumab treatment was associated with 
a reduced T1/ T2 LVR is an important one. It indicates that the effect of natalizumab on 
T1-hypointense lesion volume cannot merely be attributable to a ‘blanket effect’ on T2-
hyperintense lesions as a whole, but an additional effect on the volume of T1 
hypointense lesions per se, most likely by reducing the likelihood of new T2-
hyperintense lesions evolving into regions of T1-hypointensity, and therefore reducing 
the accumulation of the total T1 hypointense lesion load. Evidence that natalizumab 
treatment is associated with a reduced likelihood of evolution into T1-hypointense 
lesions stems from a study of data from the previous trial (Dalton et al., 2004a) and is 
consistent with postulated downstream effects of the agent on lymphocyte activation 
and inflammatory processes, once leucocyte adhesion and migration have occurred. The  
effect of natalizumab on lesion formation and evolution are therefore potentially 
twofold. Firstly, to avert new lesion formation. Secondly, once lesion formation has 
occurred, to suppress ongoing inflammation and therefore reduce the likelihood of 
axonal loss and damage.  
 
4.4.4 Subgroup analysis 
 
The effect of natalizumab treatment on MRI lesion number was evident in all subgroups 
studied. Although there was little treatment arm difference in Gd enhancing lesions in 
subjects with <9 T2 lesions, the group was small, and very little clinical or MRI 
evidence of disease activity was present during the study. This finding suggests that 
subjects with relapsing MS who have few MRI lesions are likely to experience a more 
quiescent disease course during clinical trials. There may therefore be a case for 
requiring a minimum number of lesions as a criterion for entry to future studies of 
relapsing MS. 
   
Higher levels of MRI activity during the trial were associated with higher levels of 
disease activity at baseline, most notably a higher relapse rate during the year prior to 
study entry and the presence of Gd-enhancing lesions at baseline. Similar observations 
were made in subgroups of the previous smaller Phase II study. (O’Connor et al., 2005). 
This observation suggests that subgroups selected for having more frequent recent 
relapses or Gd-enhancing lesions will be more sensitive when evaluating MRI lesion 
activity measures in treatment trials since they are likely to have more on-study activity. 
In a similar vein, an analysis of placebo data from multiple trials showed that prior 
relapse rate is correlated with the likelihood of Gd-enhancement at a single time  
point.(Barkhof et al., 2005 ) 
 
4.4.5 The use of the number of new T2-hyperintense lesions as an outcome measure  
 
It was observed during the trial that the number of new T2-hyperintense lesions 
considerably exceeds (by 10 times) the number of Gd-enhancing lesions. As such, in 
trials where annual scans are performed, new T2-hyperintense lesions may be a more 
sensitive outcome measure than the number of Gd-enhancing lesions. This is because 
the T2 measure visualizes new T2-hyperintense lesions that may have appeared at any 
time during the year, since the majority of such lesions become persistent areas of T2 
hyperintensity. In contrast, Gd-enhancement is a transient feature of new lesions that 
typically lasts for only a few weeks, and therefore depicts only active lesions at the time 
of MRI.   
 
It was also observed that new T2-hyperintense lesions are much more common (>10 
times) than enlarging lesions. Although this partly reflects the use of conservative 
criteria for enlargement that had been previously developed by an expert group 
(Molyneux et al., 1999), the approach was considered necessary since it is difficult to be 
certain of enlargement during analysis of scans, as the appearance of lesions is 
susceptible to change with minor differences in repositioning. For future studies, it may 
be considered more efficient to report new T2 lesions only and not expend extra effort in 
detecting (with less certainty) a few enlarging lesions unless there is a hypothesis that 
therapy will have a discordant effect on new vs enlarging T2-hyperintense lesions. In 
addition, genuine biological enlargement of lesions, even if not appreciated visually, 
should also be reflected in the measure of total lesion volume.    
 
4.4.6 The use of new T1-hypointense lesions as an outcome measure 
 
The total count of new T1- hypointense lesions on the precontrast scans included Gd 
enhancing lesions which may have been acute and reversible. Therefore, to determine 
the contribution of such lesions to the outcome measure, an additional analysis was 
performed on the post-contrast scans. This revealed that the majority of  new T1-
hypointense lesions were non-enhancing, and therefore more likely to reflect areas of 
persistent hypointensity associated with a greater degree of tissue matrix damage, 
including axonal loss when compared with isointense lesions (Barkhof et al., 2003; van 
Waesberghe et al., 1999). The number of new T1-hypointense lesions is a potentially 
useful outcome measure as it is more likely to reflect just such a subset of lesions, 
which are associated with more axonal loss and tissue damage, and provides more 
specific information than T2 lesion load. The reduction of such a measure and its related 
measure of T1/ T2 LVR in natalizumab treated subjects indicates the potential of 
natalizumab to reduce the accumulation of axonal loss arising from new inflammatory 
lesions in RRMS. 
 
4.4.7 Conclusion 
 
In conclusion, treatment with natalizumab is associated with a marked and sustained 
reduction in brain MRI lesions in subjects with relapsing MS. These changes mirror the 
improvements in clinical indices of the disease (Polman et al., 2006), and are consistent 
among subgroups of subjects with more or less active inflammatory disease. Taken  
together these results suggest that natalizumab is a promising new therapy for the 
treatment of relapsing MS, although account will also need to be taken of the potential 
for adverse effects, in particular the risk for PML (Kleinschmidt-Demasters and Tyler., 
2005; Langer-Gould et al., 2005; van Assche et al., 2005 ), which has been estimated to 
be about 1 in 1000 over the first 18 months of treatment (Yousry et al., 2006).  
Continued longer term follow-up with conventional MRI will be useful to explore the 
persistence of therapeutic effect on the lesion activity and volume measures reported 
herein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 5 
A study of grey and white matter atrophy in a placebo-controlled trial of 
natalizumab in relapsing remitting multiple sclerosis. 
  
5.1 Introduction 
 
Histological and MRI studies support a growing body of evidence for axonal loss within 
MS lesions and, to a lesser extent, in NAWM. Serial volumetric MRI scans, through the 
observation of changes in brain volume, provide a reproducible method for following 
brain volume change (atrophy) and inferring neuroaxonal loss over time (Anderson et 
al., 2006). This substudy of the natalizumab trial in RRMS (AFFIRM) utilised MRI to 
examine segmental (GM, WM and BP) atrophy in study subjects treated with 
natalizumab or placebo. The data was also analysed for relationships between atrophy, 
disability and MRI lesion load. 
 
5.1.1 Evidence for axonal loss or degeneration in MS 
 
The MR spectroscopy metabolite NAA is contained almost exclusively in neurones and 
axons in the human adult CNS. Reduced NAA, indicating neuroaxonal damage or loss, 
is observed in MS lesions (Fu et al., 1996), NAWM (Siger-Zajdel and Selmaj, 2005; 
Chard et al., 2002c), GM (Chard et al., 2002c; Van Au Duong et al., 2007) and in 
whole brain measures (Filippi et al., 2003) even in the earliest clinical stage of disease. 
Such reductions correlate with axonal loss and disability in early disease (De Stefano et 
al., 2001; Fu et al., 1998). The findings echo those of histological studies which  
demonstrate a reduction in axonal density within MS lesions (van Waesberghe et al., 
1999)  and evidence of axonal transection and axonal damage in MS lesions and 
surrounding NAWM (Trapp et al., 1998; Kuhlmann et al., 2002). In addition, axonal 
damage originating within the lesion can have more widespread anatomical effects, 
through antegrade or retrograde degeneration and neuronal cell body apoptosis.  This is 
supported by the finding of reduced axonal density in the corpus callosum (a structure 
with widespread cortical and subcortical connections) in a manner which correlates with 
white matter lesion load (Evangelou et al., 2000) 
 
5.1.2 Sequential volumetric MRI as a marker of brain atrophy 
 
Sequential volumetric MRI measures of the whole brain provide a reproducible and 
often sensitive marker of brain tissue loss (atrophy), and have been used in the study of 
neurodegenerative diseases such as Alzheimer disease (Fox and Freeborough, 1997). In 
MS, this approach has allowed the study of brain atrophy in vivo (Anderson et al., 
2006).  In CIS, conversion to MS is associated with ventricular enlargement (Dalton et 
al., 2002b) and GM atrophy (Dalton et al., 2004b). In early disease (within  two and a 
half years of onset of first symptoms), average brain volumes – and the volumes of grey 
and white matter - of MS sufferers are lower than healthy counterparts (Chard et 
al.,2002a), with increasing atrophy over time again being predominantly seen in the GM 
(Tiberio et al., 2005).   
 
The relationship between atrophy and MS lesion load is a complex one, with conflicting 
findings emerging from different studies (Tiberio et al., 2005; Filippi et al., 2004; 
Molyneux et al., 2000; Gasperini et al., 2002, Rudick et al., 2000). Atrophy appears to  
be temporally linked to MS lesion formation, with rates of atrophy being related to 
preceding MS lesion load, sometimes many years before.  ( Gasperini et al., 2002, 
Rudick et al., 2000, Chard et al., 2003).  A correlation with disability has also been 
demonstrated in some, but not all studies (Rudick et al, 2000; Losseff et al., 1996; 
Gasperini et al., 2002).     
 
5.1.3 Natalizumab, new lesion formation and secondary neuronal damage 
 
The effect of natalizumab on MRI-visible MS lesions in the AFFIRM monotherapy trial 
was described in detail in the preceding chapter. Natalizumab, a humanized monoclonal 
antibody directed against the α4 subunit of the leucocyte cell adhesion molecule α4β1 
integrin, was associated with a 68% reduction in annualized relapse rate and a 42% 
reduction in risk of sustained disability progression compared with placebo (Polman et 
al., 2006 ). Its effects on MRI-visible lesions is similarly dramatic (92% reduction in Gd 
enhancing lesions, 83% reduction in new or enlarging T2- hyperintense lesions and 76% 
reduction in new T1- hypointense lesions), and sustained over 2 years(Miller DH et al., 
2007).   In patients who were still experiencing relapses on IFNβ−1a, the addition of 
natalizumab to the existing therapy (SENTINEL Trial, Biogen Idec) was associated 
with a 54% reduction in annualized relapse rate and a 24 % reduction in risk of 
disability progression compared with IFNβ−1a and placebo. (Rudick et al., 2006).  
 
Treatment with natalizumab was also associated with a reduced likelihood of new Gd 
enhancing lesions evolving into persistent T1- hypointense lesions (Dalton et al.,  
2004a), a subset of lesions associated with greater incidence of disruption to the 
extracellular matrix, axonal loss and persistent demyelination (van Waesberghe et al.,  
1999; van Walderveen et al., 1998; Barkhof et al., 2003).  
 
Such studies are compatible with an action of natalizumab that, while primarily 
disrupting overt BBB breakdown and associated new lesion formation, may also limit 
axonal damage and degeneration by the disruption of downstream processes such as 
leucocyte activation and proliferation once the BBB has been breached (Dalton et al., 
2004a, Damle et al., 1991, Burkly et al., 1991) 
 
A subsidiary endpoint of the AFFIRM monotherapy study was atrophy as measured by 
changes in BPF as defined by Rudick and colleagues as the ratio of brain parenchymal 
volume over the total volume within the surface contour of the brain (Rudick et al., 
1999). Over the 2 years of the trial, there was no significant difference between the 
treatment arms in the total change in BPF. However, BPF reduction in the group 
receiving natalizumab was significantly higher than placebo between baseline and year 
1, and lower than placebo between year 1 and year 2. (Miller DH et al., 2007) The 
difference in the BPF trajectory may be attributable to the initial resolution of 
inflammation-associated oedema in the treated cohort in the first year and to reduced 
neuroaxonal loss secondary to the suppression of new inflammatory lesions in the 
second year. 
 
The present study aimed to look at segmental atrophy by applying an automated brain 
segmentation programme (SPM99, Wellcome Institute of Cognitive 
neuroscience)(Ashburner and Friston, 1997; 2000) to examine changes in normalised 
volumetric measures of GM and WM and whole brain parenchyma (BP=GM+WM) in a 
subpopulation of patients participating in the AFFIRM trial. Treatment effect on rates of  
GM, WM and BP atrophy was looked for, as were correlations between rates of 
atrophy, disability and lesion load. 
 
5.2 Methods 
 
5.2.1 Recruitment 
 
Recruitment was from 3 centres (National Hospital for Neurology and Neurosurgery, 
London UK, VU Medical Centre, Amsterdam Netherlands and St Michael’s Hospital, 
Toronto Canada) participating in the AFFIRM trial, the details of which have already 
been reported in the Chapter 4. The institutional review board and ethics committee for 
each centre approved the substudy protocol for each site, and written, informed consent 
separate from the main trial was obtained from each patient participating in the 
substudy. 
 
5.2.2 MRI Protocol 
 
Patients were scanned in 1.5T MRI scanners in their respective centres at baseline, year 
1 and year 2 of the treatment trial. At each scan session, in addition to the sequences 
obtained as part of the main trial protocol (PD/ T2 weighted fast spin echo sequence; pre 
and post-contrast T1 weighted spin echo sequence (4.3.4)), an additional 3D Inversion 
Prepared  FSPGR  Echo  sequence  was  performed  at  the  beginning  of  each  session. 
(TI=450ms; TR=13.5-15ms; TE=4.2-7ms; 1 excitation; 256X256 matrix; 250X180mm  
FoV; 124-128 contiguous axial oblique slices with a z interval and slice thickness of 
1.5mm). These produced T1  weighted sequences of high volumetric precision and good 
WM/GM contrast. 
 
5.2.3 Image processing and analysis 
 
Electronic data for the scans were forwarded to the central MRI analysis centre (NMR 
Research Unit, Department of Neuroinflammation, Institute of Neurology, London). 
SPM99 was then used to perform automated segmentation of the images into GM, WM 
and CSF fractions (Ashburner and Friston, 1997; 2000), through the calculation of the 
probability (based on location and signal intensity thresholds) of each voxel being in 
GM, WM or CSF. Using corresponding T2 weighted sequences as reference, WM 
lesions were identified on the 3D FSPGR scans. ROI were then drawn around the 
lesions and empirically assigned as WM, to avoid the erroneous assignation by SPM99 
(based partly on signal intensity) of these lesions as GM or CSF (Chard et al., 2002b). 
Binary maps of each specific tissue segment within the total intracranial volume ie GM, 
WM or CSF were then constructed (FIG 5.1), from which the volumes of individual 
segments (GM, WM or CSF) were measured. 
  
 
FIG 5.1  (From left to right) Axial brain, binary maps of GM segment, WM segment and CSF 
segment. The latter 3 obtained through automated segmentation of the 1st using SPM99 
 
Scan rescan studies on healthy controls, employing SPM99 for brain segmentation on 
3D FSPGR sequences have produced coefficients of variation of 0.5%, 0.7% and 1.1% 
for normalised BP, GM and WM volumes respectively (Chard et al., 2002b).  
 
5.2.4 Calculation of GMF, WMF and BPF 
 
The volume of each segment (GM, WM and CSF) was calculated from the binary maps. 
Volumes of GM, WM and BP were expressed as a fraction of the total intracranial 
volume (which was calculated as the sum of volumes from GM, WM and CSF) to 
produce a normalised value of GM fraction (GMF), WM fraction (WMF) and BP 
fraction (BPF). Normalising to intracranial volume was intended to reduce variations 
caused by differences in subject head size, FoV and positioning.  
 
5.2.5 Change across scanner upgrade 
 
One of the centres (London) underwent a scanner software upgrade during the second 
  
year of the study. Consequently, 13 of the 19 patients in that centre underwent their year 
2 scans after the scanner upgrade. 5 Healthy controls were scanned in London before 
and after the scanner upgrade, and WMF, GMF and BPF were obtained, to help 
determine if the aforementioned measures were influenced by the upgrade. While 
measures of WMF were stable across the upgrade, GMF was underestimated in post-
upgrade scans, possibly due to subtle changes in the GMF/CSF contrast seen mainly 
around the gyrus rectus and temporal lobe. The underestimation of GMF in post-
upgrade scans proved difficult to characterise.  Treatment arm comparisons and linear 
regression analyses took into account changes that may have been seen as a result of the 
upgrade.  
 
5.2.6 Statistical Analysis 
 
Mann-Whitney independent sample rank sum tests were employed on baseline 
parameters (Age, Gender, disease duration, lesion loads, EDSS) to determine any 
differences between the treatment groups.  
 
The atrophy measures were log-transformed so that any changes and accompanying CI 
were expressed as percentages. A paired t-test was used to look for significant atrophy 
between baseline and year 1 with regression of change performed to determine if 
atrophy differed between centres. Analysis of atrophy at year 2 then used multiple 
regression, with log(atrophy measure) as response variable and  treatment, centre, 
gender  and baseline or year 1 log(atrophy measure) as covariates.  An additional site x 
upgrade interaction term was included to accommodate for the scanner upgrade in 
London.  There was no evidence of non-normality of residuals.   
 
An independent samples t-test, correcting for baseline values, was used to determine if 
there was an effect of natalizumab on change in the volume of T1- hypointense, or T2- 
hyperintense lesions 
 
Spearman's correlation coefficients were obtained for associations between atrophy and 
measures of disability and MRI visible lesion load, with regression analysis performed 
when multiple (confounding) associations were detected to determine the independent 
association. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5.3 Results 
 
5.3.1 Descriptive Data (Table 5.1) 
 
Table 5.1 Baseline descriptive data of patients volunteering in the study.  Values are in median 
(range) unless otherwise stated.  
   Placebo Group 
(n=18) 
Treated Group 
(n=39) 
Entire Substudy group 
(n=57) 
Age  38 (25-50)  38 (19-51)  38 (19-51) 
Number of Males (%)  4 (22)  12 (31)  16 (28) 
Disease Duration at 
baseline 
6 (1-26)  5 (1-26)  6(1-26) 
EDSS at baseline  1.5 (0-4.5)  2 (0-5.5)  2 (0-5.5) 
Mean Total T2 - 
hyperintense lesion 
load per patient in 
mls (SD) 
15739 (20440)  17639 (13751)  17039 (15998) 
Mean Total T1-  
hypointense lesion 
load per patient in 
mls (SD) 
6570 (10336) 
 
7231 (7963)  7022 (8692) 
Mean Total 
Gadolinium 
enhancing lesion 
load in mls (SD) 
379 (759)  527 (897)  480 (851) 
 
Fifty-seven patients participated in the study, (twenty-five in Toronto, nineteen in 
London and thirteen in Amsterdam). Thirty-nine of the patients had been randomized to 
the treatment cohort and were receiving monthly intravenous infusions of natalizumab 
300mg.  At baseline, age, disease duration, EDSS and treatment ratio were similar 
between treatment arms and centres. Males constituted a higher proportion of patients in 
the natalizumab arm when compared with the placebo arm (30 vs 22 per cent) but this 
was not statistically significant on the Mann-Whitney test. Nonetheless, differences in 
gender distribution were taken into account while performing the treatment arm  
analysis. Of the fifty-seven subjects who were scanned at baseline, fifty-six subjects 
returned for the scan at year 1 and fifty-three at year 2. 
 
5.3.2 Changes in normalised brain volume (FIG 5.2; Table 5.2) 
 
Given the cross-upgrade discrepancies in brain volume estimation described earlier,   
mean values of normalised brain volumes at year 2 and estimated volume changes 
between baseline and year 2 are reported  excluding those who underwent their scans 
after the scanner upgrade (n=40). However, as the upgrade took place after all the year 1 
scans were performed, the corresponding values reported at year 1 include data from all 
who participated in the year 1 scan (n=56).  All values are reported with treatment arms 
combined.   
 
Estimation of percentage change in normalised brain volume employed a regression 
model which took into account differences in centre, gender and baseline values (Table 
5.2). Calculation of normalised brain volumes involved obtaining the mean values and 
standard deviation for the cohort at each timepoint (FIG 5.2). As such, apparent 
discrepancies may exist between the figures reported in Table 5.2 and FIG 5.2. 
However, the figures derived from regression analysis (Table 5.2)  provide a more 
statistically robust reflection of change in normalised brain volume between timepoints. 
 
 
 
 
  
Table 5.2 Estimated percentage change in normalised brain volume using multiple regression 
(baseline to year 2) and paired t-test (baseline to year 1). Negative values denote a reduction in 
normalised volume. Values are reported for both treatment arms combined. Numbers in 
parenthesis are 95% CIs. 
  Baseline to year 1 (n=56)  Baseline to year 2 (n=40) 
BPF  -0.81% (-0.49%, -1.13%) P<0.001  -1.12% (-0.67%, -1.56%) P<0.001 
GMF  -1.01% (-0.58%, -1.43%) P<0.001  -1.36% (-0.81%, -1.9%) P<0.001 
WMF  -0.50% (-1.00%, 0.002%) P=0.051  -0.73% (-1.38%, -0.08%) P=0.030 
 
 
 
 
    A        B        C 
FIG 5.2 Mean values (+/- standard deviation) of BPF, GMF and WMF at baseline(n=57), year 
1(n=56) and year 2(n=40).  
 
5.3.2.1 BPF: mean values and estimated changes (Table 5.2; FIG 5.2A) 
 
The mean BPF at each timepoint (0.816, 0.809, 0.815 at baseline, year 1 and year 2 
respectively with standard deviation of 0.03) is shown in FIG 5.2A.  
 
There was a statistically significant estimated 0.81% fall (95% CI: 0.49% lower, 1.13% 
lower; P<0.001) in BPF from baseline to year 1 and a 1.12% fall (95% CI: 0.67% lower, 
1.56% lower; P<0.001)  between baseline and year 2 (Table 5.2). There was no 
evidence that the fall in BPF varied between centres (P=0.14). 
  
5.3.2.2 GMF: Mean values and estimated changes (Table 5.2;FIG5.2B) 
 
Mean GMF was 0.536, 0.53 and 0.532 at baseline, year 1 and year 2 respectively with a 
standard deviation of 0.02. (FIG 5.2B) 
 
There was an estimated 1.01% reduction in GMF (95% CI 0.58% lower, 1.43% lower, 
P<0.001) from baseline to year 1 and a 1.36% fall (95% CI: 0.81% lower, 1.9% lower, 
P<0.001) from baseline to year 2. (Table 5.2) There was no evidence that these changes 
varied by centre (P=0.84) 
 
5.3.2.3 WMF: Mean values and estimated changes (Table 5.2; FIG 5.2C) 
 
Mean WMF was 0.280, 0.279 and 0.283 in baseline, year 1 and year 2 respectively. 
Standard deviation at each timepoint was 0.04. (FIG 5.2C) 
 
Statistical analysis revealed that changes in WMF were less clear cut across the 2 years, 
with a borderline significant 0.50% fall (95% CI 1.00% lower, 0.002% higher; P=0.05) 
from baseline to year 1 and a significant 0.73% fall (95% CI: 1.38% lower, 0.08% 
lower; P=0.030) in WMF between baseline and year 2 (Table 5.2). Once more, there 
was no evidence that changes in WMF varied between centres (P=0.84) 
 
5.3.3 Treatment arm analysis 
 
Treatment arm analysis was performed taking all data (pre and post upgrade) into  
account, with a correction factor for post-upgrade data. 
 
5.3.3.1 Treatment arm comparison of changes in MRI visible lesion load (FIG 5.3) 
 
     A            B 
FIG 5.3 Mean volume change from baseline to year 2 in T2-hyperintense lesions (A) and T1- 
hypointense lesions (B) 
 
Natalizumab was associated with a greater reduction in the volume of T2 hyperintense 
lesions compared to placebo (Baseline-adjusted mean treatment arm difference -
3741mls  95% CI -6689, -793 mls, P=0.01). However, no significant treatment effect 
was demonstrated on the volume of T1-  hypointense lesions (Baseline-adjusted mean 
treatment arm difference  -709mls 95% CI -2257, 837, P=0.36). 
 
 
 
 
 
 
 
P=0.01 
P=0.36  
5.3.3.2 Treatment arm atrophy comparison (Table 5.3; Fig 5.4) 
 
Table 5.3 Active vs Placebo differences in BPF, GMF, WMF, adjusting for baseline values. Figures 
represent differences as a percentage of placebo (95% CIs). Negative  values denote greater 
atrophy in the active arm.  All differences are non-significant to p=0.05 
  Year 1  Year 2 
BPF  0.29% (-0.42%, 1.0%) P=0.41  -0.16% (-1.05%, 0.74%) P=0.73 
GMF  0.70% (-0.21%, 1.6%) P=0.49  -0.23% (-0.87%, 1.33%) P=0.68 
WMF  -0.40% (-1.5%, 0.75%) P=0.13  -0.81% (-2.1%, 0.47%) P=0.21 
 
 
Multiple regression analysis of normalised brain volume adjusted for baseline values, 
centre and gender differences. It demonstrated no significant difference in atrophy 
between treatment arms at year 1 or year 2 (Table 5.3) 
 
 
 
 
 
 
 
 
  
 
      A          B   
     
 
            C 
FIG 5.4 Mean change in BPF (A), GMF (B) and WMF (C) over the course of the trial. Units 
expressed in 10
-3.  As calculated by multiple regression (Table 5.3), changes seen in natalizumab, 
placebo and combined arms were not significantly different. 
 
FIG 5.4 displays the mean changes in normalised brain volume over the course of the 
trial, as calculated by subtracting the baseline value from values at latter timepoints.  
 
Although multiple regression detected no statistically significant differences between 
the treatment arms, the charts in FIG 5.4 appear to reflect a trend toward a lower rate of 
GM atrophy in the natalizumab treated arm when compared against the placebo at both  
timepoints (GMF reduction of -4.1*10
-3 vs -7.7*10
-3 for natalizumab and placebo 
respectively at year 1 and -6.0*10
-3 vs -9.4*10
-3 for natalizumab and placebo 
respectively at year 2), and similarly a trend toward a greater rate of WM atrophy in 
natalizumab treated patients compared with placebo at both timepoints. 
 
5.3.4 Relationship between atrophy and other measures of disease 
 
5.3.4.1 Relationship between EDSS and normalised brain volumes (Table 5.4).  
 
Table 5.4 Spearman's rank correlation coefficient between normalised brain volume (BPF, WMF, 
GMF) and disability as measured by EDSS at baseline and Year 2. Significant relationships in bold 
Associations between EDSS and normalised brain volume  BPF  WMF  GMF 
Spearman's rank correlation coefficient (ρ)  -0.45  -0.0115  -0.48  Baseline (n=57) 
Significance (P)  0.0005  0.93  0.0002 
Spearman's rank correlation coefficient (ρ)  -0.41  -0.13  -0.43  Year 2 (n=56) 
Significance (P)  0.0024  0.42  0.001 
 
There was a negative association between GMF and EDSS at baseline (ρ=-0.48, 
p=0.0002) and year 2 (ρ=-0.43 P=0.001). No such relationship existed between WMF 
and EDSS at baseline or year 2 (P=0.9 and 0.4 respectively). The negative association 
observed between BPF and EDSS at baseline and year 2 therefore most probably results 
from the association with GMF. Bootstrap analysis revealed no difference in the 
relationship between EDSS and brain volume in the 2 treatment groups. 
  
5.3.4.2 Relationship between atrophy MRI lesion load measures (Table 5.5, Table 5.6) 
 
Table 5.5 Multiple bivariate spearman correlation coefficients (ρ ) between GMF/WMF atrophy 
from baseline to year 2 and various MRI visible lesion measures. Significant bivariate correlations 
are in bold 
Baseline Lesion Volumes  GMF Change  WMF Change 
Spearman Correlation Coefficient (ρ)  -0.212  -0.414  T2- hyperintense 
lesions 
P value (2-tailed)   0.128  0.002 
Spearman Correlation Coefficient (ρ)  -0.096  -0.347  T1-  hypointense 
lesions 
P value (2-tailed)  0.494  0.011 
Spearman Correlation Coefficient (ρ)  -0.175  -0.443  Gd enhancing 
lesions 
P value (2-tailed)  0.209  0.001 
Lesion volume change over 2 years  GMF Change  WMF Change 
Spearman Correlation Coefficient (ρ)  0.168  0.144  T2- hyperintense  
lesions 
P value (2-tailed)   0.228  0.304 
Spearman Correlation Coefficient (ρ)  -0.004  0.212  T1-  hypointense 
lesions 
P value (2-tailed)  0.979  0.127 
Spearman Correlation Coefficient (ρ)  0.234  0.392  Gd enhancing 
lesions 
P value (2-tailed)  0.095  0.004 
 
Multiple bivariate correlation analysis revealed no significant association between GMF 
change and any of the lesion volume measures (table 5.5).  
 
Although a number of significant bivariate correlations existed between WMF change 
and lesion volumes at baseline ( T2- hyperintense lesions, T1-  hypointense lesions and 
Gd enhancing lesions), a multiple regression analysis revealed that only the relationship 
with Gd enhancing lesions was independently significant (r=-0.349, P=0.014)(Table 
5.6) 
 
 
  
Table 5.6 Multiple regression analysis of change in WMF over 2 years and baseline lesion load 
measures. Significant multivariate correlations in bold. 
Baseline lesion volumes  Standardized Coefficients (r)  Sig. (P) 
T2- hyperintense lesions  -0.463  0.173 
T1-  hypointense lesions  0.386  0.255 
Gd Enhancing lesions  -0.349  0.014 
 
Apart from a positive association with the change in volume of Gd enhancing lesions 
(ρ=0.392, P=0.004), change in WMF was not associated with the change in volume of 
MRI visible lesions (Table 5.5). 
 
Change in WMF was therefore negatively associated with baseline volume of Gd 
enhancing lesions (r=-0.349, P=0.014) and positively associated with the change in 
volume of Gd enhancing lesions (ρ=0.392, P=0.004). The high correlation between 
these 2 measures of Gd enhancing lesions (ρ=0.983, P<0.001) precluded any multiple 
regression analysis to discern if either influence was independent of the other. 
 
5.4 Discussion 
 
This substudy of the AFFIRM trial utilised SPM99 to analyse segmental atrophy in 
patients with RRMS. Although atrophy occurred in both GM and WM, GM atrophy 
appeared to predominate over the 2 years.  
 
GM atrophy was not related with MRI-visible MS lesion load. The positive association 
of WMF change with change in Gd enhancing lesion volume suggests that such 
variations in WMF are driven by changes inflammation-associated oedema.   
 
In keeping with the AFFIRM study, treatment with natalizumab reduced the expansion 
of T2- hyperintense lesions. The lack of observed effect on T1-  hypointense lesions is 
most probably a result of the small cohort (N=56), as a significant effect was observed 
in the main study (N=942)(Chapter 4). 
 
 No significant difference in atrophy rate was demonstrated between the treatment arms 
receiving natalizumab and placebo at any timepoint within the study using multiple 
regression. However, trends toward a treatment effect may exist.  These are discussed in 
more detail in section 5.4.4. 
 
5.4.1 Rates of Atrophy 
 
The rates of atrophy observed in the substudy (1.12%, 1.36% and 0.73% in BPF, GMF 
and WMF respectively over 2 years) are in keeping with those reported from other 
studies (Rudick et al., 2000; Kalkers et al., 2002; Tiberio et al., 2005), and further 
endorse the use of serial 3D volumetric MRI to measure atrophy in RRMS.  Both GM 
and WM atrophy was observed, with GM atrophy occurring at a greater rate than  WM 
atrophy over the 2 years (1.36% vs 0.73%), a finding consistent with observations from 
other studies which detected predominantly GM atrophy in early disease (Dalton et al., 
2004b; Tiberio et al., 2005).  
 
5.4.2 Relationship between atrophy and EDSS 
  
BPF and GMF at baseline and year 2 correlated with EDSS at these timepoints. This 
finding is largely consistent with findings from other studies to date investigating the 
relationship between disability and brain atrophy, using a variety of brain atrophy 
measurement approaches (Rudick et al., 2000; Bermel et al., 2003; Rovaris et al., 2001; 
Paolillo et al., 2002; Fisher et al., 2008; Fisniku et al., 2008b). Being less subject to 
inflammation-associated oedema (Pirko et al., 2007), GMF, rather than WMF is 
potentially a more accurate reflection of underlying neuronal loss and related disability. 
 
5.4.3 Relationship between atrophy and MRI visible lesion load 
 
WMF change was significantly and positively associated with the change in the volume 
of Gd enhancing lesions, a subpopulation of lesions associated with active inflammation 
and oedema (Grossman et al., 1986; Katz et al., 1993; Miller DH et al., 1988). Such a 
relationship points to oedema playing a significant role in influencing WMF fluctuation 
in this study.   
 
No relationship was detected between GM atrophy and lesion load. Other studies have 
failed to demonstrate a clear relationship between atrophy and lesion load (Gasperini et 
al., 2002; Molyneux et al., 2000). Using a methodology very similar to that adopted in 
the current study, Tiberio and colleagues demonstrated atrophy in early RRMS confined 
mainly to the GM, which was unrelated to the underlying lesion load(Tiberio et al., 
2005).   
 
The reasons for the apparent dissociation between GM atrophy and MRI visible lesion 
load are not altogether clear. A possible explanation may be that GM atrophy is  
influenced by demyelinating lesions within the GM itself. Such lesions form a 
significant portion of the total lesion load in MS (Pirko et al., 2007), and the existence 
of such lesions do not correlate well with white matter lesion load (Kutzelnigg et al., 
2005). The majority of these lesions are invisible on standard MRI sequences(Geurts et 
al., 2005, Kidd et al., 1999), including the ones used in this study. They are associated 
with activation of cortical microglia (Bo et al., 2003, Peterson et al., 2001)  and 
increased expression of inducible nitric oxide synthase, factors contributory to axonal 
loss (Smith KJ et al., 2001). It is conceivable that a population of MRI-invisible GM 
lesions, which are not necessarily associated with WM lesions, may be the principle 
stimulus for GM atrophy and explain the apparent dissociation between GM atrophy 
rate and WM lesion load.   
 
An alternative explanation may lie in the temporal relationship between focal 
inflammation and atrophy. In a long-term follow-up study, whole brain measures of 
volume were examined in MS patients 14 years after their first clinical event. Inferred 
atrophy was significantly related with change in T2- hyperintense lesion load between 
baseline and 5 years later (Chard et al., 2003), indicating that the effect of focal 
inflammation on atrophy in MS may be temporally remote from the inflammatory event 
itself, through relatively slow processes such as antegrade or retrograde degeneration 
originating from the site of inflammation or nitric oxide- induced damage to more 
vulnerable demyelinated axons (Smith KJ et al., 2001). Such processes may result in 
axonal loss and consequent atrophy in the GM once a significant length of time has 
passed, beyond the duration of the current study. 
 
  
5.4.4 Effect of natalizumab on lesion measures and atrophy  
 
Natalizumab reduced the proliferation of T2- hyperintense lesions, a finding in keeping 
with those from existing trials (Miller DH et al., 2007; Rudick et al., 2006). The 
apparently discrepant lack of a significant effect on T1- hypointense lesions is most 
probably attributable to differences in the sample population.  
 
In spite of a clear effect on MRI visible lesions, multiple regression failed to 
demonstrate any significant effect of natalizumab on segmental atrophy (GMF, WMF, 
BPF) at any timepoint (year 1 or year 2) in the study. Non-significant trends appeared to 
suggest a greater rate of WM atrophy  and lower rate of GM atrophy in the natalizumab 
treated group in the duration of the trial. The trend toward a greater rate of WM atrophy 
in natalizumab treated patients may reflect a natalizumab-mediated suppression of 
inflammation associated oedema within the WM. Similarly, the lower rate of atrophy in 
GM, which is unrelated to WM lesion load, may be an effect of natalizumab on GM 
atrophy itself. However, it must be stressed that  none of these trends approach 
significance, and therefore, such findings should be taken with caution.  
 
The absence of a statistically significant treatment effect of natalizumab on atrophy is  a 
finding which only partly agrees with those of the whole AFFIRM cohort. This found a 
significantly greater rate of reduction in BPF in the natalizumab-treated arm in the 1
st 
year (thought to be due to an initial reduction in inflammation-related oedema) and a 
lower rate of atrophy in the treatment arm between year 1 and year 2, resulting in no 
overall difference in BPF between treatment arms in the 2
nd year (Miller DH et al., 
2007). The discrepancy in the findings of the 2 studies may be explained by the  
different methods adopted at measuring atrophy in the 2 studies (SPM assisted brain 
segmentation vs BPF), or by the differences in the size of the study populations, as 
already alluded to above.  
 
A recent study calculated population sample sizes required to demonstrate a change in 
rate of atrophy using a selection of atrophy measures (Structural image evaluation using 
normalization of atrophy; segmented brain volume difference; brain boundary shift 
interval). The study findings indicated that in order to demonstrate a 30% reduction in 
atrophy rate over 2 years, drug trials required the recruitment of at least 123 subjects 
(Anderson et al., 2007). The ability to detect differences in atrophy was influenced by 
the number of study participants (the larger the study, the more sensitive), the duration 
of the study (longer studies were able to detect smaller differences in atrophy rates) and 
the method of atrophy measures. Although measurement of SPM99-segmented brain 
volumes was not amongst the approaches examined in this study, it is possible that with 
57 patients, this substudy was of insufficient power to demonstrate a treatment effect of 
natalizumab on atrophy. 
 
However, if the findings of this study (that is, the absence of a natalizumab-mediated 
effect on atrophy) are taken to be true, they would echo the findings of other trials of 
disease modifying agents which have not shown any significant effect on brain atrophy 
(Molyneux et al., 2000, Rovaris et al,. 2001) despite a clear effect on MRI-visible 
lesions. Together, such evidence would appear to suggest that atrophy is driven by 
processes not immediately or entirely related to focal white matter inflammation.   
 
The possibility remains that the temporal relationship between focal inflammation and  
axonal loss and atrophy may be a protracted one, with atrophy resulting from lesions 
occuring years before (Chard et al., 2003). This may provide an explanation for the 
apparent lack of effect of natalizumab on atrophy, despite a clear effect on WM lesion 
formation. Follow-up studies would be required to verify if this is the case. 
 
It is also possible that Natalizumab may exert a more modest effect on GM  lesions. 
Such lesions are associated with less BBB breakdown and leucocyte infiltration 
(Peterson et al., 2001), processes mediated by the interaction of VLA-4 and its 
associated ligands.    If such lesions influence and drive atrophy within the GM, the lack 
of effect of natalizumab on GM atrophy may be a reflection of its effect on such GM 
lesions. However, it is not possible to verify this hypothesis given the MRI sequences 
undertaken in the current study, which do not detect the majority of GM lesions. 
 
5.4.5 Summary 
 
The study has demonstrated  measurable brain atrophy over 2 years, predominantly in 
the GM, driven by processes independent from concurrent WM lesions. Normalised GM 
volume is inversely related to disability as measured by EDSS. The positive association 
between WMF change and the change in volume of Gd enhancing lesions points to 
fluctuations in the WM being largely secondary to inflammation associated oedema.  
Natalizumab, having influenced the formation of WM lesions, did not appear to have an 
effect on atrophy. This could be due to a lack of power (Anderson et al., 2007). 
However,  if the findings of the study do actually reflect a lack of treatment effect of 
natalizumab on atrophy, it would indicate that atrophy does not immediately arise from 
VLA-4 mediated processes or inflammation.  Further studies are required to determine  
if the influence of natalizumab on WM lesions results in a moderation of atrophy in the 
long term. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 6 
Subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab 
 
6.1 Introduction 
 
Overt BBB disruption, as detected by visible Gd enhancement on MRI, is a consistent 
finding in new MS lesions in patients with relapsing MS. (Kermode et al., 1990). 
Histological studies of active MS lesions demonstrate the extravascular deposition of 
fibrinous exudates, indicative of BBB disruption, in conjunction with perivenular 
inflammation, lymphocyte infiltration and oedema (Adams et al., 1985). Additional 
evidence of BBB disruption in chronic, non-active lesions has come from histological 
studies, including the demonstration through confocal microscopy of  disruption of the 
intercellular network of tight junctions which form the physical BBB (Kirk et al., 2003), 
and the widespread histological finding of extravascular deposition of fibrin in non-
active MS lesions (Kwon and Prineas, 1994; Claudio et al., 1995 ; Adams et al., 1985). 
The former, when chronic and persistent,  are associated with a greater degree of axonal 
loss, extracellular matrix destruction (van Walderveen et al., 1998) and disability 
(Truyen et al., 1996; van Walderveen et al., 2001).   
 
Natalizumab has been shown to suppress overt BBB disruption (Miller et al., 
2003;2007; Tubridy et al., 1999). Its effect on low grade BBB leakage was examined in 
this study by comparing the leakage from visibly non-enhancing lesions in the placebo 
group, vs the natalizumab treated group.  
  
6.2 Methods 
 
6.2.1 Recruitment 
 
The subjects involved in the study were recruited from 3 centres (National Hospital for 
Neurology and Neurosurgery, London UK, VU Medical Centre, Amsterdam 
Netherlands and St Michael’s Hospital, Toronto Canada) participating in the AFFIRM 
trial, the details of which have already been described in chapter 4.  Subjects and study 
personnel were unaware of the treatment assignments. Subjects from the 3 
aforementioned centres were given the option of participating in this additional 
substudy of the main trial. The institutional review board and ethics committee for each 
centre approved the substudy protocol for each site, and written, informed consent was 
obtained from each subject participating in the substudy. 
 
6.2.2 MRI protocol (FIG 6.1) 
 
Subjects were scanned in their respective centres 24 weeks after the start of the 
treatment trial. All scans were performed on 1.5T scanners. Sequences were prescribed 
as 46 contiguous axial oblique 3mm slices with a 256 x 256 matrix and a 250mm x 
188mm FOV. Before scanning, a cannula attached to a long line was inserted into the 
antecubital vein of each subject, to allow for the administration of Gd-DTPA while 
keeping the subject’s position constant within the scanner. A pre-contrast FSE sequence 
(TR= 3000 to 3300 ms; TE= 15 to 24 ms and 90 to 98 ms; 1 excitation; acquisition time 
approximately 5 min) was taken initially. This produced a T2 weighted and a PD  
weighted image, both of which were used for lesion identification. T1 weighted SE 
sequences (TR= 500 to 650 ms; TE= 15 to 20 ms; 1 excitation; acquisition time 
approximately 6 min) were then obtained prior to,  and starting 2, 9, 20 and 40 minutes 
following a bolus intravenous injection of Gd-DTPA (0.3mmol/kg London, Amsterdam, 
0.15mmol/kg Toronto). The timings at which SI was read at each scan were taken to be 
at the completion of each scan, i.e. at 8, 15, 26 and 46 minutes following contrast 
administration respectively. To ensure comparable intensity in T1 weighted images 
before and after contrast administration, the initial radiofrequency amplifier gains for T1 
weighted sequences in each subject were kept constant throughout. 
  
FIG 6.1 Scan protocol timeline for each subject. Unless otherwise specified, figures are in minutes 
and seconds. Figures to the left of the central vertical arrow represent the time elapsed for 
subsequent MR sequences and related actions. Figures in italics represent the time intervals 
between subsequent sequences.  Double-headed arrows represent the post-contrast timing of the 
serial T1 weighted scans. Gd-DTPA was administered as a bolus injection over 2 minutes, with 
scanning resuming 2 minutes after its completion.   Abbreviations: FSE-Fast Spin Echo, T1WSE- 
T1 weighted spin echo 
a0.3mmol/kg for 18 subjects, 0.15mmol/kg for 22 subjects 
 
  
6.2.3 Image Registration 
 
For each subject, the PD weighted component of the FSE sequence was registered to the 
pre-contrast T1 weighted sequence using a mutual information registration programme 
(Studholme et al., 1999). Subsequent, post-contrast T1 weighted sequences were then 
registered to the pre-contrast T1 weighted sequence using an adapted co-registration 
protocol (Woods et al., 1992). Co-registration spatially aligned the images within a 
series, allowing the accurate evaluation of T1-weighted SI change resulting from Gd 
administration. 
 
6.2.4 Image Analysis: 
 
Images were analysed by a single observer (DS), unaware of the subjects’ history and 
treatment, using a Sun workstation (Sun Microsystems, Mountain View, CA, USA) and 
dispimage display software (Plummer, 1992). Visibly non-enhancing lesions were 
defined as being hyperintense on pre-contrast T2 and PD weighted sequences, but which 
did not enhance to the eye on post-contrast T1 weighted scans. These were identified on 
the co-registered PD weighted sequence, where ROIs were described around them. 
Lesions which showed visible enhancement on post-contrast T1 weighted scans were 
excluded from the analysis. For each ROI describing a lesion (ROIlesion), a matched ROI 
was placed in the contralateral NAWM (ROINAWM) (FIG 6.2).  Where it was not 
possible to do this, the lesion was excluded from the analysis. ROINAWM provided a 
basis of comparison from which the SI change of the ROIlesion could be measured in the 
primary analysis. Each visibly non-enhancing lesion described on the PD weighted 
image was also designated as T1- hypointense or isointense. A lesion is designated as  
T1- hypointense  if it has a lower SI to the eye than the surrounding NAWM in the pre-
Gd T1 weighted sequence. SI change in response to Gd was quantified, and was used to 
infer BBB leakage. 
 
 
FIG 6.2 ROIlesion were described on  a PD weighted image which was registered to the pre-contrast 
T1 weighted sequence. For each ROIlesion, a paired ROINAWM was described in the contralateral 
NAWM 
 
6.2.5 Outcome measures and statistical analysis  
 
As log transformation of the SI improved the normality of the data and stabilised 
variance, the analysis was performed with log (SI). 
 
The primary aim of the study was to investigate for low grade BBB leakage from 
visibly non-enhancing lesions in a multi-centre setting using contrast-enhanced MRI, 
and to explore whether there might be a modifying influence of natalizumab treatment 
  
on such leakage from visibly non-enhancing lesions, using NAWM as a covariate.  
 
Secondary outcome measures assessed for a modifying influence of natalizumab 
treatment in: 
 
1.SI change in ROIlesion alone, (without SI in paired ROINAWM as a covariate) 
2. SI change in ROINAWM  
 
SI change in T1- hypointense  and T1- isointense lesions were also compared, and the 
influence of natalizumab on SI change was compared in either lesion subtype.  
 
Primary analysis was performed using a multilevel, multivariate model (Goldstein, 
1995), allowing for possible dependencies within lesions belonging to the same subject, 
with a separate response variable for each of the post-contrast time points. Other 
covariates taken into account by the model were centre/Gd dosage differences, pre-
contrast SI in ROIlesion, and paired ROINAWM SI.  The model allowed for testing for 
differences between treatment arms at individual time points, as well as a joint (global) 
test which assessed the null hypothesis of no differences between treatment arms at any 
of the last three time points. The pre-specified selection of the last three time points in 
the joint test was because of the potentially larger contribution of intravascular Gd to 
the initial rise in SI on the first post-contrast scan. Secondary analyses were 
implemented within this model framework by altering the covariate terms. Statistical 
significance was taken to be at p<0.05. Analysis was implemented using MLwiN2.0  
 
  
6.3 Results 
 
6.3.1 Descriptive data (Table 6.1) 
 
Table 6.1 Descriptive data of subjects volunteering in the study.  Values are in median(range) 
unless otherwise stated. Total T2 lesion load per subject is from data taken from the AFFIRM study 
for the relevant subjects at week 0. Age, gender distribution, EDSS and distribution of treatment 
arms were similar across the 3 centres 
   Placebo Group (n=13)  Treated Group 
(n=27) 
Entire study 
(n=40) 
Age  33 (25-48)  38(19-50)  38 (19-50) 
Male (%)  4 (30%)  10 (37%)  14 (35%) 
Disease Duration   5.5 (1.5-21.5)  6.5 (1.5-23.5)  6.0 (1.5-23.5) 
EDSS  1.5 (0-5.5)  3.0 (0-4.5)  2.25 (0-5.5) 
Total T2 lesion load 
per subject in mls 
8.6 (1.0- 83.3)   12.9 (0.9-44.0)  10.4 (0.9- 83.3) 
 
 
40 subjects were scanned (22 in Toronto, 7 in London and 11 in Amsterdam). 27 of the 
subjects had been randomized to the treatment cohort and were receiving monthly 
infusions of natalizumab 300mg. Age, gender distribution, disease duration and EDSS 
were similar between treatment arms and centres. 8 out of 13 subjects (62%) in the 
placebo cohort and 1 out of 27 subjects (4%) in the treatment cohort showed visible 
enhancement with Gd. This difference in the number of subjects showing Gd 
enhancement between the treatment and placebo cohort at 24 weeks is in keeping with 
findings in the main AFFIRM trial after 52 and 104 weeks of treatment(Miller et al., 
2007, Polman et al., 2006). 
 
In total, 1812 ROI pairs were studied, of which 1159 ROI’s were of T1- hypointense  
lesions. Between 4 and 111 ROI pairs were studied per subject, the median number 
studied per subject being 40.5 (Table 6.2). The number of ROI pairs studied per subject 
did not differ significantly between centres.   
 
Table 6.2 Median number of Paired ROIs studied per subject, categorised by centre. Unless 
otherwise specified, numbers in brackets are the range of values. The numbers of ROIs studied per 
subject did not differ significantly between the centres. 
  London (n=7)  Toronto (n=22)  Amsterdam 
(n=11) 
Total study 
(n=40) 
T1- hypointense 
lesions  
22 (7-44)  22.5 (2-87)  31 (4-79)  25 (2-87) 
T2 hyperintense 
lesions 
56 (18-73)  36.5 (4-97)  39 (7-111)  40.5 (4-111) 
 
6.3.2 Low grade BBB leakage in visibly non-enhancing lesions (Table 6.3) 
  
Table 6.3 Mean percentage change from pre-contrast SI in ROIlesion and ROINAWM . All paired 
differences between changes in ROIlesion and ROINAWM are significant to p<0.01 
1
st timepoint  2
nd timepoint  3
rd timepoint  4
th timepoint  Centre 
   Lesion   NAWM  Lesion   NAWM  Lesion   NAWM  Lesion   NAWM 
Toronto   2.5  1.2  1.7  0.4  1  -0.3  0.7  -0.9 
Amsterdam   3.3  2.5  3.3  2.3  3  2  2  1.1 
London   4.1  2.5  3.5  2  2.8  1.4  1.9  0.7 
Entire 
Study 
3.1  1.9  2.6  1.2  1.9  0.7  1.3  0 
 
SI change in visibly non-enhancing lesions was consistently greater than in paired 
NAWM at all post-contrast time points in all centres (P<0.01), indicating subtle, but 
consistent and detectable leakage in visibly non-enhancing lesions.  
 
 
 
 
 
 
  
6.3.3 Treatment arm analysis (Table 6.4) 
 
Table 6.4 Mean percentage change in ROI
a SI at each post-contrast timepoint, divided into 
treatment arm. Numbers in parentheses are standard deviations. Analysis adjusting for centre and 
baseline values found no significant difference between treatment arms in any of the ROI types 
below. 
  T2 lesions  NAWM  T1- hypointense  lesions  T1- isointense lesions 
Timepoint  natalizumab  placebo  natalizumab  placebo  natalizumab  placebo  natalizumab  placebo 
1  3.2 (3.1)  3.0 (2.5)  1.8 (2.6)  2.1 (2.5)  3.5 (3.2)  2.9 (2.6)  2.6 (3.0)  3.1 (2.3) 
2  2.1 (2.5)  2.7 (2.8)  1.0 (2.6)  1.6 (2.6)  2.8 (3.3)  2.6 (3.0)  2.1 (3.0  2.8 (2.5) 
3  2.0 (3.4)  1.7 (3.0)  0.7 (3.2)  0.6 (2.7)  2.4 (3.6)  1.6 (3.1)  1.3 (2.9)  1.9 (2.7) 
4  1.3 (3.1)  1.4 (2.8)  0.0 (2.7)  0.0 (2.5)  1.6 (3.2)  1.5 (3.1)  0.8 (2.9)  1.2 (2.3) 
acrude means, not adjusted for centre and baseline values, and will thus not correspond closely to 
the model-based estimated treatment effects given in the text.  
 
Analysis of the influence of natalizumab on BBB leakage revealed no evidence of a 
treatment x centre/Gd dosage interaction (P=0.90 for the global test), indicating that 
there was no evidence of a different natalizumab effect in different centres/Gd dosages.  
 
6.3.3.1 Treatment arm analysis of SI change in ROIlesion 
 
A joint test involving the last 3 timepoints revealed no evidence of difference in SI 
change in ROIlesion between treatment and placebo groups (chi-square 4.2 
(df=3),P=0.24), adjusting for pre-contrast lesion SI, paired contralateral NAWM SI and 
centre/dosage.  Analysis of individual timepoints revealed that treatment with 
natalizumab was associated with non-significant, small % reductions in SI change in 
ROIlesion when compared against the placebo group at each post-Gd timepoint. (Mean 
natalizumab-associated change in SI at 1
st timepoint:  -0.37%; 95%CI -1.1%, 0.3%, 
P=0.30; 2
nd timepoint: -0.65%; 95%CI -1.4%, 0.1%, P=0.08; 3
rd timepoint: -0.30%; 
95%CI -1.2%, 0.6%, P=0.5; and 4
th timepoint: -0.52%; 95%CI -1.3, 0.2, P=0.16).  
Removing SI in paired ROINAWM as a covariate did not substantially change the findings 
of the influence of natalizumab on SI change in ROIlesion. (Joint test chi-square 3.7 
(df=3), P=0.29, with no substantial alteration of the p values in individual timepoints).  
 
6.3.3.2 Treatment arm analysis of SI change in ROINAWM 
 
No difference was observed between treatment arms in the SI change of NAWM 
(n=1812, joint test chi-square 3.1 (df=3), P=0.37, P values for respective timepoints 
0.30, 0.19, 0.84, 0.55).  
 
6.3.4 Leakage from T1- hypointense  vs T1- isointense lesions  
 
A variation existed between different centres in the proportion of ROIlesion that were 
classified as T1- hypointense  lesions (Table 6.2). This could have arisen from a number 
of contributing factors, including differences in scanners and sequences, as well as 
differences in the sampling of lesions. Alternatively, such an observed difference could 
reflect real differences in the composition of visibly non-enhancing lesions in the 
subjects participating in the study. However, by adjusting for centre (as well as pre-
contrast lesion SI and contralateral NAWM SI and treatment group), the analysis by 
lesion subtype allowed for centre differences in the proportion of T1- hypointense  
lesions. 
 
When comparing the post-contrast SI change between T1- hypointense  and T1- 
isointense  ROIlesion, a borderline difference was detected in the 2
nd post-contrast  
timepoint (mean SI change of hypointense ROIlesion  was 0.28% less than isointense 
ROIlesion; 95%CI 0.56%, 0.002%; P=0.049). No difference was detected in any of the 
other timepoints (P= 0.43, 0.80, 0.21 for the 1
st, 3
rd and 4
th timepoints respectively) or 
when the last 3 timepoints were tested jointly (P=0.12). When comparing the influence 
of natalizumab on lesion subtypes, ie hypointense vs isointense, no evidence was found 
of an interaction between lesion subtype and treatment over the last three time points 
(chi-square 2.074, df=3, P=0.557).   
 
6.4 Discussion 
 
6.4.1 Possible contribution of intravascular Gd to observed changes 
 
A possible confounding factor in the usage of T1 weighted SI change in the inference of 
BBB leakage would be the contribution of intravascular Gd to SI change. Following a 
bolus injection, intravascular Gd concentration reaches a peak rapidly, before following 
a biexponential curve with a mean distribution half life of the order of 10 minutes,(Tofts 
and Berkowitz, 1994) diffusing into the extracellular spaces of the body, and being 
excreted principally through the kidneys. In this study, the contribution of intravascular 
Gd would have been greatest at the initial post-contrast timepoint, receding steadily 
with each successive timepoint. The selection of the latter 3 timepoints in the joint 
statistical tests was designed to take into account the lower contribution of intravascular 
Gd in these timepoints.  
 
  
6.4.2 Low grade BBB leakage in visibly non-enhancing lesions 
 
A consistent finding in this study was the low grade, detectable leakage in visibly non-
enhancing lesions, compared with contralateral NAWM which was present up to 45 
minutes following the administration of contrast. This was apparent in all centres, and in 
both T1- hypointense  as well as T1- isointense  lesions. That such differences were 
sustained over all timepoints up to 45 minutes strongly indicates BBB leakage, rather 
than a larger blood volume, or higher perfusion, in visibly non-enhancing lesions. This 
is in agreement with findings from the previous, single centre contrast-enhanced study 
in multiple sclerosis (Silver et al., 2001b), and supports the approach of quantitative 
contrast-enhanced imaging as a way of detecting low grade BBB leakage in visibly non-
enhancing lesions in a multi-centre study. These findings are also in line with 
histological evidence, in terms of tight junction disruption (Kirk et al., 2003) and fibrin 
deposition (Claudio et al., 1995 ,Kwon and Prineas, 1994), of widespread BBB leakage 
from non-active lesions.  
 
6.4.3 Treatment arm analysis of BBB leakage in visibly  non-enhancing lesions 
 
The ability of natalizumab to suppress new lesion formation and acute, overt BBB 
disruption has been demonstrated in a series of animal (Yednock  et al,. 1992) and 
human (Tubridy et al., 1999; Miller et al., 2003; 2007) studies. It is thought that 
natalizumab, in blocking α4 integrin, interferes not only with the initial event of 
lymphocyte adhesion and trafficking, but also with the subsequent events of activation 
(Damle and Arrufo, 1991), proliferation (Burkly et al., 1991) and cytokine release-  
events critical in the formation of lesions and in the initial, overt BBB breakdown 
(Minagar and Alexander, 2003). The lack of a significant difference in post-contrast 
signal changes in non-enhancing lesions between treatment arms suggests that the more 
subtle leakage from such lesions is due to processes that are largely or entirely 
independent of α4 integrin. Histologically, vessels in non-active MS lesions often 
exhibit reparative wall thickening in concert with fibrin deposition, (Adams et al., 1985) 
suggesting that leakage from such lesions might at least in part be due to incomplete 
BBB repair, with some permanent structural and functional changes following 
resolution of inflammation. Supporting this hypothesis are findings from morphometric 
analysis of capillaries in non- active MS lesions, which have demonstrated a reduction 
in mitochondria and a rise in pinocytic vesicles, in concert with evidence, in terms of 
extravascular fibrin deposits, of BBB disruption. (Claudio et al., 1995) Such findings 
imply a profound shift in the physiology of these vessels to a more energy deficient 
state, hindering the energy dependent transport mechanisms essential in maintaining the 
BBB. It is conceivable that such changes could contribute to the low grade BBB leakage 
detected in the MS lesions in this study. 
 
6.4.4 Leakage from T1- hypointense  vs T1- isointense  lesions 
 
The finding of a slightly higher (0.28%) SI change in T1- isointense  than in hypointense 
lesions in the 2
nd post-contrast timepoint (15 minutes post-contrast) is an isolated 
finding. No similar difference is seen in the other timepoints, most notably in the 1
st 
post-contrast timepoint, indicating that the difference in the 2
nd timepoint is not due to 
differences in intravascular Gd. Moreover, a joint test involving the last 3 timepoints, 
including the 2
nd post-contrast timepoint, revealed no difference in SI change between  
hypointense and isointense lesions. The overall picture in this study is therefore of very 
little difference in BBB leakage between T1- hypointense  and T1- isointense  lesions. 
Such a finding suggests that low grade leakage in both types of lesions may occur 
through common or similar mechanisms, involving more permanent changes to the 
BBB. The absence of a differential effect of natalizumab on leakage in the 2 lesion 
subtypes suggests that such mechanisms in both subtypes are largely independent of 
α4β1 integrin.  
 
6.4.5 SI change in NAWM 
 
This study found no evidence of any difference in the SI change in NAWM between 
natalizumab and placebo treated groups. However, as there were no healthy controls for 
comparison, it is uncertain if the post-Gd SI changes seen in NAWM reflect abnormal 
BBB leakage per se.  
 
6.4.6 Limitations imposed by the use of contralateral NAWM as a covariate 
 
In order to incorporate contralateral NAWM as a covariate, a number of visibly non-
enhancing lesions were excluded as it was not possible to find a contralateral area of 
NAWM in which to place a matching ROINAWM. This was more likely in subjects with 
lesions covering large areas on both sides of the brain. There is therefore a possibility 
that lesions in subjects with larger T2 lesion loads are under represented. Total T2 lesion 
volume per subject however, did not differ significantly between the natalizumab and 
the placebo group. It is unlikely therefore that the main analyses by treatment arm  
would be affected by this methodological limitation. It was found in this study that 
analysis without including contralateral NAWM as a covariate did not change the study 
findings, and there was no significant change in the related P values. This suggests that 
it is feasible to modify the design of future contrast enhanced BBB studies to include all 
visibly non-enhancing lesions, with a related, smaller analysis employing the SI change 
in contralateral NAWM as a covariate, where possible. Such a modification in design 
would incorporate a greater proportion or visibly non-enhancing lesions, and has been 
undertaken in the study described in the next chapter. 
 
6.4.7 Gd Dosage differences between centres 
 
Subjects from a single centre inadvertently received 0.15mmol/kg of Gd-DTPA instead 
of a triple dose (0.3mmol/kg). These constituted 22 out of the 40 subjects studied. The 
different dose of Gd-DTPA resulted in post-contrast SI curves of different magnitude. 
Moreover, a proportion of lesions which would have visibly enhanced following triple 
dose Gd-DTPA could have lost their visible enhancement and been re-classified as 
visibly non-enhancing, with a lower Gd dose. (Silver et al., 1997; Filippi et al., 1996). 
Nonetheless, the balance between treated and placebo subjects is similar in the 3 
centres, and statistical analysis, which took into account centre and Gd dosage 
differences, revealed an absence of centre/Gd dosage x treatment interaction. Therefore, 
for the purpose of investigating for differences in post-contrast SI change between 
treatment and placebo arms, the differences in Gd dosage do not appear to compromise 
the main findings of the study.  
  
6.5 Summary and conclusion 
 
This substudy of the AFFIRM trial of natalizumab monotherapy versus placebo has 
demonstrated that quantitative contrast-enhanced imaging is a viable approach in 
detecting low grade BBB leakage from visibly non-enhancing lesions in a multi-centre 
trial setting, and that such leakage is a consistent feature in both T1- hypointense  and 
T1- isointense  lesions in MS. The finding that the detectable BBB leakage is not 
significantly lower in natalizumab-treated subjects suggests that it occurs predominantly 
or entirely through mechanisms other than those mediated by α4β1 integrin. Such 
leakage may occur through more permanent changes in the vascular wall, with a 
chronic, incomplete BBB repair, as suggested by findings from histological studies of 
vessels in non-active lesions, and will be studied in detail in the next chapter using an 
alternative MRI marker to T1 weighted SI change. 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 7 
Quantification of subtle blood brain barrier disruption in non- enhancing lesions 
in multiple sclerosis: A study of disease and lesion subtypes 
 
7.1 Introduction 
 
The  use  of  Gd  chelated  contrast  agents  such  as  Gd-DTPA  has  been  central  to  the 
investigation of  BBB disruption using MRI. Gd does not traverse the intact BBB, and 
local Gd enhancement has been correlated with histological markers of BBB breakdown 
in EAE - a widely recognized animal model of MS (Hawkins et al., 1990). Gd enhanced 
MRI studies have been useful in detecting focal BBB disruption in association with new 
or actively inflamed lesions in MS (Bruck et al., 2007; Grossman et al., 1986; Katz et 
al., 1993; Miller et al., 1988; Lai et al., 1996). 
 
Most Gd enhanced MRI studies in MS have been qualitative investigations, relying on 
visible post-Gd enhancement of lesions on T1 weighted images to identify overt BBB 
disruption and leakage. Quantitative investigations, where the Gd mediated change is 
measured, could facilitate the detection of more subtle and low grade BBB leakage. 
Such studies have been performed in the ischaemic rat brain (Harris et al., 2002) and 
intracranial tumours (Zhu et al., 2000). Using the proportional change of T1 weighted 
signal  intensity  as  a  marker  for  BBB  leakage,  subtle  leakage  from  visibly  non-
enhancing  lesions  up  to  40  minutes  following  triple  dose  Gd-DTPA  has  been 
demonstrated (Silver et al., 2001). 
 
Conventional MRI markers of MS, such as Gd enhancement and T2 weighted lesion  
load, correlate only modestly with clinical disability and relapse rate (Kappos et al., 
1999; IFNB MS Study Group and University of British Columbia MS/MRI analysis  
Group, 1995 ). A potential factor that could lead to such a dissociation is subtle but 
widespread BBB disruption occurring in the large majority of MS lesions that are non-
enhancing, in post-contrast scans, to the eye. Such disruption could, if prolonged and 
ubiquitous, contribute to ongoing tissue damage (demyelination and axonal loss) and 
hence disability through the continuous low grade leakage of inflammatory cells and 
soluble  mediators  of  inflammation  into  surrounding  central  nervous  system 
parenchyma.  Therefore,  the  use  of  MRI  to  detect  such  low  grade  leakage,  and  to 
determine if such leakage relates to disease course and disability, is of relevance.  
 
This present study used ΔR1/Δt as a measure of BBB leakage. ΔR1/Δt is derived from 
Gd-induced changes in measured T1 and represents a more fundamental, more sensitive 
and potentially more reproducible MR measure than T1 weighted SI change. Visibly 
non-enhancing lesions were investigated for subtle BBB disruption. BBB leakage was 
also compared between non-enhancing lesions which were hypointense on pre-contrast 
T1  weighted  scans  (T1-  hypointense  lesions)  and  those  which  were  isointense  (T1- 
isointense  lesions);  the  former  -  when  chronic  and  persistent  -  are  associated  with 
greater  axonal  loss  and  extracellular  matrix  destruction,  as  well  as  disability.(van 
Walderveen et al., 1998, Barkhof et al., 2003). Lesions from RRMS and SPMS patients 
were studied for possible differences of leakage across the 2 clinical subtypes. As eight 
of the nineteen patients were on disease modifying treatment, potential interactions with 
treatment status were also investigated. The relationship of the BBB leakage measure 
with EDSS, age and gender was also studied. 
  
7.2 Methods 
 
7.2.1 Patients 
 
Nineteen patients with clinically definite MS (Poser et al., 1983) were recruited from 
the outpatient department at the National Hospital for Neurology and Neurosurgery. All 
patients had a neurological history taken and a physical examination performed by a 
single observer (DS).  Exclusion criteria included pregnant or breast feeding women, 
previous allergy to Gd-DTPA and corticosteroid use within the previous 2 months. Each 
patient  gave  full,  written,  informed  consent  to  participate  in  the  study,  which  was 
approved by the joint research ethics committee of the National Hospital for Neurology 
and Neurosurgery and the Institute of Neurology   
 
7.2.2 MRI acquisition protocol 
 
All  imaging  was  performed  using  a  1.5  T  Signa,  superconducting  system  with  a 
standard  quadrature  headcoil.  (GE  Medical  Systems,  Milwaukee,  Wisconsin,  USA).  
Sequences were prescribed as 28 contiguous axial oblique 5mm slices with a 256 x 256 
matrix and a 240mm x 180 mm Field of View. Before starting to scan, a cannula was 
inserted into the antecubital vein of the patient. This was connected to a long line which 
was flushed with normal saline. The use of the long line enabled the patient to be 
maintained in the same position throughout the whole MR acquisition during and after 
the administration of Gd-DTPA, which was normally performed over 2 minutes.  
  
 
FIG 7.1:Scan protocol timeline for each patient. Unless otherwise specified, figures are in minutes 
and seconds. Figures to the left of the central vertical arrow represent the time elapsed between 
subsequent MR sequences and related actions. Figures adjacent to the double-headed arrows 
represent the post contrast timing of the serial T1 maps. Gd-DTPA is administered over 2 minutes, 
with scanning resuming 2 minutes after its completion.  
asequences used to make up T1maps  
 
FIG  7.1  illustrates  the  order  and  timing  of  sequences  obtained  for  each  patient. 
Radiofrequency amplifier gains in each patient were kept constant throughout the scan. 
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This  ensured  that  images  obtained  before  and  after  the  Gd  administration  were  of 
comparable intensity, and facilitated the identification and description of lesions (visibly 
enhancing vs non-enhancing, T1- hypointense vs T1- isointense) to be carried out in a 
standardized manner. 
 
7.2.2.1 Sequences for lesion identification 
 
A pre-Gd FSE sequence (TR= 2000ms; TE= 19ms and 95 ms; ETL=8; acquisition time 
5min 45s) was acquired, producing PD and T2-weighted images on which lesions were 
identified. A T1 weighted SE sequence (TR=  540ms; TE= 20ms; NEX=1; Acquisition 
time= 6min.) was performed before and from 2 minutes after the completion of Gd-
DTPA  administration  (FIG  7.1),  to  enable  the  identification  of:  (i)  T1-  hypointense 
lesions pre-contrast and (ii) visibly Gd enhancing lesions post contrast. 
 
7.2.2.2 T1 map construction 
 
PD weighted (TR= 1500ms, TE= 11ms, flip angle= 45 degrees, NEX= 1.5, Acquisition 
time=  10min  30s)  and  T1  weighted  (TR=50ms,  TE  =11ms,  flip  angle=  45  degrees, 
NEX= 3, Acquisition time= 9min 30s) GE sequences were performed prior to, and in 
series  after  the  completion  of  the  postcontrast  T1  weighted  SE  sequence  (FIG  7.1). 
Alignment  of  the  initial  PD  and  T1  weighted  images  was  achieved  using  a  mutual 
information registration technique (Studholme et al., 1999). Subsequent T1 weighted 
and PD weighted GE sequences were then registered to the initial, co-registered scans 
using  an  adapted  co-registration  protocol  (Woods  et  al.,  1992).  A  T1  map  at  each  
timepoint was then calculated from the registered PD and T1 weighted images (Parker et 
al., 2001 ). This relates the ratio of the PD and T1 weighted signal intensities to a look-
up table, accounting for slice profile and B1 non-uniformity. The timing of each post-Gd 
T1 map was taken as the start of its T1 weighted GE component, which was roughly 20, 
40 and 60 minutes after the start of Gd-DTPA administration. (FIG 7.1) 
 
7.2.3 Image Analysis 
 
All  image  analysis  was  performed  using  a  Sun  Workstation  (Sun  Microsystems, 
Mountain  View,  CA,  USA)  and  Dispimage  display  software  (Plummer,  1992).  All 
analysis was performed blinded to patient demographic and clinical data.  
 
Visibly  non-enhancing  lesions  were  identified  on  the  co-  registered  PD  weighted 
component  of  the  FSE  sequence  and  checked  against  the  post-Gd  T1  weighted  SE 
sequence to exclude those with visible enhancement. A lesion is defined as showing 
visible enhancement if on the post-Gd T1 weighted scan, it appears brighter to the eye 
than its NAWM and to its corresponding image on the pre-Gd T1 weighted sequence. 
The  lesions  were  then  outlined  on  the  co-registered  PD  weighted  image  using  a 
semiautomated lesion contouring technique (Plummer, 1992). Wherever possible, for 
each ROI describing a lesion, a matching ROI was placed in the contralateral normal 
appearing brain tissue (NABT) (FIG 7.2). These paired ROI’s formed a subset of data 
from which leakage from visibly non-enhancing lesions could be compared against that 
of matched NABT.  
 
  
 
    a              b 
FIG 7.2 Coregistered PD weighted image (a) on which focal non-enhancing lesions are identified. 
ROIs are placed on the lesions, with matched ROIs in the contralateral NABT. The resultant ROIs 
are then placed on T1 maps (b) from which T1 for the ROI is measured and the R1 is calculated. 
 
Additionally, each visibly non-enhancing lesion was visually designated as hypointense 
or  isointense  relative  to  the  surrounding  NAWM  in  the  pre-Gd  T1  weighted  SE 
sequence. The lesion cross sectional area (CSA) was also recorded for each lesion. This 
was defined as the area of the ROI describing the lesion on the T2 weighted image, and 
in  the  case  where  a  lesion  traverses  multiple  slices,  the  area  of  the  largest  ROI 
describing the lesion. 
 
ROIs  were  also  described  around  visibly  enhancing  lesions  identified  on  the  post 
contrast T1 weighted image.  
 
All ROIs were superimposed onto the serial T1 maps (FIG 7.2). The mean T1 value 
within each ROI at each timepoint on the T1 map was then recorded. 
  
 
7.2.4 Detection of subtle BBB leakage 
 
Longitudinal relaxation rate (R1), is defined as the inverse of T1.  ΔR1 is the change in 
R1 following Gd administration.  This is described in the following equation: 
 
€ 
ΔR1 =
1
T 1
−
1
T 1(0)
= r 1Ct(t)             
 
Ct(t) = local concentration of Gd at time t following its administration 
T1= value of T1  at the time t 
T10= value of T1 before Gd administration 
r1= relaxivity of Gd, a constant
1   
 
From the above equation, the gradient of ΔR1 over time elapsed (ΔR1/Δt) is proportional 
to the change in local Gd concentration over time (Ct(t)). ΔR1/Δt was therefore used to 
infer BBB disruption in this study.  
 
7.2.5 Statistical analysis 
 
For the lesion level analysis, the slice with the largest CSA was chosen to obtain the 
largest  representative  sample.  Analyses  of  response  variables  (ΔR1/Δt)  at  separate 
timepoints used hierarchical linear regression (Baltagi, 1995) on two levels, patient and 
lesion, with random patient intercepts and fixed effects for the covariates of interest. 
The  analysis  of  paired  lesions  vs  contralateral  NABT  was  similar,  but  using  the 
                                                 
1  4.5 s-1mM-1 from in-vitro studies (Tofts and Berkowitz, 1994; Tofts et al., 1999).  
difference (ΔR1/Δtlesion minus ΔR1/ΔtNABT) as response variable.  
 
In  the  case  of  visibly  non-enhancing  lesions,  the  covariate  terms  included  in  the 
regression  models  were  at  lesion  level:  log  lesion  CSA  (log  transformation  greatly 
improved normality without affecting the interpretability or validity of the analysis), 
and whether a lesion was T1- hypointense. Covariate terms at patient level included age, 
total lesion volume (continuous variables) and gender, disease subtype, treatment with 
disease modifying agents such as IFNβ or glatiramer acetate, EDSS > 3 (indicators). 
 
Where  Normality  of  regression  residuals  could  not  confidently  be  assumed,  non-
parametric  bias-corrected  bootstrap  (Carpenter  and  Bithell,  2000)  estimates  (1000 
replicates with patient clustered resampling) are reported. 
 
Results of the analyses of post-Gd leakage have been expressed as paired differences in 
ΔR1/Δt (as in the analysis of lesions vs contralateral NABT), or, in circumstances where 
analysis is between non-paired covariates (such as RRMS vs SPMS lesions), in mean 
differences in ΔR1/Δt. Results were expressed in this manner to convey the magnitude 
of  difference  in  inferred  leakage  between  the  covariates  studied.  Analyses  were 
implemented in Stata 8.2 (Stata Corporation, College Station, Texas, USA). 
 
 
 
 
 
  
7.3 Results 
 
 
Table 7.1 Demographic data of patients recruited into the study. All values are median (range) 
unless otherwise stated. 
  RRMS (n=10)  SPMS (n=9) 
Number of male patients (%)  4 (40%)  4 (44%) 
Number of patients with visible enhancement (%)  4 (40%)  3 (33%) 
Number of patients on disease modifying treatment (%)  4 (40%)  4 (44%) 
Age, years  36 (27-53)  46 (26-64) 
Disease duration, years  4.5 (1-18)  19 (4-28) 
EDSS  2 (1.5-3.5)  6 (3-7.5) 
total lesion volume, mls  4.7 (0.2-12.9)  8.4 (3.2- 29.6) 
 
7.3.1 Patient Data 
 
The demographic data of the patients are shown in table 7.1. Nineteen patients (nine 
with SPMS and ten with RRMS) participated in the study. Due to the extended duration 
of the scan series, (over 90 minutes for the entire series), five patients (four with SPMS 
and one with RRMS) were only able to tolerate the acquisition of 2 instead of 3 sets of 
post-Gd T1 maps. In addition, a single RRMS patient reported dizziness during Gd-
DTPA  administration.  The  administration  was  discontinued  and  the  patient 
consequently received 0.1mmol/kg instead of 0.3mmol/kg of Gd-DTPA. There were no 
adverse events following the procedure.  
 
 
  
7.3.2 Lesion Data 
 
A total of 581 visibly non-enhancing lesions were identified in all nineteen patients, 238 
lesions in RRMS patients and 343 in SPMS patients. Of these, 156 out of the 343 (45%) 
of the SPMS lesions were T1- hypointense, as opposed to 80 out of the 238 (34%) 
RRMS lesions (odds ratio 0.57, p=0.057). In 449 of the 581 lesions, it was possible to 
describe matching ROI’s in the contralateral NABT. Leakage from this subset of lesions 
was  therefore  analysed  against  anatomically  analogous  contralateral  NABT.  Three 
RRMS and three SPMS patients were identified as having visibly enhancing lesions. 
Between them, 76 enhancing lesions were identified.  
 
7.3.3 Associations between covariates  
 
T1- hypointense lesions had larger CSAs than isointense lesions by an estimated factor 
of 2.0, (P<0.001; 95% CI 1.8, 2.3).  RRMS patients tended to have smaller lesion CSAs 
than SPMS, by a factor of 21.4% (P=0.037; 95% CI 1.5%, 37.3%); however, after 
adjusting for hypointensity, significance is lost (P=0.156), suggesting the difference in 
CSA between disease types may be at least partly explained by a borderline significant 
lower proportion of hypointense lesions in RRMS patients (odds ratio 0.57, p=0.057). 
No association was detected between lesion CSA and EDSS, disease duration, age or 
gender but, not surprisingly, patients with larger total lesion volume tended to have 
larger lesion CSA (P=0.002).  There was evidence that patients with an EDSS greater 
than 3 had a higher proportion of hypointense lesions (odds ratio 2.09, 95% CI 1.22, 
3.56; P=0.007), but there were no significant associations between T1- hypointensity 
and age, disease duration, gender or total lesion volume once EDSS was taken into  
account. There was no association between being on disease modifying treatment and 
the other covariates of T1- hypointense lesion load, age, disease duration, gender, or 
total lesion volume, or EDSS. 
 
7.3.4 Post Gd changes 
 
 
7.3.4.1 Visibly enhancing vs visibly non-enhancing lesions 
 
The mean ΔR1/Δt in visibly enhancing lesions was significantly greater than that in 
visibly non-enhancing lesions at all timepoints (p<0.001 for each timepoint) with no 
overlap of 95% CIs or of 95% reference ranges (table 7.2). 
 
Table 7.2 Mean Δ R1/Δt in visibly enhancing vs visibly non-enhancing lesions. Values in curved 
parenthesis are 95% CIs; values in square parenthesis 95% reference ranges. Units in 10
-3s
-1min
-1 
  1
st timepoint  2
nd timepoint  3
rd timepoint 
Enhancing Lesions  41.1(32.6, 49.6) 
[25.8, 56.4] 
20.2 (17.3,23.1) 
[12.7, 27.7] 
11.1(8.6,13.6) 
[8.2, 14.1]) 
Non-Enhancing Lesions  4.2 (3.1, 5.2) 
[-11.0, 19.3] 
2.1(1.7, 2.6) 
[-5.3, 9.5] 
1.7(1.4, 1.9) 
[-1.1, 4.5] 
Difference in Mean Δ R1/Δt  
(Enhancing –  
Non-Enhancing Lesions) 
36.9 
(28.9 ,  44.9) 
P< 0.001 
18.1  
(15.3, 20.8) 
P< 0.001 
9.4  
(6.8,  12.0) 
P< 0.001   
 
 
7.3.4.2 Visibly non-enhancing lesions vs contralateral NABT 
 
The  mean  paired  difference  (ΔR1/Δtlesion  minus  ΔR1/ΔtNABT)  between  visibly  non-
enhancing  lesions  and  contralateral  NABT  was  significant  at  all  3  post  Gd-DTPA  
timepoints (p≤0.001 for all lesions overall) (table 7.3).  
 
Overall, the paired difference appears to reduce with time. The difference in (ΔR1/Δtlesion 
minus ΔR1/ΔtNABT) remained significant at all timepoints for both T1- hypointense and 
isointense  subgroups  and  for  both  RR  and  SPMS  subgroups,  with  the  exception  of 
SPMS subgroup lesions at the 3
rd timepoint (table 7.3). The paired differences in the 
lesion and clinical subgroups were not significantly different from one another at any 
timepoint(table 7.4). 
 
Table 7.3 Mean paired difference in ΔR1/Δt between lesions and contralateral NABT. Values in 
parenthesis are 95% CIs. Units in 10
-3s
-1min
-1 
Mean paired difference in Δ R1/Δt [(Δ R1/Δtlesion - Δ R1/ΔtNABT]
 a 
  1st timepoint  
449 lesions 
2
nd timepoint  
449 lesions 
3rd timepoint  
277 lesions 
All lesions  1.80 
(1.16,2.51);P<0.001
b 
1.02 
(0.64,1.40);P<0.001 
0.61 
(0.24,0.97);P=0.001 
Isointense  1.55 
(0.60, 2.49);P=0.001 
0.86 
(0.44,1.28);P<0.001 
0.45 
(0.07,0.84);P=0.02
 b 
Hypointense  2.17 
(1.14, 3.21);P<0.001 
1.26 
(0.79,1.72);P<0.001 
0.82 
(0.24,1.23);P<0.005
 b 
SPMS  1.89 
(0.65, 3.13);P=0.003 
1.01 
(0.47,1.56);P<0.001 
0.48 
(0.03,1.02);P=0.08
 b 
RRMS  1.72 
(0.50, 2.94);P=0.006 
1.03 
(0.49,1.57);P<0.001 
0.68 (0.24,1.14);P<0.005
 b 
aThis is not exactly the difference in raw means due to differential weighting in hierarchical model for 
patients contributing different numbers of lesions. 
bBootstrap derived CI and P-value. 
 
Table 7.4 Differences in mean paired difference (ΔR1/Δtlesions - ΔR1/ΔtNABT)  in lesion and disease 
subtypes. Values in parenthesis are 95% CIs. Units in 10
-3s
-1min
-1 
Difference in (ΔR1/Δtlesions - ΔR1/ΔtNABT) between lesion and disease subtypes 
  1st timepoint  
449 lesions 
2
nd timepoint  
449 lesions 
3rd timepoint  
277 lesions 
Hypointense-Isointense  0.63 
(-0.37, 1.62) P=0.2 
0.40 
(-0.08,  0.87) P=0.1 
0.37 
(-0.23,0.88) P=0.29
a 
RRMS- SPMS  -0.17 
(-1.91, 1.57) P=0.8 
0.02 
(-0.74,0.78). P=1.0 
0.20  
(-0.51, 0.80)P=0.8
a 
a Bootstrap derived CI and P-value. 
  
7.3.4.3 Relationship of ΔR1/Δt with lesion CSA 
 
There  was  a  significant  negative  association  between  ΔR1/Δt  and  lesion  CSA  at  all 
timepoints (table 7.5). 
Table 7.5 Association between ΔR1/Δt  and lesion CSA.  Coefficient is the change in ΔR1/Δt   per 
doubling of area (10
-3s
-1min
-1mm
-2) 
  Coefficient  95% CI  P-value 
1st timepoint   
581 lesions 
-0.55  -0.80 to -0.30  P<0.001 
2nd timepoint  
581 lesions 
-0.26  -0.37 to -0.14  P<0.001 
3rd timepoint  
322 lesions 
-0.21  -0.33 to -0.09  P=0.001 
 
7.3.4.4 T1- hypointense vs Isointense lesions 
 
Although  there  was  no  univariate  (unadjusted)  association  between  ΔR1/Δt  and  T1 
hypointensity, the relationship between the two is complicated by the fact that both had 
a significant association with lesion CSA; after adjusting for lesion CSA, there was a 
significantly greater ΔR1/Δt in T1- hypointense than in isointense lesions at the 1
st and 
2
nd  timepoints  post  Gd-DTPA.    The  difference  reduced  with  time  and  was  non-
significant at the 3
rd timepoint. (Table 7.6).  
 
Table 7.6 Mean difference in ΔR1/Δt  between T1- Hypointense and Isointense lesions (units in 10
-3s
-
1min
-1)
  
  Difference
a in ΔR1/Δt: 
hypointense – isointense 
95% CI  P-value  
1st timepoint   
581 lesions 
1.13  0.44 to 1.82  0.001 
2nd timepoint  
581 lesions 
0.41  0.09 to 0.73  0.013 
3rd timepoint  
322 lesions 
0.15  -0.17 to 0.48  0.353 
aDifference is adjusted for (log) lesion CSA.  
  
7.3.4.5 Comparison of relapsing remitting & secondary progressive MS 
 
Disease subtype was associated with lesion CSA, so again there is the possibility of area 
confounding the ΔR1/Δt differences between subtype.  Table 7.7 therefore reports area-
adjusted results.  There was a greater ΔR1/Δt amongst lesions in RRMS patients at the 
1
st (also significant before area adjustment) but not the 2
nd or 3
rd timepoint (also non-
significant before adjustment).  
 
Table 7.7 Mean difference in ΔR1/Δt  between lesions in RRMS and SPMS patients (units in 10
-3s
-
1min
-1)
  
  Difference
a in ΔR1/Δt: RRMS – SPMS  95% CI  P-value 
1st timepoint   
581 lesions 
1.22  0.12 to 2.42  P=0.04
b  
2nd timepoint  
581 lesions 
0.07  -0.61 to 0.74  P=0.848    
3rd timepoint  
322 lesions 
-0.03  -0.49 to 0.43  P=0.895    
aDifference is adjusted for (log) lesion CSA 
bBootstrap derived CI and P-value. 
 
7.3.5 Disease Modifying Treatment and other covariates 
 
At the time of scanning, 8 out of the 19 patients were receiving disease modifying 
treatment. 7 were receiving IFNβ (3 with RRMS, 4 with SPMS with relapses) and 1 
patient with RRMS was receiving glatiramer acetate. ΔR1/Δt was not associated with 
disease modifying treatment status at any timepoint, neither was there any association 
between ΔR1/Δt and age, gender, disease duration, or EDSS. 
 
  
7.4 Discussion:  
 
7.4.1 Consistent BBB leakage from visibly non-enhancing lesions 
 
The principal study finding was that visibly non-enhancing MS lesions (identified by 
careful  visual  inspection  and  comparison  of  the  pre-  and  post-contrast  T1-weighted 
images)  had  a  ΔR1/Δt  that  was  significantly  higher  than  contralateral  NABT  and 
significantly lower than visibly enhancing lesions at all timepoints up to 60 minutes 
after the injection of 0.3mmol/kg DTPA. These observations are compatible with a low 
grade BBB leakage in visibly non-enhancing lesions that is distinct from the more overt 
BBB leakage seen in enhancing lesions. The distinction between the leakage in visibly 
enhancing  and  visibly  non-enhancing  lesions  is  unambiguous,  with  non-overlapping 
95%  reference  ranges  and  differences  in  magnitude  by  a  factor  of  10.  Similar 
differences in magnitude of post-contrast enhancement between visibly enhancing and 
non-enhancing lesions were found in a previous study utilising Gd-DTPA (Silver et al., 
2002b). Together with the histological studies previously discussed (Adams et al., 1985; 
Gay and Esiri, 1991; Claudio et al., 1995; Kwon and Prineas, 1994), our MR-based 
findings consolidate the evidence for existence of low grade BBB disruption in visibly 
non-enhancing  lesions,  many  of  which  will  be  longstanding.  This  discernible  BBB 
leakage in non-enhancing lesions was a consistent feature in all the disease subtypes 
studied, and was present in both T1- hypointense and isointense lesions, indicating that 
low grade BBB leakage is a common and relatively non specific feature of visibly non-
enhancing MS lesions.   
  
It is important to stress that although low grade BBB leakage appears to be a consistent 
feature in visibly non-enhancing lesions, such leakage is different in degree and nature 
from that seen in visibly enhancing lesions. This is mirrored in the differences in the 
histological appearances of the two populations of lesions. Lymphocytic infiltration and 
acute  inflammation  are  features  of  visibly  enhancing  lesions.  In  contrast,  acute 
inflammation is rarely observed in visibly non-enhancing lesions.  (Adams et al., 1985; 
Gay and Esiri 1991; Claudio et al., 1995; Kwon and Prineas, 1994). Such differences 
point toward distinct underlying mechanisms of BBB breakdown in visibly enhancing 
and non-enhancing lesions, with inflammation underpinning the more florid breakdown 
in the former and incomplete BBB repair at least partly responsible for the latter. 
 
7.4.2 Potential contribution of intravascular Gd-DTPA to observed changes 
 
A possible confounder of  Gd-DTPA enhanced MRI studies on BBB disruption would 
be  the  contribution  of  intravascular  Gd  to  measured  ΔR1/Δt.  Intravascular  Gd 
concentration  reaches  a  peak  shortly  after  bolus  administration,  before  declining 
steadily  following  a  biexponential  function  with  a  mean  distribution  half  life  of 
approximately 10 minutes, diffusing into the extracellular spaces within the body and 
being  excreted  principally  through  the  kidneys  (Tofts  and  Berkowitz,  1994). 
Intravascular Gd would therefore exert its greatest influence on local ΔR1 in the earliest 
timepoint, with a relatively rapid reduction in contribution as time passes. The observed 
differences in ΔR1/Δt between lesions and NABT were sustained over the 3 timepoints 
up to an hour post-Gd. Such a sustained effect points toward changes secondary to BBB 
leakage, as opposed to intravascular Gd-DTPA. 
  
7.4.3 T1- hypointense vs T1- isointense lesions  
 
Because lesions were described on the PD weighted images, the resultant ROI’s around 
T1-  hypointense  lesions  were  often  larger  than  the  areas  of  actual  T1  hypointensity, 
encompassing within it additional areas of isointensity (FIG 7.3). This has to be borne 
in mind when interpreting the results of the lesion subtype comparison.  
 
 
    a              b 
FIG 7.3 Non-visibly enhancing lesion described on the PD weighted image (a), with its anatomical 
and spatial correlate on the T1-weighted SE image (b). The ROI, described on the PD weighted 
image, and encompasses an area greater than the area of T1 weighted hypointensity. 
 
Nonetheless,  a  clear  finding  was  that  after  allowing  for  the  negatively  confounding 
effects of lesion CSA, T1- hypointense lesions had a greater ΔR1/Δt than isointense 
lesions at the 1
st and 2
nd timepoints, with a loss of significance at the 3
rd timepoint (table 
7.6). In the light of dynamic susceptibility contrast studies on T1- hypointense lesions, 
which have revealed both a reduction in cerebral blood volume (Haselhorst et al., 2000, 
  
Wuerfel et al., 2004) and cerebral blood flow (Wuerfel et al., 2004), it would seem 
improbable that the greater post contrast ΔR1/Δt seen in hypointense lesions could be 
from greater perfusion in these lesions. Rather it seems more likely that this reflects a 
greater degree of BBB disruption, and therefore higher permeability in T1- hypointense 
lesions. Fewer patients (14 as opposed to 19 patients, with 322 instead of 581 lesions) 
contributed to the 3
rd timepoint analysis, due to the prolonged, and relatively demanding 
scanning protocol. The resultant smaller sample size might be a possible explanation for 
the loss of significance at this latter timepoint. An alternative explanation to the loss of 
a significant difference in ΔR1/Δt between the lesion subtypes at 60 minutes could be 
that Gd leakage follows different time courses in T1- hypointense and isointense lesions, 
achieving equilibrium with similar local Gd concentration in both lesion subtypes by 60 
minutes. This would be compatible with the decreasing difference in ΔR1/Δt between 
the 2 lesion subtypes over time (Table 7.6).  
 
There was an association between lesion CSA and T1 hypointensity- lesions with a 
larger CSA tending to coincide with an area of hypointensity on the pre-contrast T1- 
weighted SE sequence. This could be seen as being compatible with the idea of larger 
lesions  being  associated  with  a  greater  degree  of  tissue  and  axonal  damage,  the 
pathological hallmark of T1- hypointense lesions (Hiehle et al., 1995; Van Walderveen 
et al., 1998).  
 
In the study, a positive association was noted at patient level between the percentage of 
lesions which were T1- hypointense and advanced disability as measured by EDSS. In 
addition patients with SPMS were noted to have a higher proportion of T1- hypointense 
lesions (p=0.057). These findings are in line with those of previous studies, where T1-  
hypointense lesion load was found to correlate with disability as measured by EDSS, 
and with a SP disease subtype (van Walderveen et al., 2001). 
 
7.4.4 RRMS lesions vs SPMS lesions  
 
RRMS lesions were observed to have a greater ΔR1/Δt only at the 1
st post contrast 
timepoint  when  compared  with  lesions  in  SPMS  patients.  Given  the  borderline 
significance (p=0.04), and the absence of a sustained difference over 40 or 60 minutes, 
further studies would be required to confirm this finding. Assuming however that this is 
a real observation, it could be accounted for by differences in lesion composition in the 
2  clinical  subtypes.  As  Gd  leakage  and  therefore  ΔR1/Δt  is  proportional  to  transfer 
coefficient across the BBB (K
trans) and lesion leakage space (ve)(Tofts and Kermode, 
1991; Tofts et al., 1999), it is possible that the difference in initial ΔR1/Δt  is due to a 
relatively high permeability ( K
trans) and low leakage space (ve) in RRMS lesions. 
 
An alternative explanation for the difference seen in the post contrast ΔR1/Δt between 
RRMS and SPMS patients could be increased perfusion in lesions in RRMS, which 
would be consistent with ongoing active inflammation in a population consisting of 
newer,  more  active  lesions.  Continuous  arterial  spin  labelling  studies  on  perfusion 
across different MS subtypes (Rashid et al., 2004) have revealed increased perfusion in 
RRMS  compared  with  SPMS  patients.  However,  this  finding  was  not  confined  to 
lesions, but on segmented white matter as a whole. Another study employed dynamic 
susceptibility  contrast  enhanced  MRI  to  investigate  perfusion  in  lesions  in  RRMS 
patients (Ge et al., 2005). This revealed a population of non enhancing lesions which 
have increased perfusion with vascular changes similar to visibly enhancing lesions  
consistent with low grade inflammation. However, no SPMS patients were included in 
this study. Overall, it seems plausible that higher perfusion in the population of lesions 
seen in RRMS patients could be contributing to clinical subgroup difference seen only 
at the first post-contrast timepoint. 
 
7.4.5 Associations with lesion CSA 
 
In the present study, a robust negative relationship was found between lesion CSA and 
ΔR1/Δt.  Lesions  with  a  lower  CSA  had  a  greater  ΔR1/Δt  than  larger  lesions.  The 
observation  is  unlikely  to  be  due  to  partial  volume  effect,  wherein  smaller  lesions 
should  have  a  smaller  apparent  ΔR1/Δt.  Neither  is  it  easily  explained  by  errors  of 
alignment  or  misregistration  in  the  construction  of  T1  maps.  Although  this  may 
conceivably affect smaller lesions more, it is unlikely that such errors would introduce a 
systemic  error  resulting  in  such  a  robust  relationship.  In  addition,  explaining  the 
relationship  in  terms  of  differences  in  perfusion  is  difficult,  as  the  relationship  is 
significant and present in all timepoints. Perhaps a more likely explanation can be given 
if one assumes that the chronic BBB leakage occurs from a “central” venule around 
which  the  lesion  originally  developed.  Such  an  origin  for  MS  lesions  is  well 
documented in neuropathological studies, where lymphocytic infiltrates and fibrinous 
exudates follow a perivenular pattern (Adams et al., 1985) Persistent low grade leakage 
from such a venule is likely to result in a concentration gradient of Gd contrast, with a 
decrease  in  concentration  further  away  from  the  venule.  If  the  permeability  of  the 
central venule is the same in small and large lesions, it might be expected that post-Gd 
ΔR1/Δt would be greater per unit voxel in smaller lesions. Such an effect could also 
impede  the  detection  of  higher  leakage  in  T1-  hypointense  than  isointense  lesions,  
because the former are more commonly seen in larger lesions.  Further investigation of 
the relationship between venule location and extent of leakage might be possible by the 
application of an imaging methodology that enables the detection of venules. (Tan et 
al., 2000) 
    
7.4.6 Associations with treatment and disability 
 
ΔR1/Δt  was  not  associated  with  disease  modifying  treatment  by  IFNβ  or  glatiramer 
acetate at any timepoint, suggesting that the low grade BBB leakage in visibly non-
enhancing lesions reported in this study were not materially influenced by inter-current 
disease modifying therapy. Persistent low grade BBB leakage is likely due to relatively 
permanent  structural  changes  that  have  been  reported  in  pathological  studies  e.g. 
reparative thickening in the vessel walls in longstanding MS lesions (Adams et al., 
1985). Although no correlation was found between ΔR1/Δt and concurrent disability as 
measured by EDSS, long term follow up will be required to determine whether the 
extent  of  BBB  leakage  in  visibly  non-enhancing  lesions  is  related  to  future 
accumulation of disability. 
 
7.4.7 Limitations 
 
The present study had a number of limitations. The long acquisition time for each T1 
map limited the temporal resolution of the study, making accurate modelling and 
estimation of intravascular Gd concentration difficult. The construction of serial T1 
maps involved multiple steps of registration, which could introduce an element of error  
in the estimation of T1. The describing of ROI’s over areas of PD weighted abnormality 
complicated the interpretation of comparisons between T1- hypointense and isointense 
lesions. The study design was cross sectional and the exact age of the lesions was not 
known; nor is there longitudinal data to indicate whether the changes observed alter 
with time. The absence of healthy controls in the study precluded the investigation of 
BBB leakage in NAWM, where a number of studies using measures such as 
spectroscopy, magnetization transfer and diffusion weighted imaging have indicated the 
presence of abnormality in MS (Fernando et al., 2004; Kidd et al., 1997; Werring et al., 
1999). 
 
7.4.8 Summary and Future Work   
 
The study has clearly demonstrated that low grade BBB leakage is a feature of visibly 
non-enhancing lesions, and is detectable using contrast enhanced MRI, with ΔR1/Δt as a 
quantitative measure. The leakage is distinct from that seen in visibly enhancing lesions, 
is greater in smaller than in larger lesions, and appears to be greater in T1- hypointense 
lesions,  compared  with  size-adjusted  T1-  isointense  lesions.  In  addition,  there  is  a 
borderline observed difference between RRMS and SPMS patients in the initial ΔR1/Δt 
value.  If  true,  this  may  reflect  differences  in  perfusion,  or  in  the  permeability 
characteristics of lesions in RRMS and SPMS.  
 
The findings in this preliminary study justify the use of serial T1 maps and ΔR1/Δt as a 
sensitive measure of low grade leakage, and encourage future work in this approach, 
which could include a sequence for obtaining T1 maps with a shorter acquisition time, 
the  inclusion  of  healthy  controls,  primary  progressive  patients,  and  longitudinal  
observations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 8 
Summary and Conclusions 
 
Natalizumab and the BBB form the 2 major themes of this thesis. The BBB and its 
breakdown are central to new lesion formation and inflammation within MS (Adams et 
al., 1985; Bruck et al., 2007; Grossman et al., 1986; Katz et al., 1993; Miller et al., 
1988; Lai et al., 1996)  The postulated mechanism of action of Natalizumab is 
principally at the level of the BBB, preventing leucocyte adhesion and transmigration 
through the BBB. (Rice et al., 2005). Its effect on new lesion formation  was studied in 
a phase III monotherapy trial (chapter 4). Further studies in this thesis  investigated the 
effect of natalizumab on segmental atrophy (chapter 5) and inferred subtle BBB 
breakdown (chapter 6) 
 
Overt BBB breakdown (as detected by Gd enhancement and histological changes) is an 
established feature of new lesions and ongoing inflammation in MS. Less is known 
about low grade BBB leakage in old, non-active lesions. Such leakage could potentially 
contribute to tissue damage through the attendant leakage of inflammatory cells and 
soluble mediators of inflammation. The final study described in this thesis attempted to 
investigate BBB leakage both in visibly enhancing as well as in visibly non-enhancing 
lesions by utilising changes in R1 to infer BBB leakage (chapter 7). 
 
8.1 Effect of natalizumab on MRI measures in MS 
 
Several studies to date have demonstrated the efficacy of natalizumab in ameliorating 
the clinical manifestations of MS, as monotherapy (Miller et al., 2003; Polman et al.,  
2006) or in combination with IFNβ (Rudick et al., 2006). 
 
Much of this thesis investigated the effect of natalizumab on MS through MRI studies, 
either through conventional MRI measures of disease activity and severity such as Gd 
enhancing lesions, T1- hypointense lesion load and number of new and enhancing T2  
hyperintense lesions (Chapter 4), or through volumetric measures of GM and WM 
(Chapter 5) and inferred BBB leakage through the measurement of change in T1 
weighted signal (Chapter 6). 
 
8.1.1 Effect of natalizumab on MRI visible lesions: The AFFIRM trial results 
(Chapter 4) 
 
In this 2 year, placebo-controlled, double-blinded trial, treatment with natalizumab was 
associated with a 92% reduction in number of Gd enhancing lesions, 83% reduction in 
number of new or enlarging T2 hyperintense and a 76% reduction in the number of new 
T1 hypointense lesions. Similarly, natalizumab significantly reduced the total volumes 
of all lesion types studied compared to placebo. Such findings are in line with those of 
other studies investigating the effect of natalizumab on MRI visible MS lesions (Miller 
DH et al., 2003; Rudick et al., 2006; Goodman et al., 2009) and  complement the 
clinical results from AFFIRM and SENTINEL (Rudick et al., 2006; Polman et al., 
2006).  Together, they reinforce the evidence that natalizumab exerts a profound anti-
inflammatory effect in MS. 
 
In addition, natalizumab reduced T1/T2 LVR, indicating an additional effect on the 
formation of the more severe subset of T1- hypointense lesions over and above the  
general effect of natalizumab on all T2 hyperintense lesions.  Consistent with this is the 
finding that natalizumab reduces the likelihood that Gd enhancing lesions evolve into 
permanent T1-hypointense lesions (Dalton et al., 2004b). Together, these studies 
suggest that in addition to averting leucocyte adhesion and resultant BBB breakdown, 
natalizumab also ameliorates axonal damage once inflammation has commenced, 
presumably by further disruption of α4 integrin mediated processes downstream. 
 
8.1.2 Effect of natalizumab on segmental atrophy (Chapter 5) 
 
In this 2 year substudy of the AFFIRM trial, volumetric measures of GM, WM and BP 
were obtained. Atrophy over the 2 years occurred predominantly in the GM and was 
independent of WM lesion load, echoing  findings from a previous study (Tiberio et al., 
2005). GMF (but not WMF) was negatively related to EDSS.   
 
Although trends were detected for greater rates of WM atrophy and lower rates of GM 
atrophy in natalizumab treated patients, caution must be exercised in interpreting these 
findings as none of the trends approach significance. The lack of a significant treatment 
effect could either reflect insufficient statistical power due to the relatively small study 
population (Anderson et al., 2007), or  could represent a real absence of effect of 
natalizumab on atrophy, indicating that  atrophy does not immediately arise from VLA-
4 mediated processes or inflammation. Further studies are required to determine if the 
influence of natalizumab on WM lesions results in a moderation of atrophy in the long 
term. 
  
8.1.3 Effect of natalizumab on low grade BBB leakage in visibly non-enhancing 
lesions (Chapter 6) 
 
In this second substudy of the AFFIRM trial, subtle BBB leakage in visibly non-
enhancing lesions was inferred by detecting subtle change in SI at set timepoints up to 
40 minutes after the administration of Gd-DTPA. The scans were undertaken 6 months 
after the start of the trial, by which time the study subjects would have received 6 
infusions of either 300mg natalizumab or placebo.  
 
The study demonstrated consistent detectable leakage from non-visibly enhancing 
lesions up to 40 minutes post-contrast. It validated the use of dynamic contrast 
enhanced imaging to investigate subtle BBB leakage in a multi-centre setting.  
 
The subtle leakage was not influenced by the administration of natalizumab, implying 
that such leakage occurs through α4β1 independent processes, ostensibly through 
permanent structural and physiological changes in the vascular wall, with chronic, 
incomplete BBB repair, as suggested by findings from histological studies in non-active 
lesions (Adams et al., 1985; Claudio et al., 1995) 
 
8.1.4 Progressive Multifocal Leukoencephalopathy and natalizumab 
 
The development of PML in a handful of patients receiving natalizumab has caused 
considerable concern amongst patients and clinicians alike. PML has been reported to 
develop in patients receiving natalizumab monotherapy (Hartung, 2009) as well as in  
patients who have undergone previous or ongoing immune modulation or suppression 
(van Assche et al., 2005; Demasters and Tyler, 2005; Langer-Gould et al., 2005). 
Retrospective studies on patients receiving natalizumab estimate the annual risk of 
developing PML at 1 per 1000 patients (Yousry et al., 2006) 
 
The reasons behind the development of PML in natalizumab treated patients are 
unknown. Studies on natalizumab- treated patients show a marked paucity of leucocytes 
in CSF (Stuve et al., 2006), as well as reductions in the number of  dendritic cells and 
CD4+ T-cells in the cerebral perivascular spaces (del Pilar Martin et al., 2008), 
consistent with a restriction of α4-mediated adhesion and transmigration of leucocytes.  
It has been suggested that the disruption of leucocyte transmigration across the BBB 
compromises normal CNS immune surveillance, thereby allowing unchallenged 
replication of JC virus and the development of PML(Berger and Koralnik, 2005). 
 
 An alternative hypothesis (Ransohoff, 2005) points to the potential for B-cell and B-
cell precursors to act as reservoirs of JC virus. Such cells are mobilized from the bone 
marrow in natalizumab treated patients (Krumbholz et al., 2008). 
 
Published guidelines now inform the selection of suitable candidates for natalizumab 
therapy, and the subsequent monitoring for PML (Gold et al., 2007; Kappos et al., 
2007). The guidelines prescribe specific washout periods for previous immune-
suppressive treatments prior to the commencement of natalizumab. The suspicion of 
PML, based on clinical and radiological evidence, is accompanied by a recommendation 
for discontinuation. The possibility of a re-emergence of disease activity on drug 
withdrawal was examined in a recent study, which revealed that clinical, radiological  
and immunological markers of disease activity were stable up to 14 months following 
discontinuation of the natalizumab (Stuve et al., 2009).  
 
In a study of 12 patients receiving natalizumab, a 3-day course of plasma exchange was 
associated with a 92% reduction in serum natalizumab concentration within the 1
st 
week, and with an increased transmigratory capacity of peripheral blood mononuclear 
cells as measured in vitro (Khatri et al., 2009), suggesting plasma exchange may be of 
benefit in natalizumab related PML by hastening the clearance of natalizumab from the 
system and restoring the migratory capacity of immune cells and therefore the immune 
surveillance of the CNS.  
 
8.2 Usage of ΔR1/Δt to infer subtle BBB leakage in MS (Chapter 7) 
 
The final study described in this thesis utilised the change in R1 (the inverse of T1) to 
measure local Gd concentration and therefore infer BBB leakage after administration of 
Gd. The measure used (ΔR1/Δt) represents a more reproducible and potentially more 
sensitive measure than T1- weighted signal per se, which in addition to being inversely 
related to T1, is also directly related to PD, and influenced by amplifier gain at each 
scan.  
 
Persistent low grade BBB leakage was detected up to 60 minutes after administration of 
Gd seen in visibly non-enhancing lesions. Such low grade BBB leakage was distinct 
from the leakage seen in visibly enhancing lesions, in which a 10-fold difference in 
magnitude and non-overlapping 95% reference ranges were noted.  Leakage was greater 
in size-adjusted T1-hypointense lesions, indicating that such low grade BBB leakage  
was more severe in lesions in which there was a greater degree of neuronal damage and 
extracellular matrix disruption. A robust inverse relationship was observed between 
lesion CSA and BBB leakage, with lower ΔR1/Δt in larger lesions. This may be 
explained by a dilutional effect rather than differences in BBB permeability, with a 
larger leakage space in large lesions leading to lower local concentration of leaked Gd. 
No convincing evidence for differences in lesional BBB permeability between RRMS 
and SPMS was found.  
 
8.3 Conclusion 
 
The efficacy of natalizumab in suppressing new lesion formation and ameliorating the 
clinical manifestations of MS advocates strongly for the targeting of cell adhesion 
molecules at the level of the BBB as a potential treatment strategy in MS. The 
development of PML in a small number of patients receiving natalizumab underlines 
the need for continued, long term monitoring of patients receiving new agents for which 
long term data is lacking. It is hoped that published recommendations aimed toward the 
early detection of PML in natalizumab patients will help to reduce the morbidity and 
mortality associated with this rare but potentially fatal complication. 
 
Although treatment with natalizumab was not shown to influence segmental atrophy 
over a 2 year period, this may be due to insufficient statistical power. Non-significant 
trends appeared to suggest that treatment with natalizumab reduced the rate of GM 
atrophy and accelerated WM atrophy, ostensibly from resolution of inflammation 
related oedema. Further, follow-up studies are required to ascertain whether treatment 
with natalizumab influences atrophy in the long term.  
 
Subtle BBB leakage was investigated in the final 2 studies described in the thesis, the 
latter study utilising the novel measure ΔR1/Δt as a reproducible and sensitive measure 
of BBB leakage. Both studies demonstrated consistent, measurable low grade leakage 
from visibly non-enhancing lesions. This leakage  was distinct from the overt BBB 
breakdown in visibly enhancing lesions, and was not influenced by treatment with 
natalizumab. Such findings consolidate the evidence from histological studies of low 
grade BBB leakage from non-active lesions due to changes in vessel wall structure 
(Adams et al., 1985) and physiology (Claudio et al., 1995).  
 
 Although no correlation was found between inferred BBB leakage (ΔR1/Δt) and EDSS, 
it is hoped that long term follow up studies will determine whether the extent of BBB 
leakage in visibly non-enhancing lesions is related to future accumulation of disability. 
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